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Abstract 
 
In 2006, the secondary metabolite leiodolide A (17) was isolated from a newly 
discovered deep-sea sponge of the genus Leiodermatium. The 19-membered 
macrolide represented a new class of mixed polyketide, nonribosomal, peptide 
synthetase natural products. A total synthesis of leiodolide A is yet to be achieved and 
is of specific interest, not only for its complex structure and undefined 
stereochemistry, but also the potent cytotoxic properties it possesses, particularly 
towards leukaemia, non-small cell lung and ovarian cancers. 
 
 
 
A synthetic strategy for leiodolide A must be flexible to overcome the currently 
unresolved stereochemistry and a convergent route towards the synthesis of the 
molecule required three subunits. Following the earlier synthesis of the C21-C25 
vinyl stannane fragment, this work describes the synthesis of the C1-C10 subunit in 
the both possible diastereomeric forms. The synthesis of the two required C13 
epimers of the C11-C20 subunit is also detailed accompanied by an investigation into 
potential fragment coupling, in preparation for total synthesis. 
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 vii 
Compound numbering 
 
All compounds intended towards the total synthesis of leiodolide A will be numbered 
according to the carbon chain of the natural product. This numbering is shown on the 
structure and is used in the 1H NMR assignments. 
 
 
 
The naming of the compounds in the experimental section uses the IUPAC 
convention. 
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Chapter One 
Introduction 
 
1.1 Natural products 
 
Natural products from all manner of living organisms have been used to treat various 
ailments and maladies for centuries. This has ranged from salicin, the precursor to 
modern day aspirin, taken from the leaves of the willow tree as a remedy for aches 
and fever by the ancient Assyrians and Egyptians; to the 16th century use of quinine, 
obtained from the cinchona tree bark, for the treatment of malaria.1 
 
As science and technology developed during the 20th century, the ability to extract, 
purify and characterise these bioactive secondary metabolites became possible. They 
could then be investigated for their wide range of pharmacological properties 
including antibiotic, antifungal and cytotoxic activity. This ability to extract active 
metabolites from a plethora of biological organisms brought natural product 
chemistry to the forefront of drug discovery. Although in recent years there has been a 
shift towards high-throughput screening due to a better understanding of mechanism 
of action and target site identification, natural product chemistry still plays a vital role 
in drug development. An example is eribulin (1), which recently gained FDA 
approval for the treatment of metastatic breast cancer and acts by inhibiting the 
microtubule dynamics and ultimately, triggering apoptosis.2 Eribulin itself is not a 
natural product, but a synthetic analogue derived from the natural product 
halichondrin B (2) obtained from the Halichondria genus of marine sponge (Figure 
1.1).3,4 The production of synthetic analogues is important, as it allows the 
bioactivities of the molecules to be adapted, for example to enhance potency or to 
alter pharmacological properties, as well as providing invaluable information for 
assessing the active site and mechanism of action.  
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Figure 1.1: Eribulin (1) and halichondrin B (2)  
 
The search continues for the next natural product success story and with an estimated 
95% of the World’s oceans currently unexplored, the marine ecosystem continues to 
be a promising place to search.5 In recent years many novel bioactive metabolites 
have been isolated from marine organisms that have never been encountered in 
terrestrial organisms. The primary reason for the production of these compounds is 
defence. As many of these organisms are soft bodied and have no other form of 
physical protection, they must therefore rely upon these metabolites to guard them 
from predation.6 It is these metabolites that make ideal lead compounds for drug 
discovery and development, especially with a recent report showing that over half the 
current prescription drugs contain a natural product derived active ingredient.7 The 
demand for these natural products, often isolated in low natural abundance and from 
extremely rare species, means that synthetic pathways must be established for further 
investigation of their biological potential and possible use in treatment.  
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1.2 Lithistid sponges 
 
The sponge order Lithistida is not a true order but a polyphyletic grouping of sponges, 
of diverse origins, and based upon the make up of their skeletons, comprising tightly 
interlocking siliceous spicules, named desmas (Figure 1.2).8,9 The spicules are needle 
like structures composed of silica and give the lithistid sponges a rock-hard 
consistency. The rigid desmas skeleton divides up the sponge in to the ectosome 
(external) and endosome (internal) tissues with the varying arrangements of the 
spicules defining the overall shape of the sponge. This variation leads to the vast array 
of physical external appearances of the sponge order for example Theonella 
swinhoei10 displaying tuberculate projections and Leiodermatium11 exhibiting thin 
flaring folded lamellae (Figure 1.3). 
 
 
 
Figure 1.2: Example of the desmas of Leiodermatium villosa9 
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Figure 1.3: Lithistida order sponge examples Theonella swinhoei10 and 
Leiodermatium11 
 
This order of sponges is one principle avenue for investigation in terms of marine 
secondary metabolites, with new sub-species regularly being discovered and often 
containing novel bioactive compounds.12 These products encompass a wide range of 
molecular diversity including, but not limited to, macrolides, lipids, linear and cyclic 
peptides, alkaloids and sterols. They exhibit a variety of pharmacological properties 
such as, cytotoxicity, antimicrobial, antiviral and immunosuppressive activities. 
However the major limitation of investigating compounds derived from deep sea 
sponges, such as certain lithistids, is the logistics of species collection with natural 
habitats in depths of up to 500 metres.9 Nevertheless technical advances in recent 
years have seen huge developments in manned deep-sea submersibles, making 
exploration of these habitats feasible and further investigation of the metabolites 
possible. 
 
1.2.1 Compounds extracted from lithistid sponges 
 
A prime example of the diversity of the lithistid order of sponges is the Okinawan 
Theonella sp. sponges, from which a remarkable number of secondary metabolites 
have been isolated, including the keramamides (A-H and J-L).12 The keramamides are 
a group of cyclopeptides composed of a cyclic hexapeptide moiety of three modified 
 5 
amino acid residues linked together. They also contain an α,β-unsaturated amide 
conjugated to an oxazole (B-E)13 or thiazole (F-H, J-L)14 ring (Figure 1.4). Those 
worthy of particular mention are keramamides E and F (3 and 4), which showed 
cytotoxicity against human epidermoid carcinoma cells (IC50 of 1.6 and 1.4 µg/mL 
respectively) and against murine lymphoma (L1210, IC50 of 1.55 and 2.0 µg/mL 
respectively). 
 
 
Figure 1.4: Keramamide E (3) and F (4) 
 
1.3 Macrolides 
 
A commonly encountered subset of bioactive natural products are the polyketide 
macrolides, they possess a macrocyclic lactone functionality, with the cyclic ester 
containing more than eight atoms.15 They are also often highly oxygenated with both 
ether and hydroxyl groups, and contain numerous stereocentres. Marine derived 
macrolides exhibit a vast range of pharmacological activities including antiviral, 
antibiotic and cytotoxic properties making them desirable targets for innovative drug 
discovery. 
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To date, marine organisms have provided numerous novel bioactive macrolides with a 
range of different action mechanisms. One such macrolide is (–)-exiguolide (5), 
originally obtained from the sponge Geodia exigua collected near Amami-Oshima, 
Japan (Figure 1.5).16 Following the isolation and elucidation, a total synthesis and 
biological testing of (–)-exiguolide has been carried out by Fuwa and co-workers.17  
 
 
 
Figure 1.5: (–)-Exiguolide (5)  
 
Fuwa found this new secondary metabolite to be a potent antiproliferation agent 
against a number of human cancer cell lines including, large cell lung carcinoma 
(NCI-H460, 0.01  µM), lung adenocarcinoma (A549, 0.59  µM), ovarian carcinoma 
(SK-OV-3, 0.70 µM) and gastric carcinoma (MKN-74, 0.69 µM). Comparison of     
(–)-exiguolide, using NCI COMPARE analysis, to more than 100 anticancer agents, 
including those targeting a DNA mode of action for example; intercalating and 
alkylating drugs, as well as topoisomerase II inhibitors, showed only minor 
similarities. Fuwa concluded that it was likely (–)-exiguolide may have a unique 
biological mode of action and since then has published further work exploring the 
bioactivity through the use of synthetic analogues.18 This work identified key 
functionalities on exiguolide that are essential in the antiproliferation activity (Figure 
1.6). 
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Figure 1.6: (–)-Exiguolide synthetic analogues and respective antiproliferative 
activity against human A549 cell lines 
 
Fuwa showed that the C5 position was extremely important for activity, as although 
exchanging the methoxycarbonylmethylidene functionality for a hydroxyl (6) only 
saw a 5-fold drop in potency, masking the hydroxyl as the acetate (7) or introducing a 
methylene group (8) at C5 led to a complete loss in activity. They also found that the 
triene side chain at C19 was less important and could be replaced with a simpler 
diene-alkyl chain (9) without loss in potency compared to the C5 hydroxyl derivative, 
however truncating the side chain further (10) resulted in diminished activity. Fuwa is 
investigating this further through synthesis and evaluation of designed analogues, 
mouse xenograft studies and target identification. 
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1.4 Oxazoles in natural products 
 
A number of marine derived natural products have been isolated containing one or 
more oxazole heterocycles, with the motif formed naturally through enzymatic 
synthesis (Scheme 1.1).19 The initial peptide precursor is assembled by cellular 
enzymes from genetically encoded amino acids serine or threonine.  A zinc containing 
enzyme then coordinates with the carbonyl oxygen, activating the carbon for 
nucleophilic attack and stabilising the tetrahedral intermediate. Enzymatic bases can 
then deprotonate the nitrogen to form an imine, with zinc accepting the leaving 
hydroxide anion. A final oxidation step occurs, with flavin mononucleotide (FMN) 
acting as the biological oxidant, completing the oxazole synthesis.  
 
 
 
Scheme 1.1: Biological oxazole synthesis 
 
A particularly potent sub-group of oxazole containing metabolites are the tris-oxazole 
macrolides. They contain three consecutive oxazole moieties that form part of a 
lactone ring and often have elaborate side chains. Tris-oxazole macrolides possess 
numerous biological activities such as cytotoxic properties, antifungal activity and 
proteasomal-inhibition.20 One such family of these tris-oxazole macrolides are the 
kabiramides, isolated from a Thai marine sponge Pachastrissa nux found at a depth of 
10-15 m.21 Biological assays established them to be both antimalarial (Plasodium 
falciparum K1) and cytotoxic for breast adenocarcinoma (MCF-7). Included in 
Figure 1.7 are kabiramides B-D, G, J and K (11-16), with the tris-oxazole system 
clearly visible in the 25-membered lactone ring. The biological data shows the true 
potency of these compounds on sub-micromolar scale. 
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Figure 1.7: Kabiramide B (11), C (12), D (13), G (14), J (15) and K (16), including 
biological testing data 21 
 
The cytotoxic properties of these metabolites usually involve a mechanism of action 
via binding to actin, a multi-functional protein, which plays a vital part in many 
cellular functions including mechanical support, motility and cell division.20 Actin 
exists in two forms, a globular monomeric subunit, G-actin, or as a linear polymeric 
microfilament, F-Actin. The dynamic interchange from G-actin to the F-actin 
filaments is essential to cell motility and cytokinesis, the separation of cytoplasm 
prior to cell division. This dynamic process of assembly and disassembly is 
modulated by numerous actin-binding proteins, which include the gelsolin family of 
capping proteins. Gelsolin binds to the “barbed” fast growing ends of the 
microfilament preventing further monomer additions and thereby inhibiting the 
polymerisation. It has been shown, through X-ray crystallography, that these 
trisoxazole macrolides interact with actin in a hydrophobic cleft between the 1 and 3 
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subdomains (Figure 1.8) and thus allowing the long tail sections to participate in 
more extensive binding by becoming inserted in a further hydrophobic cavity deep 
within the actin structure.22  
 
 
 
Figure 1.8: Two orientations of actin-kabiramide C complex (1.45 Å resolution)20 
 
The subtle variations to these tail sections within tris-oxazole macrolide families 
make them extremely useful for probing and mapping various cellular and biological 
responses and functions. An overlay of kabiramide C and gelsolin shows considerable 
spatial overlap (Figure 1.9a) giving an indication that both will compete for the same 
binding site. This prospect for a similar mode of action between the two is further 
compounded by the contact interfaces for kabiramide C and gelsolin on actin 
appearing almost identical (Figures 1.9b and 1.9c). 
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a) 
 
 
 
b)       c) 
 
 
Figure 1.9: a) Overlay of kabiramide C (red) and gelsolin (blue) based on the 
superposition of the actin in their respective complexes. b) Space-fill representation 
of the interacting actin-kabiramide C residues. c) Space-fill representation of the 
interacting actin-gelsolin residues 20 
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1.5 Leiodolide 
 
1.5.1 Isolation of leiodolide A and B 
 
In 2006 a new deep-sea marine sponge, of the genus Leiodermatium, was discovered 
by Fenical and co-workers.23,24 It was found in the Pacific Ocean off the coast of 
Palau in the protected Uchelbeluu Reef, and collected at a depth of 220 metres by 
manned submersible. The lyophilised sponge was exhaustively extracted with 
methanol, before separation and purification of the biological components. Following 
biological testing of the collected fractions, two were identified as displaying 
considerable cytotoxicity against human colon cancer cell lines. Subsequent isolation 
yielded two novel metabolites named leiodolide A (17, 8 mg, 0.001% dry weight, 
Figure 1.10) and leiodolide B (18, 0.8 mg, 0.0001% dry weight). Identified as novel 
19-membered macrolides, they were the first metabolites to be extracted from a 
Leiodermatium genus sponge and a completely new class of mixed polyketide 
nonribosomal peptide natural products. 
 
 
 
Figure 1.10: Leiodolide A (17) and B (18) 
 
An initial National Cancer Institute 60-cell line panel biological assay was carried out 
on leiodolide A and showed significant cytotoxicity (mean GI50 = 2.0 µM). In 
addition it showed enhanced potency towards non-small cell lung cancer (NCI-H522, 
GI50 = 0.26 µM), leukaemia (HL-60, GI50 = 0.26 µM) and ovarian cancer (OVCAR-3, 
GI50 = 0.25 µM). 
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1.5.2 Structural elucidation of leiodolide A and B 
 
Structural determination of leiodolide A was carried out using a variety of NMR 
techniques in combination with high-resolution MALDI mass spectrometry. The mass 
spectral analysis showed leiodolide A to have molecular mass of 598.2992             
([M + Na]+) with molecular formula of C31H45NO9 and consistent with the 1H and  
13C NMR data. Analysis of the data received from COSY, HMBC, NOESY and 
variable temperature NMR techniques showed leiodolide A to possess four olefinic 
carbon bonds, a conjugated oxazole-containing 19-membered macrolide core and an 
α-hydroxyl-α-methyl carboxylic acid terminus side chain at C17.  
 
Ozonolysis degradation studies enabled the assignment of the C24 stereocentre 
through comparison of the chiral GC of the methylated product with authentic (R)- 
and (S)-dimethyl citramalate. Further derivatisation using Mosher’s methods was 
utilised in an attempt to assign the relative and absolute stereochemistry of the 
remaining stereogenic centres of leiodolide A. Initial ring opening of the lactone with 
sodium methoxide provided the methyl ester and 1,2-diol 19 (Figure 1.11), which 
was in turn treated with 2,2-dimethoxypropane and pyridinium p-toluenesulfonate to 
yield acetonide 20. It is at this point that the first indication to the apparent confusion 
regarding the stereochemistry at C4 and C5 can be observed. In a comparison of the 
published structures of leiodolide A (17) and the ring opened form (19a) a flip in the 
stereochemistry at C4 is clearly visible. This results in the C4-C5 stereochemistry 
being depicted with a syn configuration (with respect to the open chain form) in 17 
and an anti relationship in 19a. It is also evident that there is a flip in the three 
stereocentres at C15, C16 and C17 when going between the lactonised and ring open 
products, however this has been corrected to 15S,16R,17S in an amendment to the 
original paper (19b).23  
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Figure 1.11: Published leiodolide A degradation products. Highlighted areas 
indicating flip in stereochemistry 
 
Further evidence for the stereochemical ambiguity at C4 and C5 arises from the 
derivatisation following reaction with α-methoxy-α-trifluoromethylphenyl acetic acid 
(MTPAA), using modified Mosher’s ester method to form tris-MTPA esters at C5, 
C16 and C24. The stereocentre at C5 was assigned as R with H6 exhibiting a large 
negative Δδ(S-R) shift difference and Me4 a large positive value. The other surrounding 
protons at H2, H3, and H4 however unexpectedly gave small negative shift values. It 
was assumed that, due to the macrocyclic nature of leiodolide, the C16 ester is able to 
exert transannular interference, reaching across the ring, thus inducing the negative 
Δδ(S-R) shift difference. Unfortunately with limited material they were unable to carry 
out any further analysis on the centres at C4 and C5 leading Fenical to describe the 
suggested 4S,5R configuration as a “tenuous interpretation”. 
 
13
N
O
4
1
16
O
O
HO
OMe
OH
24
HO
O
OH
HO
O
OH
OH
OH
OMe
O
N 4 1 OMe
OOH
HO
O
OH
OMe
O
N 4
1 OMe
OOH
OO
19a
20
HO
O
OH
OH
OH
OMe
O
N 4 1 OMe
OOH
19b
 15 
Further ambiguity arises from the undetermined C13 stereocentre, which due to its 
structural isolation from the rest of the molecule made it impossible to define the 
absolute stereochemistry of this methyl group using spectroscopic techniques alone. 
 
Leiodolide B (18), co-isolated with leiodolide A, is hypothesised to be formed via 
enzymatic bromination of 17, promoting cyclisation to form the THF ring (Scheme 
1.2). Although it was not possible to assign the stereochemistry at the α-hydroxyl-α-
methyl carboxylic acid terminus C24 of leiodolide B due to lack of material, it was 
assumed, following this hypothesis to be the same as leiodolide A. 
 
 
 
Scheme 1.2: Hypothesised biosynthesis of leiodolide B from leiodolide A 
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1.6 Stambuli synthesis of key leiodolide A fragments  
 
To date there has been no reported synthesis of leiodolide A, with the only paper 
published on the synthesis of the molecule being by Stambuli et al., which 
documented the synthesis of their key fragments, but not their assembly.25 There has 
however been a synthesis of the published structure of leiodolide B by Fürstner et al., 
unfortunately the data acquired from their synthetic sample did not match that of the 
isolated natural product.26  
 
1.6.1 Stambuli retrosynthetic analysis  
 
Initial assessment by Stambuli, shown in Scheme 1.3, identified a disconnection 
between C18 and C19 to reveal the macrolide and envisaged the side chain (21) could 
be installed via a Julia olefination. The macrocycle could then be broken down further 
to three fragments, C1-C7 stannane 22, the oxazole ring (23) and polyoxygenated 
C11-C18 fragment 24, containing the unknown C13 stereocentre.  
 
 
 
Scheme 1.3: Stambuli retrosynthetic analysis 
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1.6.2 Subunit synthesis 
 
The C19-C25 subunit synthesis employed homopropargylic alcohol 25 (Scheme 1.4) 
as the starting point and following a Mitsunobu reaction with 2-thiobenzothiazole and 
oxidation with mCPBA afforded sulfone 26. The carbon skeleton of the subunit (27) 
was then completed via copper-mediated addition on to 2-methallyl chloride. From 
this point the carboxylic acid (28) could be accessed via Sharpless asymmetric 
dihydroxylation and TEMPO oxidation of the resultant primary alcohol. Final acid-
catalysed protection as 2-(trimethylsilyl)ethyl ester 29 and (Z)-selective palladium 
catalysed alkyne reduction completed the fragment. Trimethylsilylether ester was 
chosen as the protecting group to allow a single final deprotection step, while also 
eliminating the need to carry out a selective saponification in the presence of the 
macrolide. 
 
 
 
Scheme 1.4: Stambuli side chain 21 synthesis 
 
The C1-C7 subunit was synthesised in three steps from Davies' SuperQuat 
oxazolidinone (30, Scheme 1.5) and known aldehyde (31), initially via an Evans aldol 
reaction to yield the alcohol (32). DIBAL cleavage of the chiral auxiliary revealed 
aldehyde 33 that underwent Horner-Wadsworth-Emmons (HWE) olefination to 
complete the subunit.  
OH
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Scheme 1.5: Stambuli synthesis of C1-C7 subunit 22 
 
The oxazole fragment was synthesised over two steps from 2-thiooxazole 34 (Scheme 
1.6) via a previously published method.27 This involved deprotonation with n-BuLi at 
the 5-position followed by quenching with iodine to produce iodooxazole 35. A 
halogen dance rearrangement with LDA then gave access to 2-butylthio-4-
iodooxazole (23).28 
 
 
 
Scheme 1.6: Synthesis of oxazole fragment 23 
 
The northern C11-C18 subunit was synthesised from known alcohol 36 (Scheme 1.7), 
which was initially converted to the methyl ether 37 before undergoing ring opening 
to the corresponding Weinreb amide. To prevent recyclisation back to lactone 37 on 
silica it was necessary to immediately protect the free hydroxyl as the triethylsilyl 
ether (38) before purification. DIBAL reduction of amide 38 to the aldehyde enabled 
homologation of the subunit via Wittig olefination with salt 39, resulting in olefin 40 
in a 1 : 1 (E : Z) mixture.   
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Scheme 1.7: Stambuli synthesis of C11-18 precursor 40 
 
The next step, reduction of the alkene and benzyl deprotection, proved to be 
problematic as treatment with various palladium sources resulted in hydrogenolysis of 
the benzyl ether to alkane 41 (Scheme 1.8). This mechanistic pathway has been 
previously described with both homoallylic cyclopropanes29 and homoallylic ethyl 
ethers.30 It is a result of olefin migration to form palladium π-allyl species 42 
followed by elimination of the benzyl ether.  
 
 
 
Scheme 1.8: Hydrogenolysis pathway 
 
This problem was solved by switching to a two-step platinum/palladium process 
previously utilised by Nicolaou in the synthesis of englerin A (Scheme 1.9).31 The 
epimeric alcohols (43a and 43b) were then separated by column chromatography and 
assigned through analysis of the X-ray structure of silyl deprotected alcohol 43b. The 
two alcohols were then converted into the requisite bromides (24a and 24b) using 
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Appel conditions. The late stage formation of the stereocentre at the undefined C13 
position gives rapid access to both epimers and will therefore aid in the determination 
of the overall stereochemistry of leiodolide A. Once the assignment has been 
determined, this methodology would not be suitable for future synthesis of leiodolide 
A as it generates a 50:50 ratio of the two possible optical isomers, therefore wasting 
half of the material synthesised. With all the required fragments in hand Stambuli is 
currently working on a coupling strategy to lead to the completion of leiodolide A. 
 
 
 
Scheme 1.9: Synthesis of epimeric C11-C18 subunits 24a and 24b  
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1.7 Fürstner synthesis of leiodolide B isomers 
 
Fürstner and co-workers achieved their initial aim of synthesising the two possible 
published structures of the methyl ester of leiodolide B (44a and 44b, Figure 1.12), 
unfortunately the data obtained from the synthetic samples did not match that of the 
isolated natural product. Further work by Fürstner enabled the synthesis of two 
additional stereoisomers at C4 and C5 (44c and 44d) but they also failed to result in 
an authentic sample of leiodolide B, with the discrepancies in the data associated with 
the ambiguous C4,C5 region of the molecule. 
 
 
 
Figure 1.12: Four diastereomers of leiodolide B methyl ester synthesised by Fürstner 
 
1.7.1 Fürstner retrosynthetic analysis 
 
In their retrosynthetic analysis of leiodolide B, a section of the molecule containing 
the polysubstituted THF ring as well as the undefined stereocentre at C13 was 
identified as the key fragment (45, Scheme 1.10). Following a disconnection of the 
lactone, further disconnections between C11-C12 as well as C21-C22 released this 
fragment along with the side chain subunit 46 and fragment 47 containing the oxazole 
motif. 
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Scheme 1.10: Fürstner retrosynthetic analysis 
 
1.7.2 Subunit synthesis 
 
Initial work focused on the synthesis of the key fragment, specifically the THF ring, 
which was formed in three steps from chiral epoxide 48 (Scheme 1.11). Conjugative 
ring opening of this epoxide in the presence of MeMgBr in conjunction with 
stoichiometric amounts of CuCN and P(OPh)3, yielded allenol 49. Dihydrofuran 50 
could then be afforded via Marshall and Pinney Ag(I)-induced cyclisation conditions 
to efficiently transfer the chirality from the allenol to the product.32 The final two 
stereocentres could then be installed through bromo-esterfication with NBS in 
aqueous DMF to yield the fully elaborated THF ring (51).33 A series of protecting 
group manipulations was followed by a Dess-Martin oxidation, which allowed the 
incorporation of the unknown C13 stereocentre via addition of freshly prepared 
Grignard reagent of either stereoisomer of 52 (R-series shown for clarity). Addition of 
the enantioenriched C13 containing fragment at a late stage in the subunit synthesis is 
advantageous for future leiodolide B synthesis as it gives complete control over the 
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C13 stereochemistry. Final functional group manipulations of the resultant PMB ether 
53 afforded the key C12-C21 subunit 45 as the required iodide.  
 
 
 
Scheme 1.11: Fürstner (13S) poly-substituted THF subunit synthesis 
 
Synthesis of the oxazole containing C3-C11 fragment 54 (Scheme 1.12) began with 
the installation of the C4 and C5 stereocentres by subjecting the stannylated aldehyde 
31 to Evans boron-aldol conditions. The chiral auxiliary of aldol adduct 55 was then 
reductively cleaved with LiBH4 to yield the diol, which in turn was protected as an 
acetal, before Stille cross-coupling with oxazole triflate 56 to complete the fragment. 
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Scheme 1.12: Synthesis of oxazole containing subunit 
 
The final side chain terminus fragment (46) was synthesised in five steps from          
L-malic acid 57 (Scheme 1.13). Initial protection with pivaldehyde afforded acid 58, 
which then underwent diastereoselective methylation and borane reduction to yield 
alcohol 59. Conversion of the alcohol to the Wittig salt, via the intermediate iodide, 
then set the scene for coupling. 
 
 
 
Scheme 1.13: Synthesis of side chain subunit 
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1.7.3 Subunit assembly 
 
The coupling strategy began with the key C12-C21 fragment and construction of the 
C11-C12 bond via alkylation (Scheme 1.14).34 Reductive ring opening of the PMP 
acetal of alkylation product 60 released the primary alcohol at C3 in readiness for 
macrolactonisation. Previous model studies in house had shown that side chain 
installation should be given priority, therefore temporary protection of the alcohol as 
the benzoate ester was carried out. Selective deprotection of the TBDPS ether at C21 
in the presence of the TIPS ether, followed by Dess-Martin oxidation to aldehyde 61, 
enabled Wittig olefination with the ylide formed from phosphonium salt 46. 
Treatment of the C3-C25 advanced intermediate 62 with NaOMe in MeOH resulted 
in concomitant benzoate cleavage at C3 and conversion of the terminal acetal into the 
methyl ester. Further elaboration through HWE olefination with the aldehyde 
resulting from DMP oxidation at C3 yielded the completed open chain of leiodolide B 
(63). Silyl group deprotection followed by palladium catalysed unveiling of the   
seco-acid at C1 enabled Yamaguchi lactonisation to form the macrolide ring. Final 
PMB cleavage afforded leiodolide B as the methyl ester 44a. The C13 epimeric 
methyl ester was synthesised in an analogous manner using the (13R)-THF subunit.   
 
Comparisons of the methyl esters to the natural product data failed to produce a 
match, with small but significant differences in the spectra. As these initial 
comparisons were made between the free acid natural product and the methyl ester 
synthetic products, Fürstner attempted to clarify that the methyl ester was not the 
source of the difference in spectra, and therefore synthesised the free acid. 
Unfortunately they had great difficulty in selectively cleaving the methyl ester in the 
presence of the macrolide, however they were able to obtain a small quantity of the 
free acid 18 through saponification with excess Me3SnOH followed by HPLC 
purification. The spectra obtained from free acid 18 and the methyl ester 44a were, as 
expected, almost identical and this could consequently be ruled out as the cause of the 
inconsistencies with the natural product spectra. 
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Scheme 1.14: Subunit coupling and completion of leiodolide B 
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Upon further examination of the product data, especially the 13C NMR data, Fürstner 
found large discrepancies in chemical shifts between the isolated natural product and 
the (13S)- and (13R)-synthetic products. Believing it to be a related to the 4S,5R 
ambiguity, the 4R,5S diastereomers of both epimers at C13 were synthesised, but the 
data from these was also inconsistent with the data from the elucidation paper (Figure 
1.13). In particular, the C6,C7 and C21,C22 vinylic carbons show a large deviation 
(2-3 ppm) in chemical shift from that found in the natural product. Fürstner concluded 
that constitutional assignment still appeared correct with the chemical shift 
differences being too small to suggest misassigned geometries in these olefinic 
“hotspot” regions. He suggests that it is more likely that the disparity between the data 
sets comes from a subtle structural difference and Fürstner is currently attempting to 
ascertain this difference. 
 
C# Isolated 4S,5R,13R 4S,5R,13S 4R,5S,13R 4S,5R,13S 
4 45.1 44.7 44.5 45.6 46.2 
5 71.7 72.0 72.0 71.9 71.6 
6 131.2 128.3 128.0 128.9 129.5 
7 125.5 128.4 129.2 129.1 128.4 
8 143.3 143.1 143.6 143.7 143.5 
       
19 84.0 84.5 84.7 84.4 84.2 
20 37.6 37.3 37.3 37.5 37.8 
21 126.5 127.9 127.9 127.9 127.8 
22 130.4 128.4 128.4 128.5 128.5 
23 39.2 39.2 39.2 39.2 39.2 
24 76.4 75.7 75.7 75.8 75.7 
 
∆∂ ≥ 1 ppm, 0.5 ppm ≤ ∆∂ < 1 ppm, 0.3 ppm  ≤ ∆∂ < 0.5 ppm 
 
Figure 1.13: Comparison of the 13C NMR data between the isolated natural product 
of leiodolide B (18) and Fürstner’s four synthetic diastereomeric esters ([D4]MeOH) 
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1.8 Florence leiodolide A synthetic strategy 
 
1.8.1 Retrosynthetic analysis 
 
Any proposed strategy for the synthesis of leiodolide A must be flexible so as to take 
into account both the currently unidentified stereochemistry at C13 and the mounting 
uncertainty regarding the integrity of the stereocentres C4 and C5. Therefore a 
convergent approach that will accommodate the installation of these functionalities in 
an efficient manner is of paramount importance.  
 
It is also important, within this strategy, to be able to manipulate the key subunits in 
such a way that mechanistically useful analogues can be produced. This is because the 
overall aim of this investigation is not just to ascertain the absolute stereochemistry of 
leiodolide A and establish a route to total synthesis, but also to explore the mechanism 
behind the bioactivity of leiodolide A, that is currently unidentified. 
 
Leiodolide A presents numerous synthetic challenges, not least of these is the 
installation of seven stereocentres and the formation of the 19-membered macrolide. 
Our retrosynthetic approach initially involves the disconnection of the lactone linkage 
at C17, with the macrolactonisation occurring in the forward reaction via a Mitsunobu 
reaction of the seco-acid precursor, with inversion of stereochemistry. The straight 
chain leiodolide backbone could then be further disconnected between C10-C11 and 
C20-21 yielding three subunits 64, 65 and 67 of comparable size and complexity, 
ideal for a convergent strategy. The formation of the bonds in the forward steps can 
be kept flexible at this stage to accommodate a whole host of possible cross-coupling 
partners, with examples provided in Scheme 1.15. 
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Scheme 1.15: Florence retrosynthetic analysis of leiodolide A 
 
1.8.2 Previous work 
 
Previous work in the group on the synthesis leiodolide A has focused on three areas; 
development of a vinylogous Mukaiyama aldol reaction (VMAR) for installation of 
C4 and C5 stereocentres (Scheme 1.16), completion of the C21-C25 side terminus 
fragment and synthetic efforts towards the C11-C20 subunit.35 A new syn approach to 
the VMAR would enable the rapid, asymmetric construction of the C1-C10 subunit 
and will be discussed in detail in the next chapter.  
 
 
 
Scheme 1.16: General reaction scheme for 1,2-syn VMAR  
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The first step in the C21-C25 fragment synthesis was a one-pot allylation of methyl 
pyruvate to install the α-hydroxy α-methyl quaternary centre at C24 (Scheme 1.17). 
This was introduced via initial addition of allyl bromide to a prepared Sn(II) 
catecholate-(+)-diisopropyl tartrate (DIPT) catalyst, followed by the directed addition 
of the methyl pyruvate 67. The resulting allylated product 68 was produced in good 
yield and enantiomeric excess and the free hydroxyl was then protected as the 
triethylsilyl ether (TES).  
 
 
 
Scheme 1.17: C24 quaternary stereocentre installation   
 
Subjecting alkene 69 to ozonolysis conditions provided the aldehyde, which in turn 
could be converted to the dibromoalkene (70) by treatment with carbon tetrabromide 
and triphenylphosphine (Scheme 1.18). The final step involved a one-pot 
debromination, followed by Pd-mediated cross coupling to yield exclusively the    
(Z)-vinyl stannane. The selectivity of this two step process is a result of the initial 
highly stereoselective, oxidative palladium insertion into the least sterically hindered 
bromine-carbon bond. Transmetallation with tributyltin hydride followed by reductive 
elimination then yielded the (Z)-vinyl bromide, which undergoes standard cross-
coupling with hexamethyl distannane to afford the completed subunit (64).  
 
 
 
Scheme 1.18: Completion of C21-C25 subunit  
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Work on the C11-C20 subunit unfortunately encountered difficulties due to the 
polyoxygenated nature of the fragment. These problems included poor reactivity of 
aldehydes to standard olefination conditions and difficulties involving protecting 
groups with; silyl migrations and a general lack of reactivity in both protection and 
deprotection of hydroxyl groups  (Scheme 1.19). It was clear that a new route to this 
subunit must be devised and will therefore be one of the aims of this work. 
 
 
 
Scheme 1.19: Previous C11-C20 problems 
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Chapter Two 
Synthesis of the C1-C10 subunit 
 
2.1 Computational studies 
 
The tenuous assignments given in the isolation paper, allied with the publication of 
Fürstner's work on leiodolide B,26 led to a computational investigation being 
undertaken to gain further insight into the C4, C5 and C13 stereocentres.  
 
2.1.1 Bifulco computational chemistry 
 
The use of computational modelling in the assignment of the stereochemistry of 
organic compounds was pioneered in 2002 by Bifulco and co-workers and has since 
become an increasingly popular tool to natural product chemists.36,37 They were able 
to demonstrate that structural reassignments made following total synthesis of a 
number of natural products could, in fact, have been made through comparisons of the 
experimental and calculated chemical shift data. The computational data was 
calculated using an ab initio method at the Hartree-Fock (HF) level of theory for the 
geometry optimisation, which then allowed GIAO (Gauge Including Atomic Orbitals) 
13C NMR chemical shift calculations to be made.  The experimental and calculated 
13C NMR data were then compared to one another in a correlation plot, from which 
the linear correlation coefficient (r) could be calculated.  Initially this work was 
applied to three test cases of low-polarity and structurally rigid natural products, 
wherein, the initial structural assignments from the original experimental data were 
erroneous. One such example is the alkaloid antidesmone (71, Figure 2.1), which was 
previously wrongly assigned as the isoquinoline derivative 72. Using their 
comparison method, Bifulco was able to show that the revised structure 71 was a 
better fit for the experimental data with an r value of 0.998, compared to 0.985 for 72. 
This indicates that the isoquinoline derivative is a less probable structure for 
antidesmone than 71 and they were able to confirm this by looking at the 13C data for 
individual carbon atoms. Significant deviations from the experimental data were seen 
for C2, C3 and C4 of 72, providing the final evidence for 71 being the correct 
structure. 
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Figure 2.1: The two possible structures for antidesmone 
 
Bifulco followed up this work by applying it to more flexible organic compounds in a 
bid to distinguish between the four stereoisomers 73-76 (Figure 2.2).37 In an 
analogous manner, he calculated the optimised geometries of the most stable 
conformers (up to a limit of 25 kJ mol-1 from lowest energy conformer) for each 
stereoisomer. The GIAO 13C NMR chemical shift data could then be calculated for 
each conformer, with the Boltzmann-average for each carbon plotted against the 
experimental data. Using a Boltzmann-average value gives a greater weighting to the 
lower energy conformers whilst also taking into account the possibility of higher 
energy conformers being present. The correlation plot enabled him to calculate the     
r values once again and these were used to assign both isomer 73 and 76, with a value 
of 0.999. Isomers 74 and 75 could be distinguished less unequivocally through the 
linear correlation coefficient (both 0.998), and it was therefore necessary to interpret 
the data using another parameter. This parameter was corrected mean absolute error 
(CMAE) or Δδ, defined as the difference between the scaled-calculated shift values 
and the experimental 13C NMR chemical shift values. Utilising this parameter it was 
possible to determine the departure of fit for a single 13C data point for each of the 
possible conformers considered. This approach removes the risk of systematic errors 
in the shift calculation and enabled the final two assignments to be made for 74 and 
75. Following the publication of these two pieces of work these methods have been 
used by various groups in their stereostructural assignments and reassignments of 
numerous natural products.38–41  
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Figure 2.2: The four stereoisomers investigated by Bifulco  
 
2.1.2 Goodman CP3 and DP4 progression 
 
Bifulco’s work was then taken forward by the Goodman group who identified that 
while the use of the Δδ parameter did reduce some of the systematic errors in the shift 
calculation, it failed to take into account that these errors could be different for 
different carbon types.42 They looked to remove the errors by comparing the 
differences in calculated shift between two possible diastereoisomers with the 
differences in experimental shift. In doing this they developed a new parameter, CP3, 
which was significantly more reliable in making the correct stereostructural 
assignment than those employed by Bifulco. They were able to demonstrate the 
effectiveness of the new parameter on a range of structures including comparisons 
between pairs of diastereoisomers (for example 77 and 78 in Figure 2.3). This new 
parameter also offers a measure of the confidence level of the assignment (through 
Bayes’ theorem), using a combination of the 1H and 13C NMR data, rather than their 
individual use, offered the highest probability as to the correct assignment. 
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Figure 2.3: Diastereoisomer pairs assigned with CP3 parameter 
 
Unfortunately the CP3 parameter has one major limitation in that, for a given 
structure with only two possible diastereoisomers, it requires the experimental data 
for both isomers. This is extremely problematic when looking towards natural 
products with only a single isolation data set available that could have many possibly 
structural assignments. The Goodman group then looked, therefore, to develop a new 
methodology that would have the advantageous attributes of the CP3 work, without 
the necessity of the expensive and time-consuming task of synthesising all possible 
stereoisomers. The new method is the DP4 probability, which, rather than being a 
parameter obtained from the data, is a probability directly calculated from the data for 
each possible structure.43  
 
The computational method employed is similar to the previous work by Bifulco with 
initial conformational searches conducted using the Monte Carlo Multiple Minimum 
(MCMM) method with the Merck Molecular Force Field (MMFF) and a 50 kJ mol-1 
upper energy limit. All conformers that were within 10 kJ mol-1 of the global 
minimum were then carried forward for single-point ab initio calculations. The        
10 kJ mol-1 cut off was found to be sufficient to get reliable results, an increase to    
25 kJ mol-1 in previous work did not lead to improved accuracy.44 The energy and 
GIAO shielding constants could then be carried out at the B3LYP level of theory with         
6-31G(d,p) basis sets using the Jaguar programme. Using the shielding data, the NMR 
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shifts were calculated in the usual way after being subject to Boltzmann averaging. 
For the DP4 probabilities to be calculated extra data points are also required and these 
are obtained from a group of reference compounds (with known experimental data) to 
give a data set containing 1717 13C and 1794 1H shift data points. This provides the 
mean (µ) of 0, standard deviation (σ) of 2.306 ppm (13C) and 0.185 ppm (1H) and 
degrees of freedom (v) of 11.38 (13C) and 14.18 (1H). All of this data can then be 
simply put into an applet provided by the Goodman group or, alternative calculated 
longhand using the equation in Figure 2.4. 
 
 
 
Figure 2.4: DP4 probability (based on Bayes’ theorem)43 
 
Using this methodology Goodman was able to distinguish between the two possible 
isomers of nankaurine A (79 and 80, Figure 2.5) with only one set of experimental 
data. Nankaurine A, isolated in 2004 was initially assigned as 80 by Kobayashi,45 
however in 2006 the same group reassigned the structure as 79.46 The configuration of 
79 was finally confirmed by Overman in 2008, through the total synthesis of both 
isomers, followed by comparison to the isolation data.47 
 
 
 
Figure 2.5: Possible structures of nankaurine A 
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The DP4 probability calculations of the 13C NMR shifts assigned structure 79 with a 
probability of 79.5% and structure 80 with a 20.5% chance of being correct. The same 
calculations carried out using the 1H NMR shift data identified a probability nearly 
100% in favour of 79 and only a 3.2 x 10-6 % possibility of the data corresponding to 
80. Combining the carbon and proton NMR data, the structure of nankaurine can be 
assigned as 79 with a near 100% probability and 80 with a 10-7 % possibility. This is 
in stark contrast with Bifulco’s CMAE Δδ parameter, which gives no clear indication 
as to the correct structure with a 50:50 likelihood of assignment. Goodman was able 
to further show the effectiveness of the DP4 probability in the assignment of the 
correct structure from eight possible isomers for neopeltolide (81, Figure 2.6) and 
both aspergillide A (82) and B (83). This evidence shows how powerful a tool 
computational chemistry, combined with DP4 probability calculations, can be in the 
field of natural product structural assignment. 
 
 
 
Figure 2.6: Neopeltolide (81), aspergillide A (82) and B (83) probabilities 
 
2.1.3 Computational investigation of leiodolide A 
 
In the case of leiodolide A, there are eight diastereoisomer possibilities that may 
require synthesis, so any indications offered by computational analysis, not 
necessarily limited to identifying the correct isomer, but simply excluding the least 
likely configurations, is likely to save both considerable time and expense in the 
overall assignment and synthesis. Following Goodman’s approach, the eight possible 
configurations, accounting for the ambiguous stereochemistry at C4 and C5, as well 
as the unassigned stereocentre at C13, were investigated. The conformational searches 
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were carried out using Macromodel, interfaced via Maestro, and the evaluations 
completed using MCMM method and the MMFF force field with an upper energy 
limit of 50 kJ mol-1. Use of this method identified 99 conformers that were within    
10 kJ mol-1 of the global minimum window for the 8 possible diastereomers, with the 
number found for each specific configuration shown in Figures 2.8 and 2.9. The high 
number of conformations is attributed to the number of rotatable bonds in the ring 
that, through rotation, enable small energy increases in one portion of the macrolide to 
be minimised else where around the ring. An overlay plot of 4S,5R,13S (Figure 2.7) 
gives a representative example of the possible conformations that the molecule can 
adopt within the relative energy window. 
 
 
 
Figure 2.7: Overlay plot of 4S,5R,13S 
 
Unfortunately computational issues hampered the ability to carry out the energy and 
GIAO shielding constant calculations. Nevertheless, significant observations could be 
made from the conformational search results of the eight diastereomers shown in 
Figures 2.8 and 2.9.  
 39 
 
 
 
Figure 2.8: (13S) series lowest energy conformations (number of conformations 
found within 10 kJ mol-1 of the global minimum) 
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Figure 2.9: (13R) series lowest energy conformations (number of conformations 
found within 10 kJ mol-1 of the global minimum) 
 
An immediate observation is that the side chain plays no part in affecting the low 
energy conformers, this is because it becomes locked through hydrogen bonding 
between the C25 carboxylic acid proton and alcohol at C16. This is pleasing as it 
removes the potential for all the lowest energy conformations possessing just simple 
variations of the side chain position over the macrocyclic ring.  What is also clear 
from first impressions is the vast differences in the conformation of the macrocycle 
arising from the various stereochemical configurations. This is typical of polyketide 
macrolides whereby small changes in stereochemistry are translated through the 
whole ring system.48 There are, however, consistencies between all eight structural 
isomers, for example, the arrangement of the lactone linkage. This has the C17 proton 
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and the carbonyl oxygen eclipsing one another, minimising the steric interactions of 
the side chain with the C1 carbonyl group, while also allowing possible induction of 
hydrogen bonding between the two. The oxazole position in the ring, however, differs 
a great deal between the isomers, in the (5S)-configuration the oxazole moiety sits in 
the plane of the ring, whereas in the (5R)-conformers, it is pulled into a perpendicular 
position. This difference is due to the C5 proton eclipsing the C7 methyl group to 
minimise the A1,3-strain, and thereby resulting in the whole conjugated C6-C10 
oxazole containing system becoming shifted in position. The geometry of C1-C3 
system is also variable and dependent upon the configuration at C4. In the            
(4S)-isomers the α,β-unsaturated lactone sits in an s-trans conformation (Figure 
2.10), which from a steric viewpoint will be favourable to minimise the A1,3 strain 
between the carbonyl and vinylic proton at C3. This is in contrast to the isomers with 
a (4R)-configuration, which prefer to adopt an s-cis relationship, however, the barrier 
to rotation between the two arrangements is very small and inter-conversion is seen in 
higher energy conformations. 
 
 
 
 Figure 2.10: Geometrical arrangements of C1-C3 
 
Finally, with respect to the protons at C4 and C5, in the syn isomers (4R,5S and 
4S,5R) the protons in these positions sit antiperiplanar to one another, however, in the 
anti isomers (4R,5R and 4S,5S) the protons are held gauche to each other. This is 
again to reduce the steric interaction experienced by the methyl and hydroxyl groups 
in these positions. The 3J coupling constants calculated for the region further highlight 
the gauche and antiperiplanar arrangements of the protons. Extrusion of the coupling 
constants enables some qualitative data to be taken from these projected conformers 
and comparison of this data, to that published for leiodolide A in the isolation paper is 
shown in Table 2.1 (Entry 1). Although only a preliminary evaluation, this data 
agrees with the conclusion made by Fürstner and tends away from the syn C4,C5 
relationship (Entries 2-5) suggested in the isolation paper and towards an anti 
configuration (Entries 6-9).26 
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Entry 3J 
3-4H 
(Hz) 
4-5H 
(Hz) 
5-6H 
(Hz) 
 
1 
Natural 
Product 9.5 2.0 8.5 
 
2 4S,5R,13R 11.7 8.2 10.9 
syn 
3 4S,5R,13S 11.9 8.7 10.5 
 
4 4R,5S,13R 11.9 8.8 9.6 
 
5 4R,5S,13S 11.9 8.9 11.0 
 
6 4S,5S,13R 11.7 1.4 10.5 
anti 
7 4S,5S,13S 11.6 1.8 10.0 
 
8 4R,5R,13R 11.7 1.4 9.8 
 
9 4R,5R,13S 11.7 1.3 10.5 
 
 
Table 2.1: 1H coupling constants for lowest energy conformations 
 
To reinforce these preliminary conclusions, and to hopefully identify the most likely 
configurations at C4, C5 and C13, density functional theory (DFT) calculations 
followed by a DP4 probability study must be carried out. Without a confirmed 
configuration, the retrosynthetic route must take into account all possible isomers and 
a flexible synthetic pathway planned accordingly. 
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2.2 C1-C10 subunit 
 
2.2.1 Retrosynthetic analysis 
 
The primary focus within the synthesis of the C1-C10 subunits (84 and 85) was the 
installation of the stereochemistry at C4 and C5, with the need to develop a flexible 
approach due to the inherent ambiguity surrounding these two positions. The strategy 
proposed in Scheme 2.1 shows a disconnection of the C4-C5 bond allowing 
incorporation of both stereocentres in single step. This bond scission reveals an 
aldehyde and silyl ketene acetal 86 (derived from an unsaturated ester), which could 
be realised via a vinylogous Mukaiyama aldol reaction (VMAR). This approach 
allows investigation at this position to address the ambiguity outlined by Fürstner, and 
allow assignment of the relative and absolute stereochemistry. Further disconnection 
between C7 and C8 reveals 4-iodooxazole 87 and vinyl stannane coupling partner 31, 
to enable bond formation via a Stille reaction in the forward direction. 
 
 
 
Scheme 2.1: Retrosynthetic analysis of the C1-C10 subunit 
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2.2.2 Synthesis of the C5-C10 fragment 
 
The starting point for the C5-C10 subunit was the synthesis of the oxazole fragment 
outlined in Scheme 2.2. The diiodooxazole 88 was prepared using the Vedej’s 
iodination procedure49 with modifications made by Greaney.50 Treatment of oxazole 
89 with LiHMDS in the presence of DMPU over 14 days gave 2,4-diiodooxazole.  
 
 
 
Scheme 2.2: Iodooxazole synthesis 
 
The mechanism (Scheme 2.3) involves initial lithiation at the most reactive               
2-position, followed by ring opening to the lithium enolate. This enables iodination 
into the 4-position, reformation of the oxazole ring and final halogen exchange to 
provide 88.49  
 
 
Scheme 2.3: Oxazole iodination mechanism 
 
The diiodooxazole 88 was readily protected at the 2-position with a TIPS group. This 
protection is necessary to block the most reactive iodide position of the oxazole and 
prevent the Stille coupling occurring preferentially at the 2-position over the desired, 
but less reactive 4-position. The TIPS group was chosen as earlier work by Miller and 
co-workers had shown it to be stable under aqueous and silica chromatography 
conditions, unlike the TMS or TBS derivatives.51 They also showed that it was 
necessary to use a silyl triflate for C2 silylation, rather than a silyl chloride which 
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instead silylates the oxygen to yield α-isocyano silyl enol ethers (Scheme 2.4). The 
TIPS group was installed via selective lithiation at the 2-position, ring opening to the         
α-isocyano enolate, followed by silyl addition and ring closure. 
 
 
 
Scheme 2.4: Silylation pathways51,52  
 
With iodooxazole 87 in hand the synthesis of vinyl stannane aldehyde 31, coupling 
partner for the Pd-mediated cross-coupling, could be undertaken. The (E)-stannane 89 
was selectively prepared from 2-butyn-1-ol 90 via stannyl cupration using the mixed 
cuprate Bu3Sn(Bu)CuCNLi2 (Scheme 2.5). Thermodynamic temperature conditions 
of -10 ºC and methanol as a proton source are required to achieve the desired 
selectivity.53 Lower temperatures lead to the (Z)-isomer, with the regioselectivity of 
cuprate addition inverted. 
 
 
 
Scheme 2.5: Stannane synthesis 
 
Mechanistically, the stannyl cupration occurs through syn addition of the 
cyanocuprate to the alkyne bond and the regioselectivity of the addition is controlled 
by the reaction temperature (Scheme 2.6).54 This is followed by protonation of the 
double bond, which allows rotation about the C-C bond to bring the cuprate 
antiperiplanar to the tributyltin group, and into the plane of the empty π orbital. The 
cuprate moiety can then be eliminated forming the desired (E)-vinyl stannane. 
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Scheme 2.6: Stannyl cupration mechanism53 
 
The resulting allylic alcohol was then oxidised to the requisite aldehyde (31) with 
manganese dioxide in excellent yield (Scheme 2.5).55 With the aldehyde and iodide 
87 in hand, the Stille cross coupling reaction was investigated. Discovered in 1977 by 
Stille and co-workers, this process uses a palladium catalyst to mediate the C-C bond 
formation between a stannane and halide or pseudohalide.56 The catalytic cycle, 
shown in Figure 2.11, commences with the reduction of the Pd(II) source to the 
reactive Pd(0) species (a), followed by oxidative insertion into the carbon-halide bond 
(b). Transmetallation with the organostannane (c) and elimination of the stannane 
halide (d) produces the palladium intermediate (e), which, by reductive elimination, 
forms the new C-C bond in the product (f). 
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Figure 2.11: Stille catalytic cycle 
 
Since the discovery of the Stille reaction, numerous additives have been investigated 
to enhance both the yield and reaction rate, with the most commonly encountered 
being copper salts, stannane scavengers and chlorides. Copper additives are used to 
enhance the rate of the reaction in two ways; firstly they undergo initial 
transmetallation of the stannane to the more reactive cuprate before further 
transmetallation on to the palladium species.57,58 Secondly, it has been shown that 
copper salts can act as ligand scavengers in competition with the Pd source, thus 
preventing strongly coordinating ligands, such as PPh3, from having a retarding effect 
on the transmetallation.59 Chloride ions, usually in the form of lithium chloride, cause 
an increase in the reaction rate through exchange with the halide or pseudohalide, 
following the oxidative addition step.60 The chloride is much smaller than the 
commonly used triflate or iodide groups and therefore results in much less steric 
hindrance to the incoming organostannane allowing transmetallation to occur much 
faster. 
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The attempted Stille cross coupling between stannane 31 and iodide 87, proved 
problematic with low yields of between 0 and 34% achieved at a small scale (25 mg), 
over a range of reaction conditions, as outlined in Table 2.2. Initial work using 
Pd(PPh3)4 as catalyst with a copper (I) thiophenecarboxylate (CuTC) additive57 
generated promising results with an initial yield of 10% (Entry 1), which could be 
further increased to 29% through the implementation of a [Bu4N]+[PhPO2] stannane 
scavenger (Entry 2). Employing the Baldwin conditions with CuI and a CsF 
scavenger had a detrimental effect and failed to produce any of the desired product, 
even at elevated temperatures (Entry 3).58,61 The relatively poor results observed with 
the Pd(PPh3)4 catalyst led to a screen, at 90 ºC, of alternate palladium sources 
(Entries 4-6). This found that Pd(MeCN)2Cl2, in conjunction with a lithium chloride 
additive provided the best yield of 34% (Entry 6).27 Unfortunately, none of these 
findings could be replicated on a larger scale (250-500 mg), which was initially 
thought to be due to dimerization of the stannane, however, slow addition via a 
syringe pump to discourage dimerization failed to give any improvements in yield. 
 
 
 
 
Table 2.2: Aldehyde-Stille coupling results 
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The poor yields achieved were therefore believed to be associated with the instability 
of aldehyde 31 with the reaction conditions and addressed by attempting the Stille 
coupling again using the vinyl stannane alcohol 89. This change showed a marked 
improvement in results, and, following optimisation, the use of Pd(MeCN)2Cl2 and 
lithium chloride additive in DMF at 90 ºC led to yields of 75% (Scheme 2.7). This 
elaborated allylic alcohol 92 was then oxidised to aldehyde 91 in good yield, utilising 
the same manganese oxide protocol as before.  
 
 
 
Scheme 2.7: Synthesis of aldehyde 91 via alcohol Stille coupling 
 
To generate consistent results with the Stille coupling it was necessary to adapt the 
reaction conditions to prevent the propensity of the product to undergo desilylation at 
the 2-position of the oxazole to yield alcohol 93. These changes included flame 
drying and storing the lithium chloride under argon prior to use, degassing the DMF 
solvent, using fresh catalyst and ensuring the purity of the iodooxazole prior to use. 
The alcohol following the cleavage of the TIPS group could still be carried forward, 
however, the loss of the silyl group greatly increased the polarity of the molecule and 
therefore reduced the workability of the compound.  
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2.3 Installation of C4 and C5 stereocentres 
 
Asymmetric aldol addition reactions are an important tool for organic chemists and 
one of the most versatile methods for the formation of C-C bonds, whilst also 
imparting control on the resulting stereocentres. This methodology is certainly 
applicable to the C4-C5 bond juncture of leiodolide A where stereocontrol is required 
over both centres.  
 
2.3.1 Vinylogous Mukaiyama aldol reaction 
 
The initial focus of the Florence group for the formation of the C4-C5 bond was the 
vinylogous Mukaiyama aldol reaction (VMAR) which would be advantageous as it 
offers access to the completed C1-C10 subunit in a single step from aldehyde 91. The 
VMAR is an efficient method for installing both polyacetate and polypropionate 
functionalities, with high degrees of regioselective and stereoselective control. 
 
The first vinylogous aldol reaction, reported in 1975 by Mukaiyama and Ishida, 
showed that, in the presence of a Lewis acid, aldol product 94 could be synthesised 
from the reaction of an acetal (95) and a silyl dienol ether (96) with excellent 
regioselectivity of 99 : 1, γ : α (Scheme 2.8).62 
 
 
 
Scheme 2.8: Mukaiyama’s vinylogous alkylation of a silyl dienol ether 62 
 
These “extended dienolate” species, accessed from γ-enolisable α,β-unsaturated 
substrates, can be employed due to the polar nature of their enolate precursors. This 
polar nature allows the vinylogous extension of these reactions and is defined as “the 
transmission of electronic effects through a conjugated π system of a C=C double 
bond.”63 In essence, the properties of a functional group can affect the reactivity of a 
distant part of a molecule through the conjugated system. Given this activation of the 
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vinyl systems of ketene acetals and dienol ethers, reactivity could occur at either the 
α- or γ-positions (Scheme 2.9).  
 
 
 
Scheme 2.9: Regioselectivity of dienolates 
 
Activation at both the α- and γ-carbons of these dienol ethers should result in mixed 
products, however, Mukaiyama and Ishida demonstrated excellent γ-regioselectivity 
with the silyl dienol ether 96.62 This selectivity can be rationalised by looking at both 
the electronic and steric effects experienced by both silyl dienol enolates and 
metallodienolates. Figure 2.12 shows the electronic structures of these molecules and 
draws particular attention to the orbital coefficients (O.C., the electron population 
with respect to the wave function for an atom), and the electrophilic susceptibilities 
(E.S., how prone to electrophilic attack a position is), for each carbon. The O.C. and 
E.S. for the (E)-lithium enolate of methyl crotonate (97) are larger for the C2 carbon 
than C4, implying that α-addition is more probable. This is in contrast to both the  
(E)-trimethyl silyl ketene acetal (98) and the (E)-trimethyl silyl enol ether (99), for 
which a γ-addition is predicted, with both the O.C. and E.S. being higher at the C4 
carbon than C2. The difference in values between the C4 and C2 positions are, 
however, not large enough to warrant the high levels of selectivity observed in 
Mukaiyama and Ishida’s work, and it is therefore necessary to look at the steric 
implications at both carbon centres. The C2 α-position of both 98 and 99 is adjacent 
to the large silyl group, which is likely to introduce steric hindrance and therefore 
further favour reaction at C4. 
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Figure 2.12: Electronic structures of lithium dienolate 97, silyl ketene acetal 98 and 
silyl enol ether 99 63 
 
Introduction of a bulky silyl group into the dienol ethers and the inherent γ-selectivity 
in Lewis acid promoted VMAR has enabled the development of enantioselective 
catalytic methodologies. One such investigation by Denmark and co-workers 
demonstrated that their bisphosphoramide catalyst system 100 (Scheme 2.10) could 
be used in the addition of silyl ketene acetal to a variety of aldehydes.64 The 1,2-anti 
motif was constructed with excellent levels of regioselectivity and high enantio- and 
diastereocontrol with 5 mol% catalyst loading. 
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Scheme 2.10: Denmark’s bisphosphoramide catalysed anti-aldol reaction 64 
 
Selective access to 1,2-syn motifs through VMAR is less well established, however, 
recent work by Kalesse and Simsek has shown high degrees of syn-selectivity can be 
achieved through VMAR-type additions.65 This work utilised a proline-based chiral 
oxazaborolidinone catalyst 101, with the optimal catalyst substituents shown in 
Scheme 2.11. In general they found that the best selectivities were achieved with 
alkyl aldehyde substituents, for example valeraldehyde (Entry 1). Aromatic and 
unsaturated aldehydes, however, had much poorer γ-selectivity and only moderate 
stereoselectivities, as exemplified by cinnamaldehyde (Entry 2). 
 
 
 
Scheme 2.11: Kalesse’s syn-aldol reaction 65 
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2.3.2 Vinylogous Mukaiyama aldol applied to leiodolide A 
 
The stereoselective nature of the VMAR addition and it’s ability to offer a different 
stereochemical outcome through simple changes to reaction conditions (rather than 
changing the reactants) make it a useful tool in the synthesis of leiodolide A, 
especially amidst the uncertainty surrounding the C4 and C5 stereogenic centres. 
Application of Denmark’s bisphosphoramide catalyst system could potentially be 
used to construct the 1,2-anti isomer of leiodolide A (suggested by computational 
work), and access to the 1,2-syn motif (postulated in the isolation paper23) could be 
accessed through a Ti-(IV)-(S)-BINOL catalyst system, developed in the Florence 
group.66 An in depth optimisation study of the reaction within the group found that 
best results could be achieved with a 40 mol% catalyst loading, at -50 ºC and 0.1 M 
reaction concentration. Diethyl ether was found to be the optimum solvent and 4 Å 
molecular sieves (MS) as the drying agent. These optimal conditions enabled a 
screening of the scope of the reaction with various aldehydes to be completed (Table 
2.3).35 In general the yields ranged from 35-79% and there was a modest degree of 
diastereoselectivity to a maximum of 2 : 1 in favour of the syn-aldol adducts. The 
enantioselectivity, however, was excellent for all the syn-aldol products and good to 
excellent for the anti-aldol products, when isolation was possible.  
 
 
 
Table 2.3: Previous in-house investigation of aldehyde substrate scope35 
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The applicability of the Ti-(IV)-(S)-BINOL VMAR to the synthesis of leiodolide A 
was also demonstrated through the use of model aldehyde 102 (Scheme 2.12) 
containing an unsubstituted alkene. Subjecting 102 to the optimised VMAR 
conditions, with silyl ketene acetal 86 gave the syn-aldol adduct 103 in good yield 
with the best diastereoselectivity of any of the screened aldehydes with 2.3 : 1.  
 
 
 
Scheme 2.12: VMA of model oxazole aldehyde 102 
 
To attempt the VMAR on the C1-C10 precursor aldehyde 91, the required silyl dienol 
ether was prepared by trapping the lithium enolate of α,β-unsaturated ester 104 with 
TBSCl. The (Z)-configured silyl ketene acetal 86 is produced in high yield and with 
high levels of C3-C4 (Z)-olefin selectivity (>20 : 1). 
 
 
 
Scheme 2.13: Silyl ketene acetal 86 synthesis 
 
The addition of DMPU as a coordinating solvent is critical in controlling the enolate 
geometry and therefore overall (Z)-selectivity of the silyl ketene acetal product. This 
was initially rationalised by Kende as a result of deconjugation leading to an acyclic 
transition state in which 1,3-allylic strain is the primary controlling factor.67 However, 
work since by Galatsis, has refuted this and shown that it is more likely to occur 
through a 10-membered transition state (TS1, Scheme 2.14),68 due to LDA primarily 
existing as a dimer in the presence of DMPU.69 The work also proposes that an         
8-membered transition state (TS2) could not be discounted, which could offer optimal 
geometry for abstraction of a proton with a monomeric LDA. There were however, 
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several examples in which the stereochemistry could only be accounted for through 
TS1 and therefore this can be considered the most viable transition state. 
 
 
 
Scheme 2.14: Silyl ketene acetal transition states68 
 
The vinylogous Mukaiyama aldol addition was then attempted on the C5-C10 
aldehyde substrate 91 and silyl ketene acetal 86 using the previously optimised 
conditions (Scheme 2.15).  
 
 
 
Scheme 2.15: Vinylogous Mukaiyama aldol with aldehyde 91 
 
Although the reaction proceeded, it was in disappointing yield (35%) and in favour of 
the anti-diastereomer with moderate d.r. of 3 : 1. This inversion in diastereoselectivity 
is in direct contrast to all previously screened aldehydes including the model oxazole 
aldehyde 102. The diastereomers also proved inseparable and this, coupled with the 
low yield made it apparent that this current methodology would not be viable as a 
route to the C1-C10 syn-diastereoisomer.  
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It is clear that this VMA methodology warrants further investigation with respect to 
leiodolide A, for access to the syn-isomer, especially given the highly selective work 
of Kalesse (Scheme 2.11). Due to time constraints, however, it was necessary to push 
forward with other methodologies for this bond formation to enable work towards the 
completion of leiodolide A to continue.  
 
2.3.3 Boron-mediated aldol addition 
 
The boron aldol addition methodology has been extensively developed since the 
initial work by Brown and co-workers,70 with numerous total syntheses published 
since exploiting the highly predicable stereoselective nature of the reaction on a wide 
range of different substrates.71–73 The high degree of diastereoselectivity is attributed 
to the “closed” type transition states that occur during the reaction. Strongly 
coordinating metal counterions, such as lithium and boron, form six-membered 
transition states through coordination to the enolate and the carbonyl oxygen atom of 
the substrate. The ligands on the metal ion are then able to impart steric and electronic 
effects on the transition state, resulting in the exclusion of the least favourable 
conformations. 
 
The relative stereochemistry of the addition (syn or anti) is controlled by the enolate 
geometry, and therefore the initial ketone enolisation step.74 In general (Z)-boron 
enolates give syn-aldol products, with the anti-aldol adducts accessed via (E)-boron 
enolates. The selective enolisation of the ketones is controlled depending on the 
selection of ligand, leaving group and base.75 Sterically undemanding ligands, such as 
n-butyl, and a large triflate leaving group on the boron, in conjunction with a bulky 
base leads to the formation of the (Z)-boron enolate. The bulky triflate group must be 
orientated as shown in TS1 in Scheme 2.16 to limit the steric interactions with the 
ketone substituents, this forces the bulky base to deprotonate the least hindered proton 
in a trans manner. 
 
Generation of (E)-boron enolates requires the use of sterically demanding ligands, 
cyclohexyl for example, and a small leaving group such as a chloride. The chlorine 
atom not only reduces the steric implication, but more importantly, induces a strong 
anomeric effect through electron donation from the oxygen lone pair to the        
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boron-chlorine antibonding orbital (σ*). This forces the chlorine atom into a position, 
which eclipses the C=O bond, with the bulky ligands reinforcing this conformation as 
shown in TS2. This means the chlorine atom is now directed towards the hydrogen 
atoms, inducing a partial negative charge on the α-carbon and thus activating the 
molecule for cis deprotonation with an unhindered base (e.g. triethylamine). The 
anomeric effect is reduced as the dihedral angle (Cl-B-O=C) increases, therefore with 
the bulky triflate group described previously this electronic preference is diminished. 
 
 
 
Scheme 2.16: Selective formation of boron enolates 
 
The diastereoselectivity of boron aldol addition reactions was initially rationalised 
through the use of Zimmerman-Traxler chair transition state models as shown in 
Scheme 2.17 with a (Z)-boron enolate example.76 Here minimisation of the            
1,3-diaxial interactions between the ligand (L), the enolate side chain (R1) and 
aldehyde alkyl group (R3) places the R3 group in a pseudo-equatorial position, 
resulting in TS1, and a syn-aldol product. TS2 is disfavoured due to the 1,3-diaxial 
interactions between R1 of the enolate and R3 of the aldehyde and therefore unlikely to 
result in the anti-aldol product. 
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Scheme 2.17: Zimmerman-Traxler transition state model of (Z)-boron enolate aldol 
addition 
 
Whilst this chair transition state rationale held true for (Z)-boron enolate products, 
anomalous results for some (E)-boron enolate models have been observed which 
could not be rationalised using this transition state. An example of this is the poor 
aldehyde enantiofacial selectivity in the addition of a methyl-ketone derived boron 
enolate, using the isopinocampheyl (Ipc) ligand (Scheme 2.18).77 
 
 
 
Scheme 2.18: Anomalous enatiofacial selectivity 
 
These results, inconsistent with the rationale at the time, led to a thorough 
examination of the reliability of the chair transition state in boron aldol additions by 
Goodman and Paton.77 They used DFT computational analysis to assess the 
competing transition states for these types of additions and found that for (Z)-boron 
enolates the energetically favoured and therefore the predominant conformation is, as 
previously rationalised, the chair transition state (Figure 2.13). The two boat 
transition states for the (Z)-boron enolate led to 1,4-steric interactions between the 
enolate substituent and one of the ligands on the boron atom, destabilising the 
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transition states and leading to the increase in energy, relative to the chair 
conformation (1.30 and 3.37 kcal mol-1). For the (E)-boron enolates, however, there is 
greater competition between the possible transition states, ultimately resulting in the 
Boat A conformation being preferred. This is a result of the alleviation of the         
1,3-diaxial interactions between the boron ligand and enolate substituent experienced 
in the chair transition state (+0.55 kcal mol-1). It is, however, the small difference in 
relative energy between the two possible boat conformations (+0.67 kcal mol-1), 
attributed to the 1,3-diaxial interactions between the enolate and aldehyde groups, that 
results in a slight drop in diastereoselectivity. Using this work the relative populations 
of each transition state could also be calculated and predict the outcome of the 
additions of each enolate, with (Z)-boron enolates 100 : 0 in favour of the syn-adduct 
and (E)-boron enolates forming the anti-adduct more favourably in 87 : 13. 
 
 
 
Figure 2.13: Competing transition states (relative energies in kcal mol-1)77 
 
This new boat rational for the (E)-boron enolates enables the new transition state 
models to be drawn as shown in Scheme 2.19. Here TS1 is preferred as the            
1,3-diaxial interactions of R1 on the enolate and R3 of the aldehyde are minimised, 
leading to the anti-aldol adduct.77 In TS2, this interaction is clearly visible and 
therefore not favoured for production of the syn-product.  
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Scheme 2.19: Boat transition states for (E)-boron enolate aldol addition 
 
The absolute stereochemical outcomes of these aldol additions can be controlled in 
numerous ways. Evans has shown that with his oxazolidinone based chiral auxiliaries 
in conjunction with Bu2BOTf and Hünig’s base will give access to syn-aldol with 
excellent stereoselectivity (Scheme 2.20).78 Evans has also been able to gain access to 
the anti-propionate aldol product the use of thiazolidinethione chiral auxiliaries, 
catalysed by an Mg(II) source (MgBr2•OEt2) and triethylamine as base.79 Although 
both of these methods give excellent stereoselectivity the overall cost associated with 
the oxazolidinone (£46.40 per gram/£8,222 per mol) and thiazolidinethione (£50.80 
per gram/£10,634 per mol) chiral auxiliaries make them prohibitively expensive for 
any large scale synthesis. 
 
 
 
Scheme 2.20: Evans syn- and anti-aldol chemistry78,79 
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Alternatively the Paterson group have demonstrated chiral ethyl ketones obtained 
from inexpensive (S)-ethyl lactate (£0.05 per gram/£6 per mol), could be used to 
attain high degrees of both syn- and anti-selectivity in boron-mediated aldol additions. 
They showed that simply changing the protecting group could modulate the 
stereoselectivity, with a benzyl group leading to syn-aldol products and a benzoate 
ether protecting group affording anti-products (Scheme 2.21).74 
 
 
 
Scheme 2.21: Paterson chiral ethyl ketone aldol chemistry74 
 
The absolute stereochemistry of the anti-additions can be rationalised in the use of a 
benzoate ether in a position alpha to the initial chiral ketone, which dictates the         
π-facial selectivity through both electronic and steric contributions.74,80 The reaction 
must again be placed in to the lowest energy transition states, with the A1,3-strain 
between the aldehyde and enolate substituents minimised (Scheme 2.22). This offers 
two transition states, of which the Si-faced attack in TS1 is the lowest energy 
conformer, as it minimises the destabilisation that results from the lone pair repulsion 
between the n(O) enolate and the benzoyl group.  The A1,3-strain between the enolate 
methyl group and α-stereocentre is also minimised by placing the methyl 
pseudoequatorially. This placement results in the benzoate carbonyl being positioned 
so as to induce hydrogen bonding to the formyl proton, stabilising the transition state. 
Although this directs the benzoyl group into the transition state, the induced 
stabilisation explains the contrasteric, diastereoselective outcome of the reaction. 
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Scheme 2.22: Stereodirecting effect of benzoate ether 
 
2.3.4 Boron-mediated aldol addition for anti-C4-C5 bond construction 
 
The synthesis of the anti-C4,C5 product for leiodolide A, was investigated using the 
Paterson boron aldol methodology and the α-benzoyl ketone 106 derived from        
(S)-ethyl lactate (107), as outlined in Scheme 2.23.80 Weinreb amide 108 was formed 
from the lactate by addition of the Weinreb salt, N,O-dimethylhydroxylamine 
hydrochloride 109, activated by the non-nucleophilic Grignard iso-propylmagnesium 
chloride. Treatment of the amide with ethylmagnesium chloride at 0 ºC, followed by 
protection of the free hydroxyl as the benzoate ether gave ketone 106 in high yield 
over three steps. 
 
 
 
Scheme 2.23: Benzoyl ketone synthesis 
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The ketone was then submitted to the boron aldol addition reaction, with aldehyde 91, 
using dicyclohexylboron chloride and triethylamine as the base (Scheme 2.24). The 
resulting coupling was highly stereoselective with a diastereoselectivity of 97 : 3 
established through analysis of the 1H NMR spectrum.  
 
 
 
Scheme 2.24: Boron aldol reaction with benzoate ketone 106 
 
The expected anti-selectivity was confirmed using the 1H NMR data, with particular 
reference to the coupling constants of the protons at C4 and C5. In a nonpolar NMR 
solvent it is expected that a hydrogen bond will form between the carbonyl oxygen 
and the alcohol to give a pseudo-six membered ring, which results in two possible 
conformations for both the syn and anti-aldol products.81,82 The C4 and C5 protons of 
both the syn conformers adopt a gauche relationship, while in the anti-product only 
one conformation holds the protons gauche, in the other they are in an anti 
relationship (Figure 2.14). As a result, the coupling constants for syn-isomers are 
between 4-6 Hz and between 8-10 Hz for anti-adducts. Comparison of this Stiles-
House method with the data of 110 (the product of the boron aldol addition) is 
consistent with an anti-assignment given the 3J coupling constant of 8.7 Hz. 
 
 
 
Figure 2.14: 3J coupling constants for syn and anti aldol products 
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Confirmation of the stereochemistry allowed further elaboration of the aldol product 
110, which was subject to hydroxyl protection as the TIPS ether using 2,6-lutidine 
and TIPS triflate (Scheme 2.25). The resultant ketone 111 was then reduced with 
sodium borohydride, before subsequent cleavage of the benzoyl group with potassium 
carbonate yielding diol 112.80,83 
 
 
 
Scheme 2.25: Vicinal diol synthesis 
 
Sodium periodate cleavage of the vicinal diol 112 gave the desired aldehyde, with the 
mechanism proceeding via initial cyclic periodate ester formation. Subsequent 
breakdown of the periodate ester cleaves the C-C bond, releasing aldehyde 113 and 
acetaldehyde (Scheme 2.26).80 
 
 
 
Scheme 2.26: Periodate cleavage mechanism 
 
The aldehyde 113 was used immediately in a Masamune-Roush modified Horner-
Wadsworth-Emmonds (HWE) olefination for the final carbon chain extension, 
installing C1 and C2 in the molecule (Scheme 2.27).84 The use of a Li+ source forms 
a lithium chelate within the phosphonoacetate and enhances the acidity of the              
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α-protons, removing the requirement of a strong base. Using lithium chloride in 
conjunction with Hünig’s base resulted in homologation as anticipated, whilst also 
giving the desired alkene geometry in 61% yield over 2 steps. 
 
 
 
Scheme 2.27: Elaboration of diol 112 to completed anti-C1-C10 subunit 85 
 
The desired (E)-alkene in the product was confirmed through 1H NMR spectroscopy, 
the two vinylic protons having a coupling constant of 15.7 Hz, indicative of a trans 
double bond. The observed selectivity can be rationalised through comparison of the 
two addition pathways shown in Scheme 2.28.85 In the initial, reversible aldehyde 
step, the anti-product (a) forms faster than the syn-product (b) due to a minimisation 
of the steric hindrance between the aldehyde side group and the phosphonate group. 
The formation of the syn-oxaphosphetane intermediate (c), however, is much less 
favourable, again due to the higher levels of steric interaction than occurs in the 
formation of the anti-oxaphosphetane (d). The resulting formation of the                
syn-oxaphosphetane intermediate is much slower than both the reverse reaction (to 
starting materials) and the formation of the anti-oxaphosphetane. This extremely slow 
step has the effect of forcing the overall equilibrium of the reaction towards the 
formation of the anti-oxaphosphetane, overcoming the initial hindered step and 
therefore resulting in the (E)-alkene.  
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Scheme 2.28: HWE selectivity 
 
2.3.5 Boron-mediated aldol addition for syn-C4-C5 bond construction 
 
After the completion of the anti-C1-C10 subunit, attentions could turn to the          
syn-isomer synthesis, for which the (Z)-boron enolate was required. Although 
traditionally (Z)-boron enolates have been formed through the use of small ligands 
and large leaving groups on the boron atom, as shown in Scheme 2.16, both Paterson 
and Urpí have shown this to be possible by using c-Hex2BCl as the Lewis acid and 
varying the group alpha to the ketone.74,86 The Paterson work was based around a 
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benzyl substituent, whereas Urpí focused on the use of silyl ethers for the synthesis of 
syn-aldol adducts (Scheme 2.29) with marginally better diastereomeric ratios 
achieved with the silyl ether ketones. 
 
 
 
Scheme 2.29: Paterson and Urpí syn-boron aldol examples 
 
Urpí rationalised the synthesis on the anti-syn-product 114 (as shown in Scheme 
2.30) on competition of the reaction pathways.86 The formation of the (Z)-boron 
enolate could be achieved through two possible complexes: firstly through the 
chelation of boron with both the carbonyl and the α-silyloxy group, with concomitant 
displacement of the chloride from boron, as in C1, or through C2, in which the 
electrostatic interactions between the C-OB and the Cα-O dipoles result in an 
antiperiplanar arrangement to stabilise the less favoured trans-complex. It is also 
noted, however, that this stabilisation would also be apparent in C3, which would, in 
turn, lead to the (E)-boron enolate, and therefore the undesired anti-product via the 
previously described transition state. They reason that at low temperatures C1 will be 
the most favourable transition state, minimising the A1,3-strain and therefore proceed 
to the syn-aldol product. Warmer reaction conditions allow the higher energy 
conformer to be adopted and an inversion in stereoselectivity is observed. 
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Scheme 2.30: Diastereoselectivity with chiral 
 
The Urpí boron aldol methodology was adopted for the syn-C1-C10 subunit and the 
requisite α-TBS ketone was accessed from the previously synthesised Weinreb amide 
108 via silyl protection using TBSCl (Scheme 2.31).87 Subsequent treatment of amide 
115 with ethylmagnesium bromide yielded ketone 116.88 
 
 
 
Scheme 2.31: α-TBS ketone 116 synthesis 
 
With the ketone in hand, the boron aldol addition was attempted with aldehyde 91 and 
the desired syn-aldol product 117 achieved in good yield (Scheme 2.32). The product 
was confirmed as the syn-adduct through analysis of the coupling constants in the 1H 
NMR of 5.7 Hz, indicative of the syn-configuration.  
 
 
 
Scheme 2.32: Boron aldol conditions with α-silyloxy ketone 116 
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2.3.6 TiCl4-mediated aldol addition for syn-C4-C5 bond construction 
 
Further work by Urpí and co-workers, with titanium tetrachloride as the Lewis acid 
has also been shown to give access to the syn-aldol products.87,89 Using the α-silyloxy 
ketone and a range of aldehydes, including allylic examples, they were able to 
synthesise the syn-aldol adducts in excellent yield and diastereoselectivity (Scheme 
2.33). Following extensive NMR studies at low temperature (-78 ºC) they were able 
to show that the initial complex formed with the carbonyl and silyloxy group 
antiperiplanar to one another, minimising the dipole moments. The NMR 
investigation also gave clear evidence for the (Z)-titanium enolate with the 2D 
NOESY NMR revealing crosspeaks between the C=CH and the OTBS group, 
indicating they are in close proximity through space.89 
 
 
 
Scheme 2.33: TiCl4-mediated aldol addition 
 
The use of TiCl4 as the Lewis acid was implemented with ketone 116 and aldehyde 
91. This also gave access to the syn-aldol adduct, with indicative 1H NMR coupling 
constants of 5.7 Hz, in excellent yield (Scheme 2.34). The higher yield and simpler 
reaction procedure led to the TiCl4 aldol chemistry to be taken forward in place of the 
boron aldol chemistry for the syn-subunit. 
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Scheme 2.34: TiCl4 aldol addition and protection of syn-aldol product 117 
 
The elaboration of this fragment towards the final subunit was then undertaken 
following the methodology established in the synthesis of the anti-isomer. Protection 
of the free hydroxyl as the TIPS ether, using the triflate and 2,6-lutidine, was again 
efficient. 
 
Selective deprotection of the secondary TBS group in the presence of the newly 
formed secondary TIPS ether and TIPS-oxazole group was, however, more 
problematic. Under standard acidic conditions in methanol using p-toluenesulfonic 
acid or camphorsulfonic acid a complex mixture of degraded starting material was 
formed (Entries 1-3, Table 2.4). Using HF•pyridine in pyridine or HF (aq) was clean, 
however, only succeeded in cleaving the C-Si bond of the oxazole-TIPS group and 
not the desired O-TBS bond (Entries 4 and 5). Careful treatment of the silyl ether 
with 3 M HCl in methanol was successful in deprotecting the desired O-TBS bond 
(Entry 6). This also resulted in cleavage of the C-TIPS bond, but this is 
inconsequential, as the primary requirement of the group in preventing Stille coupling 
at the 2-position, had already been accomplished. It was necessary to actively monitor 
the reaction by TLC as, at around 50% conversion, the third silyl group began to 
cleave. At this point the reaction was quenched giving a 41% yield of diol 119, with 
the mass balance made up of unreacted starting material and further recycling enabled 
a 50% yield in total of diol to be achieved.  
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Table 2.4: Silyl ether cleave conditions 
 
Subjecting the vicinal diol to sodium periodate cleavage afforded aldehyde 120, 
which under the previous HWE olefination conditions gave access to the completed 
syn-C1-C10 subunit 84 in moderate yield over these two steps (Scheme 2.35). 
 
 
 
Scheme 2.35: Completion of syn-C1-C10 subunit 84 
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2.4 Summary 
 
In summary, although the practical application of the vinylogous Mukaiyama aldol 
addition in accessing the C1-C10 subunit in five steps was shown here, it was clearly 
not viable and required an alternative method. The key C4 and C5 stereocentres could 
be installed through the use of Paterson chiral ethyl ketone boron-aldol chemistry and 
provided a route to the anti-aldol product in ten steps, in the longest linear route, in an 
overall yield of 11%. The stereocentres were installed in the syn-product using a TiCl4 
Lewis acid method and enabled the final subunit to be synthesised in 7% yield, also 
over ten steps. This work also optimised the iodooxazole Stille cross coupling to give 
reliable results in good yield.   
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Chapter Three 
Synthesis of the C11-C20 subunit 
 
3.1 Retrosynthetic analysis 
 
After the difficulties encountered in the previous synthetic efforts towards the      
C11-C20 subunit within the group (Chapter One), it was necessary to develop a new 
strategy. The key lesson learned from the preceding work was to avoid highly 
oxygenated intermediates, especially those with numerous contiguous oxygen 
containing groups. It was also advisable to eschew the excessive use of bulky 
protecting groups where possible, thus preventing the chance of steric hindrance 
limiting reactivity. The newly proposed approach is shown in Scheme 3.1, with the 
C11-C20 subunit 65 envisaged to arise from the C2 symmetric diol core 121, a readily 
accessible tartrate derivative. The core could then be built up through a single 
olefination to furnish the C18-C19 alkene, before installing the unknown C13 
stereocentre through alkylation. The C13 containing fragment can be synthesised in 
both epimeric forms (122 and 123) via Myers alkylation methodology. This strategy 
enables rapid assembly of the subunit, while limiting the number of contiguous 
oxygen containing centres to four, with a maximum of six oxygen atoms present at 
any one time.  
 
 
 
Scheme 3.1: Retrosynthetic analysis of C11-C20 subunit 
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3.2 C11-C20 central core synthesis 
 
The starting point of the new strategy for the C11-C20 subunit synthesis was the 
inexpensive and commercially available (S,S)-tartaric acid 124. Use of this acid 
enabled the immediate installation of two hydroxyl stereocentres at C16 and C17, 
with the stereocentre at C17 ultimately being inverted in the Mitsunobu lactonisation 
step. Initial esterification of the acid to 125 then allowed the free hydroxyls to be 
protected as the cyclopentylidene acetal 126 (Scheme 3.2).90 It was envisaged, that by 
using a single and much smaller group to protect the two hydroxyls, that the 
previously observed problems associated with lack of reactivity would be greatly 
reduced. The use of the cyclopentylidene acetal also limits the free rotation of the 
molecule around the C16-C17 bond, this is again in an effort to improve reactivity 
and prevent the reacting centres from being folded into unfavourable conformations.  
 
 
 
Scheme 3.2: Esterification and protection of tartaric acid 124 
 
The diester 126 was then reduced to diol 127 with lithium aluminium hydride, before 
desymmetrisation via mono TBS protection (Scheme 3.3).91 At this point, the 
flexibility of the strategy allows the elaboration in either the northern or southern 
segments of the subunit from this alcohol, and the decision was taken to investigate 
the olefination and furnish the southern part of the molecule first. 
 
 
 
Scheme 3.3: Desymmetrisation of dimethyl tartrate 126 
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 3.3 Furnishing the southern segment of the C11-C20 subunit 
 
Initial olefination studies on the aldehyde, resulting from Swern oxidation of alcohol 
128, focused on the HWE reaction (Table 3.1). The Masamune-Roush conditions, 
which worked so effectively in the C1-C10 subunit were of key interest, unfortunately 
these were low yielding and gave no selectivity for the desired (E)-isomer (Entry 
1).84 The best E : Z selectivity that could be achieved for the HWE olefination was     
5 : 1 using barium hydroxide conditions (Entry 2),92 with the alkene geometry 
confirmed by nOe analysis of the reduced and separated products (Figure 3.1). 
 
 
 
Table 3.1: Olefination reaction comparison 
 
 
 
 
Figure 3.1: Comparison of the alkene geometry by nOe 
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Reverting to the classical Wittig reaction gave not only a significant increase in yield, 
but it also gave the unsaturated ester 129 as essentially one isomer (E : Z, 96 : 4) 
(Entry 3). The requisite ylide (130) was readily prepared in two steps from the 
bromopropionate 131 through initial phosphonium bromide 131 synthesis, followed 
by deprotonation to the phosphorane with NaOH (Scheme 3.4).93 With the Wittig 
product in hand, synthetic efforts now focused on the northern portion of the subunit 
containing the undefined C13 stereocentre. 
 
 
 
Scheme 3.4: Phosphorane synthesis 
 
3.4 Myers alkylation chemistry 
 
In the early 1990’s, the Myers group investigated the use of pseudoephedrine as a 
practical chiral auxiliary. The state-of-the art auxiliaries at the time, and still heavily 
utilised today, were the Evans oxazolidinones.94 These oxazolidinones are 
commercially available, at a considerable cost (Entries 1 and 2, Table 3.2) and are 
readily alkylated with predicable and high levels of diastereoselectivity (Scheme 
3.5).95 The requisite carboxylic acids, esters or primary alcohols can then be obtained 
by cleavage of the auxiliary. There are, however, limitations with oxazolidinone 
auxiliaries, in addition to the price, imide derived enolates only alkylate efficiently 
with reactive halides, for example allylic halides, and they are unreactive with n-alkyl 
iodides.  
 
  
 
Scheme 3.5: Evans oxazolidinone example94 
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Table 3.2: Cost comparisons of chiral auxiliaries 
 
Myers looked to address these limitations to provide a chiral auxiliary that was cheap 
and would undergo alkylation with a wide variety of alkyl halides, efficiently and 
with high diastereoselectivity.96–98 The first limitation is immediately rectified, as can 
be seen from Entries 3 and 4 in Table 3.2, pseudoephedrine is more than five times 
cheaper than the equivalent oxazolidinone, making it much more suitable for large 
scale industrial applications.  
 
Myers was able to show that pseudoephedrine 133 would readily undergo N-acylation 
(to 134 for example) in high yield, with a range of carboxylic acid derivatives 
(including both symmetrical and mixed anhydrides and acid chlorides), to form the 
corresponding tertiary amides. Although the presence of an external base was not 
found to be strictly necessary when using carboxylic acid anhydrides, reaction times 
could be greatly increased by the addition of triethylamine (1.2 eq) (Scheme 3.6). 
Acylation involving acid chlorides, however, does require a small excess of base to 
occur readily at 0 ºC. 
O NH
Bn
O
Ph
OH
N
H
O NH
Bn
O
Ph
OH
N
H
Chiral Auxilary Cost per gram
£11.46
£18.78
£2.43
£2.48
Cost per mole
£2029
£3326
£401
£410
 79 
 
 
Scheme 3.6: Myers’ pseudoephedrine acylation example96 
 
Selective alkylation of the pseudoephedrine amides could then occur via enolate 
formation with LDA, in the presence of lithium chloride (6.0 eq), followed by 
reaction with the alkylating agent. The resultant alkylation products were obtained in 
high yields (80-95%) and excellent diastereoselectivity (96-99% isolated de), with the 
incoming alkyl chain adding in a 1,4-syn manner to the methyl group on the chiral 
auxiliary (Figure 3.2).  
 
 
 
Figure 3.2: Mnemonic for pseudoephedrine amide enolate alkylation 
 
The lithium chloride was essential for ensuring that the alkylation proceeded to 
completion while also suppressing possible O-alkylation of the chiral auxiliary. A 
large excess of lithium chloride is required as the reaction rates are markedly slower 
and do not proceed to completion at lower concentrations. In the absence of lithium 
chloride the alkylation of pseudoephedrine propionamide with n-butyl iodide 
proceeded to only 32% conversion after 5 h at 0 ºC, however, the same reaction with 
6 eq of lithium chloride reached completion within 1.5 h. The diastereoselectivity 
observed in the product was not influenced by the presence or absence of the lithium 
chloride. It is believed that a large excess of lithium chloride is required to saturate 
the reaction as the solubility limit, under typical alkylation conditions, is 5 eq at 0 ºC 
and 6 eq at 23 ºC, therefore 6-7 eq is recommended to ensure lithium chloride 
saturation. The use of more than 7 eq of lithium chloride was found to have no 
discernible difference to rate, yield or diastereoselectivity. The specific role of the 
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lithium chloride has not yet been identified, but it has been postulated by Seebach that 
it may modify the aggregations state of the enolate in solution and in doing so, 
increase the reactivity.99 
 
The key advantage of this methodology is that electrophiles that do not react with the 
imide enolates (formed from oxazolidinones derivatives), such as primary alkyl 
halides, will undergo reaction with pseudoephedrine amide enolates (Entry 1, Table 
3.3). This is due to the pseudoephedrine amide enolates being highly nucleophilic and 
able to readily react even at -78 ºC (with slight de enhancement). This high 
nucleophilicity also enables efficient and highly diastereoselective reactivity of not 
only poorly reactive substrates, such as ß-oxygenated n-alkyhalides (Entry 2), but 
also ß-branched primary alkylhalides (Entry 3). This enhanced reactivity can also be 
attributed to the excellent thermal stability of the enolates, enabling alkylation 
reactions of these ordinarily unreactive species to occur at higher temperatures (23- 
45 ºC).  
 
  
 
Table 3.3: Pseudoephedrine amide alkylation examples98  
 
The efforts to understand the origins of the stereochemistry were hampered by 
unsuccessful crystallisation of the pseudoephedrine amide enolate. It is, however, 
suggested that the lithiated alkoxide, coordinated to solvent molecules, will block the 
ß-face of the (Z)-lithium enolate (top face in Figure 3.3). The alkylation is then 
forced to occur from the bottom face and results in the observed stereochemistry. For 
this to be a reactive conformer of the pseudoephedrine amide enolate the side chain 
must adopt a staggered conformer, with the C-H bond α to the nitrogen and lying in 
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the plane of the enolate oxygen. This staggered conformation is supported in evidence 
from the crystal structure of pseudoephedrine glycinamide monohydrate, which 
shows a minimisation of both allylic and torsional strains (Figure 3.4). This structure 
also places the second alkoxide on the ß-face of the enolate, which, when coordinated 
with a lithium cation, may offer further steric hindrance to that face.  
 
 
 
Figure 3.3: Proposed reactive enolate conformation98 
 
 
  
 
Figure 3.4: Crystal structure of pseudoephedrine glycinamide monohydrate98 
 
Diastereoselective synthesis of tertiary amides would be of little use to synthetic 
methodology unless the products could be turned into useful building blocks, 
therefore, Myers has developed a number of strategies to this effect. He has been able 
to directly transform these alkylated amides into chiral carboxylic acids, ketones, 
aldehydes and alcohols, all with high ee. It is the production of these primary alcohols 
that are of interest for the synthesis of the C13 containing fragment of leiodolide A. 
Initially he looked at expanding the work of Singaram et al and their use of the 
lithium pyrrolidide-borane reagent (LPT) after finding that pseudoephedrine amides 
are inert to lithium triethylborohydride and 9-BBN.98 Although LPT was found to be 
effective in certain cases, there were a number of problems encountered. These 
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included partial decomposition of starting materials and for one substrate, erosion and 
inversion in stereochemistry (Entries 1 and 2, Table 3.4). These problems were 
attributed to base-induced epimerisation of the intermediate aldehydes, with inversion 
occurring via enolisation of the aldehyde, facilitated by a chiral, pseudoephedrine-
derived base.  Subsequent enantioselective protonation and reduction yields the 
primary alcohol. It was also found that as a result of its size, LPT was inert towards 
more sterically hindered amides. To address these problems, Myers developed a new 
reagent in the form of lithium amidotrihydroborate (LAB) (Entries 3 and 4). LAB is 
prepared by the deprotonation of a borane-ammonia complex with a lithium base. 
Initially he reported the use of n-butyllithium, however, it was noted that this led to 
the formation of butylboron alkoxide products that were difficult to hydrolyse. 
Switching to LDA circumvented this problem, and also enabled the reduction to occur 
under milder conditions (0 ºC) before an acidic workup gave rise to a mixture of the 
desired alcohol and labile alkoxyboron species, which readily cleaved upon flash 
column chromatography. 
 
 
 
Table 3.4: Myers’ comparison of reductants98 
 
It is clear that this methodology provides a highly efficient route to enantioenriched 
primary alcohols and is therefore applicable to the synthesis of the C13 stereocentre 
containing fragment of leiodolide A. The inherent flexibility offered with this 
chemistry allows access to both of the required iodides (122 and 123), simply by 
changing either the configuration of the pseudoephedrine (d or l) or through varying 
the chain length of the acylating and alkylating agents.  
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3.4.1 Myers alkylation chemistry applied to (13R)-C11-C14 fragment 
 
The Myers alkylation was first applied to the (13R)-C11-C14 fragment, via initial 
acylation of (1S,2S)-(+)-pseudoephedrine with propionyl chloride, and a small excess 
of triethylamine, to give access to the propionamide 134 (Scheme 3.7).100,101 
Stereoselective alkylation of 134 using the standard Myers’ conditions (LDA (2.1 eq) 
and LiCl (7.0 eq)) for the generation of the enolate, followed by addition of iodide 
135 (formed in 2 steps from ethylene glycol 136)102 yielded tertiary amide 137. It 
should be noted that the lithium chloride must be thoroughly flame dried and stored 
under argon prior to use in the reaction, this is due to the highly hygroscopic nature of 
lithium chloride and any water of hydration present will quench the LDA and 
therefore limit the degree of enolisation. Upon formation of the enolate, the chiral 
auxiliary (as previously described) directs alkylation on to the bottom face of the 
molecule giving the desired diastereomer. 
 
 
 
Scheme 3.7: Installation of (13R) stereocentre 
 
The tertiary amide can then undergo reductive cleavage in the presences of LAB to 
produce the desired (13R) primary alcohol 138 (Scheme 3.8).103 
 
 
 
Scheme 3.8: Reductive cleavage to (13R) primary alcohol 
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The 1H NMR of the tertiary amide 137 is greatly complicated due to the rotameric 
nature of the product, and the slow interconversion of the rotational isomers about the         
N-C(O) bond on the NMR time frame.98 This makes identification of diastereomers 
extremely difficult via NMR and therefore the stereochemical assignments were 
confirmed through comparison of the optical rotation data with literature data for the 
cleaved products. The  +11.4 (c 1.0, CHCl3) for alcohol 138 was slightly larger 
than the literature value of  +9.8 (c 1.0, CHCl3).104  
 
3.4.2 Myers alkylation chemistry applied to (13S)-C11-C14 fragment 
 
Attention then turned towards the (13S)-subunit and using the same chiral auxiliary, 
as per the (13R)-enantiomer, however, this time the initial acylation installed the 
longer chain, and was followed by alkylation with methyl iodide. Changing the chain 
length of alkylating agent means that although the alkylation is still directed on to the 
same face by the pseudoephedrine auxiliary, the resulting stereochemistry is flipped 
with respect to the two methyl groups. The long chain acylating agent was 
synthesised by the ring opening and benzylation of γ-butyrolactone 139 to produce 
carboxylic acid 140.105 The in situ formation of the mixed pivaloyl anhydride of 140, 
followed by addition of pseudoephedrine, gave access to the long chain tertiary amide 
141 (Scheme 3.9).106  
 
 
 
Scheme 3.9: Synthesis of the long chain tertiary amide 
 
The amide 141 was then subjected to the standard alkylation conditions, with methyl 
iodide as the alkylating agent to produce the desired diastereoisomer 142, with an 
optical rotation of  +93.9 (c 1.87, CHCl3), consistent with the literature reported 
 +93.6 (c 1.88 CHCl3).106 Subsequent reductive cleavage, again, with LAB 
yielded the primary alcohol 143 in good yield (Scheme 3.10).107  
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Scheme 3.10: Synthesis of the (13S) primary alcohol 
 
The two epimeric alcohols could both be readily converted to the requisite iodides 
(122 and 123) under Appel conditions with iodine and triphenylphosphine (Scheme 
3.11). Iodide 122, with an optical rotation of  -5.0 (c 1.04, CHCl3), was much 
more consistent with the reported value of  -4.9 (c 1.0, CHCl3)104 than the 
precursor alcohol.  
 
 
 
Scheme 3.11: Synthesis of epimeric iodides  
 
3.5 C14-C15 bond construction 
 
With both the iodides (122 and 123) and the ester (129) in hand the alkylation could 
be investigated. This proceeded with initial TBS ether cleavage of 129 to the primary 
alcohol 144 (Scheme 3.12), which was followed by oxidation to aldehyde 145. 
Oxidation using either DMP or Swern conditions gave comparable results, but the 
Dess Martin protocol taken forward. 
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Scheme 3.12: Synthesis of aldehyde 145 
 
3.5.1 Kobayashi sulfonamide chemistry 
 
At this point it was anticipated that halogen exchange of iodide 122 or 123 with a 
metal would enable alkylation of the aldehyde. It was also hoped that it would be 
possible to get some level of stereocontrol over this addition so as to install the 
desired stereochemistry at C15 for leiodolide A. One such method to gain 
stereoselectivity is to utilise a modified Lewis acid and an electron withdrawing chiral 
ligand, which will not only impart the stereoselectivity but also increase the acidity, 
and therefore reactivity, of the Lewis acid. Work by Kobayashi has shown that the use 
of chiral sulfonamides and organozinc reagents could enable catalytic enantioselective 
alkylation to a range of aldehydes.108 Sulfonamides were chosen due to their increased 
acidity (relative to alcohols), their ease of synthesis from a variety of chiral amines 
and also because the rotation about the S-N bond should be restricted in the chiral 
metal complex and therefore form a more rigid and effective chiral environment. 
Initial investigation of the alkylation of benzaldehyde using diethylzinc and N,N'-
((1R,2R)-cyclohexane-1,2-diyl)bis(trifluoromethanesulfonamide) 146 as the chiral 
ligand were disappointing, with only moderate yield and enantioselectivity (Scheme 
3.13). It was assumed that the zinc complex 147 was not a strong enough Lewis acid 
to activate the aldehyde for alkylation, even in the presence of the electron 
withdrawing ligand.  
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Scheme 3.13: Initial Kobayashi investigation108 
 
However, use of titanium isopropoxide (0.048 eq) as the Lewis acid led to both a 
greatly improved yield and enantioselectivity (Scheme 3.14), through the formation 
of the chiral ethyltitanium complex 148. This complex is more reactive than other 
ethylmetal species that could potentially be generated due to the electron withdrawing 
effect of the sulfonamide. Kobayashi also found that increasing the equivalents of 
Ti(Oi-Pr)4 (to 1.2 eq) had no effect on the enantioselectivity confirming their 
assumption of 148 being the active species. It was further noted that the reaction 
showed excellent levels of catalytic efficiency as reduction of the sulfonamide to only 
0.0005 eq saw negligible drop in yield (97%) and ee (98%). 
 
 
 
Scheme 3.14: Kobayashi alkylation example108 
 
Finally, Kobayashi was able to demonstrate the enantioselective process on both 
longer chain dialkylzinc compounds to yield 149 (Figure 3.5) and also with alkyl 
aldehydes, albeit in some cases with a slight erosion in ee for 150 or a small drop in 
yield for 151.108 
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Figure 3.5: Further Kobayashi alkylation examples108 
 
3.5.2 Knochel’s application of sulfonamide chemistry 
 
This sulfonamide catalysis chemistry was also demonstrated by Knochel in his 
enantiomerically pure synthesis of 2,5-disubstituted cis- and trans-tetrahydrofurans.109 
In this case the dialkylzinc compounds were formed via iodide-zinc exchange, 
mediated by diethylzinc, followed by reaction with the aldehyde in the presence of the 
Lewis acid and chiral ligand. Knochel’s work showed that the chemistry was also 
viable with polyoxygenated side chains on both the organozinc reagent and the 
aldehyde (Scheme 3.15). 
 
 
 
Scheme 3.15: Knochel demonstration of sulfonamide catalysis 
 
3.5.3 Application of sulfonamide chemistry to leiodolide A 
 
Following the precedent set by Knochel, it was envisaged that a dialkylzinc 
intermediate 152 could be formed through iodide-zinc exchange with either iodide 
122 or 123 (Scheme 3.16). This would then undergo directed addition to aldehyde 
145 to yield the required alcohol stereochemistry and complete the carbon backbone 
of the C11-C20 subunit. Unfortunately, in our hands this chemistry failed to produce 
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the desired alcohol 153, with no reactivity observed, the only detected products of the 
reaction being the products of the dehalogenation of iodide 122 and reduction of the 
aldehyde 145. 
 
 
 
Scheme 3.16: Sulfonamide catalysis attempt on aldehyde 145 
 
3.5.4 Investigation of lithiating agents on the alkylation 
 
Given the inherent complexity of the Kobayashi methodology in incorporating the 
alkyl addition and stereoselectivity into a single step, the decision was taken to 
separate the two steps instead. Therefore, an alkylation step to install all the required 
carbons could be carried first, followed by installation of the desired stereochemistry. 
This centre would most likely be installed through oxidation of the resultant alcohol 
and then diastereoselective ketone reduction. The alkylation was investigated by 
transmetallation onto zinc (Entry 1, Table 3.5) and through the use of numerous 
lithiating reagents (Entries 2 and 3).110,111 The reaction conditions employed are 
summarised in Table 3.5, however none of the various attempts succeeded in 
producing any of the anticipated alcohol 153, with just deiodinated starting material 
recovered.  
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Table 3.5: Attempted alkylation conditions 
 
At this point it was thought that the presence of the ester group could be preventing 
reaction due to the inherent constraint of the conjugated system, some of this 
constraint could therefore be removed by reduction of the ester in the hope of 
increasing reactivity. The synthesis returned to post olefination product 129, which 
could undergo reduction to the primary alcohol (154) with diisobutylaluminium 
hydride (DIBAL) (Scheme 3.17). At this point, the small impurity of the minor      
(Z)-isomer, resulting from the Wittig olefination, could be separated via column 
chromatography and the major (E)-isomer taken forward exclusively. The free 
hydroxyl group was then protected, as the para-methoxybenzyl (PMB) ether 155, in 
good yield. The orthogonal PMB group was chosen to enable selective deprotection 
of the TBS group at a later stage. 
 
 
 
Scheme 3.17: Reduction and protection of Wittig product 
 
In an analogous manner to the ester containing series, the TBS group was cleaved 
with TBAF, followed by oxidation of the resultant alcohol 156 to aldehyde 157 with 
DMP, both in excellent yield (Scheme 3.18).  
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Scheme 3.18: Synthesis of aldehyde 157 
 
At this point, the most promising lithiation conditions from the previous alkylation 
attempts were explored with aldehyde 157 (Table 3.6). This included halogen 
exchange with both t-BuLi and LiDBB, however once again no reactivity (to alcohol 
158) was observed. The lithiation methodologies were also repeated with the 
truncated, pre-Wittig aldehyde but again, all suffered with the same lack of reactivity. 
 
 
 
Table 3.6: Alkylation attempts on reduced aldehyde 157 
 
3.5.5 Weinreb amide methodology for the (13R) subunit 
 
The poor reactivity of this aldehyde was reminiscent of the previous work on this 
subunit and therefore a new approach was required to enable reactivity and the 
desired connectivity. Previous literature work with the iodides derived from the 
pseudoephedrine chemistry has shown that alkylation into Weinreb amides to be 
feasible.104 Alkylation of the Weinreb amide would then result in the ketone that 
could be selectively reduced to install the C15 stereocentre. An initial small scale, 
model reaction was carried out to assess the viability of this chemistry in the case of 
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the C11-C20 subunit. The model study started with the pre-Wittig alcohol (128), 
which, under Swern conditions, followed by Pinnick conditions was oxidised to the 
carboxylic acid 159 (Scheme 3.19). Subsequent conversion of 159 to the Weinreb 
amide was achieved using N,N’-dicyclohexylcarbodiimide (DCC). 
 
 
 
Scheme 3.19: Model Weinreb amide synthesis 
 
The side chain iodide 122 then underwent lithium-halogen exchange, with t-BuLi as 
the lithiating agent, before addition to Weinreb amide 160 (Scheme 3.20). 
Gratifyingly, this resulted in the required coupling to yield ketone 161 in modest 
yield. This successful coupling allowed the synthesis to move forward, although 
unfortunately not from ketone 161.  Even though the inherent flexibility of the subunit 
could allow the Wittig olefination to occur after the alkylation, in this iteration, the 
two primary TBS ethers are indistinguishable and therefore a strategy redesign was 
necessary.  
 
 
 
Scheme 3.20: Alkylation of model system 
 
Attentions instead turned back to the post-Wittig PMB ether series. Oxidation of 
alcohol 156 gave access to carboxylic acid 162, which in turn could be converted to 
the Weinreb amide 163 in excellent yield over the three steps (Scheme 3.21).  
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Scheme 3.21: Synthesis of Weinreb amide 163 
 
Treatment of the Weinreb amide 163 with the lithiated side chain was effective in 
producing ketone 164 and completed the carbon backbone for the C11-C20 subunit, 
in 67% yield on half-gram scale (Scheme 3.22). 
 
 
 
Scheme 3.22: Completion of the carbon backbone of the C11-C20 subunit 
 
Successful alkylation of the Weinreb amide resulted in the ketone at C15, which 
required selective reduction and methylation to produce the desired functionality in 
leiodolide A. A preliminary reduction of the model ketone 161, under Luche 
conditions, was promising for future efforts on the full subunit (Scheme 3.23). 
Although there was no diastereoselectivity, the good yield demonstrated that the 
ketone could be readily reduced to alcohol 165. 
 
 
 
Scheme 3.23: Model Luche reduction 
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3.6 Diastereoselective C15 reduction investigation 
 
The full subunit was then subjected to a variety of reducing agents to investigate the 
reduction and an attempt to impart the desired diastereoselectivity, as outlined in 
Table 3.7. An early observation of the reduction was that over the temperature range 
0 ºC to RT the reaction rate was very quick but with no selectivity (Entry 1). At a 
much lower temperature of -78 ºC the reduction was extremely slow, but gave modest 
diastereoselectivity (Entry 2) therefore reaction vessels were left for prolonged 
periods of time (18 h) at -78 ºC using a cryocool apparatus. 
 
 
 
Table 3.7: Comparison of C15 reduction 
 
Initial work using the bulky reducing agent lithium tri-tert-butoxyaluminium hydride 
(Li(Ot-Bu)3AlH) gave a good yield, but relatively poor selectivity, at -78 ºC (Entry 
2). Employing zinc borohydride as the reducing reagent led to an improved 
selectivity, however, poor reactivity only enabled a maximum conversion of 63%, 
even after extended reaction times (Entry 3).112,113 The Selectride® series of reducing 
agents showed an enhancement in selectivity. A small improvement over               
Li(Ot-Bu)3AlH was observed with L-Selectride® (Entry 4). Gratifyingly the best 
diastereoselectivity of 6.4 : 1 achieved with K-Selectride® (Entry 6).114 In contrast 
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using N-Selectride®, however, caused an inversion in diastereoselectivity to 1 : 2.6 
(Entry 5). 
 
There is literature precedent for this type of reduction, adjacent to a cyclopentylidene 
acetal, from Roush’s synthesis of the durhamycin A (Scheme 3.24).115 In this case 
under Luche conditions the (S)-configured alcohol was accessed in good yield and 
selectivity. 
 
 
 
Scheme 3.24: Selective reduction in durhamycin A synthesis 
 
It can be envisaged that, in the reduction at C15 of the C11-C20 subunit, the 
selectivity observed with Li(Ot-Bu)3AlH and L- and K-Selectride® arises from Felkin 
control,116 with the hydride attacking the carbonyl via the least  hindered approach 
(TS1, Figure 3.6). This approach is more favourable over the possible approach via 
TS2, which would force the hydride to pass within close proximity of the bulky 
carbon chain substituent. 
 
 
 
Figure 3.6: Felkin model for reduction 
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The zinc borohydride reduction, however, would be expected to chelate with the 
carbonyl and adjacent oxygen and undergo chelation-controlled hydride attack as 
shown in TS3 of Figure 3.7.112 This clearly not occurring as the selectivity with zinc 
borohydride is still for the (S)-configured alcohol, which is not preferred via the 
chelation model. One possible rationale for the observed stereochemical outcome 
could be chelation with the oxygen beta to the carbonyl and thus forming a             
six-membered chelate (TS4). This would then lead to attack on the opposite face of 
the carbonyl and result in the 1,2-syn diastereoselectivity. 
 
 
 
Figure 3.7: Chelation model for reduction 
 
The flip in selectivity witnessed with N-Selectride® is interesting as the active 
reducing agent in all of the Selectrides® is the same (tri-sec-butylborohydride) with 
the only difference being the counter ion. In the case of N-Selectride®, the sodium ion 
must be causing the substrate to adopt a different conformation and thereby impart the 
reversed selectivity. This could be rationalised to be occurring via a chelation model 
akin to TS3, with the sodium ion chelating between the carbonyl and the alpha 
oxygen, directing the hydride onto the opposite face. Although not perfect, the         
K-Selectride® reduction conditions were carried forward as they gave the best 
selectivity, and consistent yield. 
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3.7 Determination of the C15 absolute stereochemistry  
 
An established method of determining the absolute configuration of secondary 
alcohols is through the use of a chiral derivatising agent (CDA), the most common of 
these being the formation of α-methoxy-α-trifluoromethylphenylacetate (MTPA) 
esters, and 1H NMR analysis. The initial method was introduced in 1973 by Mosher 
and Dale,117,118 before being taken forward by Kakisawa and co-workers with their 
advanced Mosher method.119 This method requires the preparation of the (R)- and   
(S)-MTPA esters of the secondary alcohol, through esterification with either the        
α-methoxy-α-trifluoromethylphenylacetic acid (MTPAA) or acid chloride. 
Anisotropic effects imparted by the phenyl group of the CDA on the substrate 
substituents results in shielding/deshielding in these positions depending on the 
configuration of the compound (Figure 3.8). This effect, through comparison of the 
1H NMR data variation, allows a correlation to be made regarding the spatial 
positions of the alcohol substituents with respect to the CDA. The difference between 
the shielding for a specific proton is expressed as Δδ(S-R), and is equal to the chemical 
shift of the (S)-MTPA ester minus the chemical shift of the (R)-MTPA ester. Those 
protons shielded in the (S)-MTPA derivative are shifted upfield in the 1H NMR 
spectrum, and therefore show a negative Δδ(S-R) opposed to those shielded in the     
(R)-MTPA derivative expressing positive Δδ(S-R) values. 
 
 
 
Figure 3.8: Planar arrangement of the (R)- and (S)-MTPA esters 
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method was attempted to synthesise the (R)-MTPA ester 167, unfortunately due to a 
lack of reactivity it was necessary to convert the (R)-MTPAA into the (S)-MTPA acid 
chloride in order to produce a sufficient amount of ester 168 to carry out the analysis. 
The data obtained from esters 167 and 168 is shown in Table 3.8, with the protons 
H1-H4 shielded in the (R)-MTPA ester (Ha, Hb, Hc in Figure 3.8), therefore a positive 
Δδ(S-R) value recorded. The Δδ(S-R) value is negative for the protons H5-H7 (Hx, Hy, Hz 
in Figure 3.8), which are shielded in the (S)-MTPA ester. These values enable the 
alcohol 166 to be assigned as the (15S)-configuration, the desired stereochemistry for 
leiodolide A.  
 
 
 
Table 3.8: 1H NMR data comparison for (R)- and (S)-MTPA esters 
 
3.8 Final functional group manipulation of C11-C20 subunit 
 
With the stereochemistry at C15 assigned, the final step in completing the C11-C20 
subunit is conversion of alcohol 166 into the required methyl ether 169 (Scheme 
3.25).93 This was achieved through a Williamson ether synthesis using sodium 
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hydride to deprotonate the alcohol, followed by SN2 substitution of methyl iodide 
with the resulting alkoxide. 
 
 
 
Scheme 3.25: Methylation of C15 hydroxyl 
 
3.9 Completion of the (13S)-C11-C20 subunit 
 
With a route now set for the synthesis of the completed (13R)-epimer, the antipodal 
subunit 170 was synthesised using the established Weinreb amide methodology and 
iodide 123. The alkylation coupling was carried out in good yield, with fresh t-BuLi 
vital for consistent yields in the reaction (Scheme 3.26). Subsequent reduction to 
alcohol 171 with K-Selectride® and formation of the methyl ether 172 were also both 
achieved in good yield. 
 
 
 
Scheme 3.26: Synthesis of 13S C11-C20 subunit 
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The C15 stereocentre was assigned through comparison of the 13C NMR data of 171 
with the previously synthesised subunit 166 as displayed in Figure 3.9. This 
comparison showed that there was very little variation in the data around the C14-C18 
region of the molecule and could therefore be assigned as the 1,2-syn-diastereomer 
analogous to subunit 166. This reduction also showed that the C13 stereocentre has 
little bearing on the overall selectivity of the reaction, with only a slight erosion in the 
diastereoselectivity. This gives further evidence that the oxygenated cyclopentylidene 
acetal side of the molecule is driving the selectivity rather than the alkyl chain. 
 
 
 
 
 
Figure 3.9: 13C NMR data comparison between alcohols 166 and 171 
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3.10 Summary 
 
The subunit was successfully synthesised in fifteen steps in the longest linear 
sequence, with an overall yield of 7% for both diastereomers. Evolution of the 
synthetic route was required in order to overcome several problems encountered 
during the synthesis, most notably employing Weinreb amide 163 in the completion 
of the subunit carbon backbone. The use of the cyclopentylidene acetal protecting 
group on the tartrate core and limiting the number of oxygen containing groups, as 
proposed in the retrosynthetic strategy, also increased the reactivity of the 
intermediates, unfortunately not sufficiently to allow direct alkylation of aldehydes 
145 or 157. Completion of the subunit enabled the total synthesis to move forward 
and allowed an investigation of the coupling strategy to proceed, which is detailed in 
Chapter 4. 
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Chapter Four 
Construction of the C10-C11 bond 
 
4.1 Coupling strategy 
 
With access to both syn- and anti-configured C1-C10 subunits (84 and 85), both C13 
epimers of the C11-C20 subunit (169 and 172) accomplished and the C21-C25 side 
chain previously synthesised,35 attention turned towards their coupling to assemble 
the carbon backbone of leiodolide A. Connectivity between C10 and C11, followed 
by cleavage of the C5 TIPS ether would give access to intermediate 173 (Scheme 
4.1), which will be key in assignment of the stereochemistry at C4 and C5, potentially 
allowing the assignment to be made early, negating the necessity of completing  
multiple syntheses of diastereomers. This could be attained as data is provided in the 
isolation paper for two ring-opened derivation products (19b and 20),23 which could 
be used in a comparison study, especially with derivative 20 having an acetonide 
moiety installed across the two oxygen atoms, C16 and C17, consistent with the acetal 
in the C11-C20 synthetic subunits 169 and 172.  
 
While comparisons between the authentic and synthetic data sets may not be able to 
identify the C13 configuration, it will certainly offer insight into the assignment at C4 
and C5, with the right hand side of the molecule sets being identical in functional 
group construction. If the configuration of C4 and C5 can be confirmed considerable 
time could be saved in the final total synthesis, with six fewer diastereoisomers 
requiring synthesis and just a single stereocentre (C13) to be assigned. 
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Scheme 4.1: Intermediate 173 and isolation paper derivatives (19b, 20 and 20b) 
 
4.2 Suzuki-Miyaura cross-coupling 
 
Our strategy was based upon an sp2-sp3 coupling between the oxazole at C10 and the 
alkyl chain of the C11-C20 subunit. Unfortunately there have only been a handful of 
examples in this area and very few directly concerning an oxazole.120 One example of 
an sp2-sp3 coupling is the Suzuki-Miyaura cross-coupling reaction which was used by 
Marshall and co-workers to great effect in their total synthesis of the natural product 
discodermolide (Scheme 4.2).121 The Suzuki-Miyaura cross-coupling follows a 
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similar catalytic cycle as that of the Stille reaction outlined previously, however, the 
transmetallation step involves a boronic acid or ester, in conjunction with a base, 
rather than the stannane.122 In the case of Marshall’s work the late stage coupling is 
between an alkyl iodide and a vinyl iodide. The first step was formation of the 
boronate complex (174) from alkyl iodide 175 via the lithiated species, which was 
then added to the vinyl iodide (176), pretreated with base and palladium catalyst to 
give coupled product 177 in good yield.  
 
 
 
Scheme 4.2: Suzuki coupling in Marshall’s discodermolide synthesis122 
 
Manipulation of subunit 169 was required to begin an investigation into this coupling 
strategy and began through TBS ether cleavage with TBAF (Figure 4.3), followed by 
Appel iodination of the resultant alcohol 178 to give the required iodide (179), in 
excellent yield.  
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Scheme 4.3: Synthesis of alkyl iodide 179 
 
A preliminary study into the coupling was then carried out using the alkyl iodide 179, 
which using the Marshall conditions was converted into the requisite boronate 
complex before coupling with phenyl iodide to give 180. This initial reaction gave 
promising results and the desired bond construction occurring, with a diagnostic 
signal in the 1H NMR at 2.62 ppm for the -CH2Ph protons. 
 
 
 
Scheme 4.4: Model Suzuki coupling 
 
To test the coupling on the real substrate the 2-iodooxazole anti-C1-C10 subunit 181 
was accessed through treatment of 85 with iodine and TBAF (Scheme 4.5), using a 
method adapted from Inoue and co-workers iterative poly-oxazole coupling work.123 
This protocol did give access to the desired iodide in moderate yield, but it also gave 
rise to a large amount of desilylated product 182. Unfortunately further optimisation 
of reaction conditions failed to give an increase in the amount of the desired iodide 
compound. 
O
O
OPMB
OMe
13 OTBS
169
O
O
OPMB
OMe
13 OH
O
O
OPMB
OMe
13 I
178
179
TBAF, THF, 0 ºC, 2 h
99%
I2, Ph3P, Im, RT, 1 h
97%
O
O
OPMB
OMe
13 I
179
1. t-BuLi, Et2O, -78 ºC, then    9-BBNOMe, THF, -78 ºC to RT, 1.25 h
2. PhI, PdCl2(dppf), K2PO4, DMF, RT, 18 h
O
O
OPMB
OMe
13 Ph
180
 106 
 
 
Scheme 4.5: Iodination of the oxazole subunit 
 
Repeating the model reaction conditions with the C1-C10 substrate failed to give rise 
to the desired coupled product 183 (Scheme 4.6). Instead the de-iodination products 
of both 179 and 181 were observed. This suggests that while oxidative insertion into 
the iodine-carbon bond of the oxazole has taken place, the required transmetallation 
with the boronate complex failed to occur. One possible reason for this lack of 
reactivity could be the bulky TIPS group at C5 providing steric hindrance, and thus 
preventing the transmetallation. 
 
 
 
Scheme 4.6: Attempted C10-C11 coupling 
 
To investigate this possible interaction the conditions were repeated towards 184 with 
the smaller diiodooxazole 88 but unfortunately the same lack of reactivity was 
observed (Scheme 4.7), with de-iodinated starting materials recovered. Although 
there were some early optimistic results this potential coupling method was 
abandoned. 
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Scheme 4.7: Model oxazole cross coupling  
 
4.3 C-H activation coupling 
 
Another possible method of forming the C10-C11 bond, predominantly focused on an 
oxazole moiety is the work of Hoarau, who was able to couple ethyl oxazole-4-
carboxylate (185), in the 2-position, to a range of benzylic, allylic and alkyl halides 
(186).124 This methodology uses a palladium acetate catalyst in conjunction with the 
JohnPhos ligand and a metal carbonate base (Scheme 4.8).  
 
 
 
Scheme 4.8: Hoarau’s C-H activation and coupling of oxazole124 
 
Mechanistic studies for the addition proposed a strongly base assisted, palladium 
catalysed, non-concerted metallation-deprotonation (nCMD) mode of action (Scheme 
4.9).125 Initial insertion of the palladium into the carbon-halide bond is followed by 
coordination of the palladium to the carbonate base and the nitrogen on the oxazole 
ring, enhancing the acidity of the proton at the 2-position. Subsequent directed 
deprotonation of this position and formation of the carbene allows a 1,2-shift of the 
palladium to the 2-position before eventual reductive elimination. 
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Scheme 4.9: C-H activation and nCMD mechanistic pathway125 
 
This coupling strategy was attempted for leiodolide A (Scheme 4.10), using the 
desilylated product 182, by product of the iodination, and the iodide 179. 
Unfortunately, the desired product 183 was not produced, instead the product of 
coupling an acetate ligand, from the palladium catalyst, to the C11 position was 
observed. The expected catalytic cycle can be used to rationalise this result, with the 
initial insertion of the palladium into the carbon-iodide bond at C11 occurring. At this 
point it appears that the coordination with the oxazole did not occur and reductive 
elimination of the palladium resulted in the acetate-carbon bond forming.  
 
 
 
Scheme 4.10: C-H activation coupling attempt 
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4.4 Myers tosylhydrazone chemistry 
 
Moving away from catalytic couplings processes, attentions turned to a reductive 
alkylation method developed by Myers and Movassaghi, which enables alkylation of 
aldehydes with simultaneous deoxygenation.126 This methodology involves formation 
of an aldehyde tosylhydrazone, followed by treatment with TBSOTf in the presence 
of triethylamine, to yield the N-silylated tosylhydrazone (Scheme 4.11). This 
hydrozone then undergoes the subsequent 1,2-addition of an organolithium species, 
which following warming and addition of acetic acid and trifluoroethanol leads to the 
elimination of p-toluenesulfinic acid and protodesilylation to the diazene. A final 
radical loss of dinitrogen gives access to the alkylated product. 
 
 
 
Scheme 4.11: Myers-Movassaghi reductive alkylation pathway126 
 
Myers and Movassaghi were able to use this alkylation strategy on a range of 
aldehydes with a representative aromatic example shown in Scheme 4.12, with the 
addition of phenyllithium into tosylhydrazone 187 to give 188 in good yield. 
 
 
 
Scheme 4.12: Reductive alkylation example with phenyllithium126 
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Application of this methodology to leiodolide A requires the aldehyde 189, obtained 
via Dess Martin oxidation of alcohol 178, which was used without further purification 
in the condensation with tosylhydrazine to give tosylhydrazone 190 (Scheme 4.13). 
The product of subsequent silylation of hydrazone 190 was also used immediately due 
to their propensity to readily hydrolyse, especially on silica gel. Regrettably treatment 
with the lithiated oxazole subunit 191 failed to yield any of the desired product 183, 
with oxazole starting material recovered. There was also no reactivity observed with 
phenyllithium as the alkylating agent. 
 
 
 
Scheme 4.13: Reductive alkylation attempt for leiodolide A 
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4.5 Alkylation and deoxygenation 
 
Failure of the previous methods to form a bond between an oxazole moiety and the 
C11-C20 subunit led to a model system study based solely on establishing this type of 
bond juncture. This investigation utilised citronellol as the C11-C20 subunit mimic 
and the previously synthesised diiodooxazole (88) in place of the C1-C10 subunit. 
Oxidation of the citronellol (192) under Swern conditions gave access to citronellal 
(193), which gratifyingly, when treated with lithiated oxazole yielded alcohol 194, 
with a bond between the 2-position on oxazole and the hydroxyl carbon (Scheme 
4.14). This alcohol was then subjected to Barton-McCombie radical deoxygenation127 
through synthesis of xanthate 195, followed by treatment with tributyltin hydride and 
initiator AIBN, to give the alkyl oxazole 196.128 
 
 
 
Scheme 4.14: Model alkylation and deoxygenation route 
 
Following this success, the methodology was expanded to the Stille coupled oxazole 
fragment 93 following protection as the benzyl ether 197 (Scheme 4.15). Addition of 
n-BuLi to the oxazole, followed by benzaldehyde, unfortunately resulted in no 
formation of the desired product 198, instead addition of a butyl group into the 
aldehyde was observed (199). This result implies that n-BuLi was ineffective in 
lithiating the oxazole 2-position, which therefore resulted in the butyl addition. 
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Scheme 4.15: Attempted alkylation oxazole fragment 198 
 
Due to time constraints it was not possible to further investigate the lithiation 
methodology on either iodooxazole anti-C1-C10 subunit 181 or oxazole syn-C1-C10 
subunit 84 with the C11-C20 aldehyde 189. The coupling is, however, tantalisingly 
close and this route has the potential to afford the coupled intermediate 173, thereby 
offering an opportunity for comparison of the C4,C5 stereochemistry with the natural 
product derivatives.  
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Chapter Five 
Summary and future work 
 
5.1 Summary 
 
The synthetic work outlined has provided access to the major subunits of leiodolide 
A, while also overcoming several unforeseen difficulties and especially the 
complications arising due to the stereochemical discrepancies and ambiguity in the 
original isolation paper. Completion of the two core subunits offers a solid foundation 
for the total synthesis of the natural product and ultimately accomplishing the overall 
aim of the project in assigning the absolute stereochemistry of leiodolide A.  
 
The work building on the previous 1,2-syn vinylogous Mukaiyama aldol studies35 and 
the possible application to the C1-C10 subunit was disappointing and ultimately  
found to be to a non-viable route. Revising the approach, however, allowed access to 
both the syn- and anti-adducts using α-substituted chiral ethyl ketones and the 
titanium and boron chemistry respectively, circumventing this problem and giving a 
practical route to the completed subunit (Scheme 5.1). The Stille coupling strategy 
was also found to be feasible for the installation of the oxazole moiety, with 
optimisation of the reliability of the reaction essential in enabling the completion of 
the C1-C10 subunit in either syn or anti form. 
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Scheme 5.1: Summary of C1-C10 subunit synthesis  
 
The work on the C11-C20 subunit using a C2-symmetric acetal-tethered core was also 
able to overcome some of the previously observed difficulties in reactivity (Scheme 
5.2), however, alkylation into the aldehyde was still found wanting. This could be 
improved by employment of a Weinreb amide, followed by diastereoselective 
reduction under Felkin-Ahn control. The Weinreb amide enabled the installation of 
both epimers of the C13 containing fragments, synthesised through the use of Myers 
alkylation chemistry. Application of a Wittig reaction over HWE olefination was also 
significant in providing the desired alkene geometry in good yield. 
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Scheme 5.2: Summary of C11-C20 subunit synthesis 
 
5.2 Future work 
 
Looking towards the future, now would be an optimal time to complete the 
computational chemistry investigations. Synthetic routes are now in place to produce 
all the subunits required for the eight possible diastereomeric isomers of leiodolide A, 
so any direction towards the most likely structure at this point could prove invaluable 
for efficiency in total synthesis completion. 
 
With all three subunits in hand significant headway has been made towards the 
coupling of the two major subunits, with some success achieved through alkylation in 
the model study. Moving forward, it is hoped that replacing the diiodooxazole with 
the lithiated C1-C10 subunit 191 (Scheme 5.3) and aldehyde with 189, with 
subsequent xanthate formation and elimination to complete the deoxygenation will 
give advanced intermediate 183. At this point cleavage of the C5 silyl ether would 
give access to 200, which can be used for comparison with the previously described 
natural product derivative 20.23  
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Scheme 5.3: Synthesis of advanced intermediate 183 
 
At this point deprotection of the cyclopentylidene acetal and unveiling of the seco-
acid at C1 will set the scene for a Mitsunobu macrolactonisation, with inversion of the 
hydroxyl at C17 (Scheme 5.4). The formation of the macrolide core (201) also offers 
another opportunity to compare the synthetic data to that of the natural product to gain 
further insight into the C4,C5 stereochemistry. Finally cleavage of the PMB ether at 
C20 and subsequent formation of allylic carbonate 202 offers the coupling partner for 
palladium-mediated π-allyl Stille coupling of the C21-C25 stannane side chain.129 
Global deprotection of the remaining silyl protecting groups and saponification of the 
methyl ester will give access to leiodolide A (203) in 27 steps in the longest linear 
route.  
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Scheme 5.4: Final assembly of leiodolide A (assuming 4S,5S stereochemistry) 
 
The completion of a viable synthetic route for one potential isomer of leiodolide A 
will also allow preparation of all the eight possible isomers to unambiguously 
establish the relative and absolute stereochemistry of leiodolide A.  
 
Given the problems that were observed with the attempted coupling between the    
C1-C10 and the C11-C20 subunits it would be prudent to have a contingency plan. 
This could entail performing the alkylation with the truncated post-Stille oxazole 
subunit 204 to give coupled product 205 (Scheme 5.5). The robust aldol chemistry 
could then be used to install the C4,C5 stereochemistry at this point and subsequent 
elaboration would complete the C1-C4 section. 
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Scheme 5.5: Alternative coupling with truncated C1-C10 subunit 
 
If this alkylation is unsuccessful then the known addition of the lithiated 
diiodooxazole into an extremely similar aldehyde could be repeated on the C11-C20 
subunit (189). However, rather than performing the radical elimination immediately 
after xanthate synthesis (206) and the concomitant iodide elimination, the Stille 
coupling could be undertaken first (Scheme 5.6). Then from allylic alcohol 207 an 
analogous synthesis to that outlined above could furnish the remainder of the 
advanced intermediate 183. 
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Scheme 5.6: Alternative coupling strategy with diiodooxazole 
 
Following completion of the total synthesis and unambiguous structural elucidation of 
leiodolide A further investigations can be made into the proposed biosynthetic 
pathway for the formation of leiodolide B (208), by treating leiodolide A (203) with a 
range of electrophilic brominating reagents (Scheme 5.7).130 The total synthesis of 
leiodolide A will also allow further derivatives to be synthesised and enable the 
biological mode of action to be probed as it is currently unknown.23  
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Chapter Six 
Experimental 
 
6.1 General procedures 
 
1H Nuclear Magnetic Resonance (NMR) spectra were recorded on Bruker Avance 
300 (300.1 MHz), Bruker Avance II 400 (400.1 MHz) and Bruker Avance III 500 
(500.1 MHz) instruments, and referenced using deuterated chloroform to 7.26 ppm or 
deuterated benzene to 7.16 ppm. The chemical shifts are reported in parts per million 
(ppm) on the delta (δ) scale (δTMS = 0). The multiplicity of each signal is indicated by: 
s (singlet); br s (broad singlet); d (doublet); dd (doublet of doublets); dt (doublet of 
triplets); dq (doublet of quartets); t (triplet); tt (triplet of triplets); app t (apparent 
triplet); q (quartet) or m (multiplet); and the coupling constant (J) measured in Hz. 
The number of protons (n) for a given resonance is indicated by nH. 
 
13C NMR were recorded on Bruker Avance 300 (75 MHz), Bruker Avance II 400 
(101 MHz) and Bruker Avance III 500 (126 MHz) instruments, at ambient room 
temperature and internal deuterium lock. The chemical shifts are reported in ppm on 
the δ scale (δTMS = 0) and referenced using deuterated chloroform to 77.00 ppm. 
 
Infrared (IR) spectra were recorded on a Shimadzu IR Affinity-1 FTIR spectrometer, 
using attenuated total reflectance (ATR) as the sampling technique. Absorption 
maxima are reported in wave numbers (cm-1). 
 
Optical Specific Rotations were measured using a Perkin Elmer Model 341 
automatic polarimeter instrument at 589 nm (sodium D line), in a cell with path length 
of 1 dm and are reported as: , concentration (c in g/100 mL) and solvent. 
 
20
D][α
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High Resolution Mass Spectroscopy (HRMS) were recorded by the EPSRC 
National Mass Spectrometry Service at Swansea on a Thermo Fisher LTQ Orbitrap 
XL mass spectrometer, a Finnigan MAT 900 XLT mass spectrometer, a Micromass 
Quattro II mass spectrometer, a Waters ZQ4000 mass spectrometer or a Thermofisher 
DSQ-II mass spectrometer using Atmospheric Solids Analysis Probe (ASAP), 
Electron Impact (EI), Chemical Ionisation (IP), Electrospray Ionisation (ES), Fast 
Atom Bombardment (FAB) and Atmospheric Pressure Channel Ionisation (APCI) 
techniques. 
 
Chiral High Performance Liquid Chromatography (HPLC) was performed using 
a Gilson HPLC with Waters 486 tuneable absorbance detector equipped with an    
OD-H Chiralpak column (0.46 cm I.D. x 25 cm L) using HPLC grade i-PrOH and 
hexane as eluent. 
 
Analytical Thin Layer Chromatography (TLC) were carried out on pre-coated 
(25µm) Merck Kieselgel 60 F254 plates with visualisation by ultraviolet (UV) light at 
254 nm and/or heating the plate after staining with a solution of 20% ceric ammonium 
molybdate w/v in H2O. 
 
Flash column chromatography was carried out on Merck silica gel 60 (40-63 µm) 
under a positive pressure of compressed air. 
 
Kugelrohr bulb-to-bulb distillations were carried out using a Büchi glass oven      
B-585 machine. The boiling points recorded are uncorrected. 
 
Reagents and solvents were purified by standard methods. Diethyl ether (Et2O), 
dichloromethane (CH2Cl2), tetrahydrofuran (THF) and toluene were dried by passage 
through two columns of alumina using a MBRAUN SPS-800 solvent purification 
system. Methanol was distilled from CaH2 in a recycling still under argon. Anhydrous 
DMF was purchased from Aldrich UK and dried by distillation from 4 Å molecular 
sieves under argon. Triethylamine (Et3N), diisopropylamine (i-Pr2NH), Hünig’s base 
(i-Pr2NEt) and 2,6-lutidine were dried over CaH2, distilled under argon at atmospheric 
pressure and stored over CaH2. 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
(DMPU) was dried over CaH2, distilled under high vacuum and stored over CaH2.  
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Dimethylsulfoxide (DMSO) was dried over CaH2, distilled under high vacuum and 
stored over 4 Å molecular sieves. Oxalyl chloride was dried over K2CO3, distilled at 
atmospheric pressure and stored over K2CO3. Titanium tetraisopropoxide (Ti(Oi-Pr)4) 
was dried over CaH2 and distilled into 4 Å molecular sieves. All other reagents were 
purchased from Sigma Aldrich UK, Alfar Aesar UK, Acros Organics UK or TCI 
Europe and were used as received, unless otherwise stated. All reactions were 
performed under anhydrous conditions and in an inert atmosphere of argon, using a 
vacuum manifold with argon passed through a calcium chloride and self-indicating 
silica gel column, unless otherwise stated. Room temperature (RT) refers to a 
temperature of approximately 20 ºC. 
 
Miscellaneous: All experiments were performed in flame-dried flasks under a 
positive pressure of argon with magnetic stirring, unless otherwise stated. The term 
“brine” refers to a saturated aqueous solution of sodium chloride in deionised water 
with all further aqueous solutions saturated unless otherwise stated. Reactions carried 
out at -78 ºC were achieved with a mixture of acetone and dry ice, and experiments 
requiring extended reaction times at low temperatures (-20 ºC to -90 ºC) were 
performed using a Neslab CC100 immersion cryocool. 
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6.2 Preparation of reagents 
 
Copper (I) thiophene-2-carboxylate (CuTC)57 
 
 
 
A solution of thiophene-2-carboxylic acid (8.95 g, 69.8 mmol) and red copper (I) 
oxide (2.50 g, 17.5 mmol) in toluene (50 mL), was fitted with a Dean-Stark trap and 
heated under reflux for 14 h. The reaction mixture was cooled to 60 ºC, filtered 
through a sinter, under an atmosphere of argon via an upturned filter funnel and 
washed with MeOH (25 mL) to remove excess acid. The resultant solid was then 
washed with Et2O (4 x 25 mL) until the eluent was colourless (previously green), 
before a final wash with hexane (3 mL). The product was dried under argon for 2 h, 
before being dried fully in vacuo yielding orange air sensitive solid (5.79 g, 87%). 
 
 
Tetra-n-butylammonium diphenylphosphinate131 
 
 
 
To a solution of diphenylphosphinic acid (4.00 g, 18.3 mmol) in MeOH (20 mL) was 
added a solution of tetra-n-butylammonium hydroxide (1.0 M in MeOH, 18.33 mL, 
18.3 mmol) and the mixture shaken briefly. The resulting solution was passed through 
Celite® and the solvent removed in vacuo leaving a pale yellow oil. This was placed 
under high vacuum overnight producing a semi-solid. The product was recrystallised 
from Et2O/hexane to give colourless, hygroscopic plates (7.74 g, 91%).  
 
1H NMR (300 MHz, CDCl3) δ 7.89 (2H, m), 7.23 (8H, m), 3.31 (8H, app t, J = 8.6), 
1.57 (8H, m), 1.35 (8H, m) and 0.94 (12H, t, J = 7.3 Hz). 
O
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Dicyclohexylboron chloride (c-Hex2BCl)132 
 
To a stirred solution of cyclohexene (10.0 mL, 98.5 mmol, distilled from CaH2) in 
Et2O (64 mL) at -10 ºC was added monochloroborane•dimethylsulfide (5.14 mL, 49.2 
mmol) in a drop-wise manner. The resulting solution was stirred for 1 h at 0 ºC and 
then 1 h at RT before the solvent and volatiles were removed by distillation at 
atmospheric pressure. The product was purified by distillation under reduced pressure 
to afford c-Hex2BCl (7.50 g, 71%) as a colourless oil.  
 
B.pt. 106-109 ºC / 1 mbar, (Lit133 104-105 °C / 0.67 mbar) 
 
 
Zinc Borohydride (Zn(BH4)2) 
 
A round bottom flask was charged with anhydrous ZnCl2 (4.12 g, 29.5 mmol), NaBH4 
(2.62 g, 67.5 mmol) and THF (60 mL) and stirred for 24 h. The resulting clear 
solution c 0.5 M was used directly. 
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6.3 Experimental for Chapter 2 
 
2,4-Diiodooxazole (88)50 
 
 
 
To a solution of 1,3-oxazole (2.00 mL, 29.8 mmol) in a mixture of anhydrous THF 
(12.8 mL) and anhydrous DMPU (10.4 mL) at -78 ºC was added dropwise LiHMDS  
(1 M in THF, 65.6 mL) and the solution stirred for 1 h.  Iodine (15.20 g, 59.6 mmol) 
was then added and the reaction mixture stirred for a further 1 h before the reaction 
mixture was allowed to warm to RT and stirred for 14 days under a low positive 
pressure of Ar. The reaction mixture was poured into aqueous Na2S2O3 (10%,        
200 mL) and the aqueous layer extracted with Et2O (3 x 200 mL). The organic phase 
was washed with brine (200 mL), dried (MgSO4), filtered and the solvent removed in 
vacuo. The product was purified via flash column chromatography (0-20% 
EtOAc/hexane) to give diiodooxazole 88 (6.23 g, 65%) as a white crystalline solid.  
 
Rf 0.45 (10% EtOAc/hexane); M.pt. 97-99 ºC (Lit.50 98-100 ºC); 1H NMR           
(300 MHz, CDCl3) δ 7.79 (1H, s, ArH); 13C NMR (75 MHz, CDCl3) δ 149.1, 101.7, 
and 83.3; HRMS (ASAP) calcd. for C3H2I2NO  [M +H]+  321.8220, found 321.8220. 
 
 
4-Iodo-2-(triisopropylsilyl)oxazole (87)50 
 
 
 
To a solution of 2,4-diiodooxazole 88 (1.00 g, 3.15 mmol) in THF (30 mL) at -78 ºC 
was added n-BuLi (1.6 M in hexane, 2.34 mL, 3.74 mmol) dropwise and stirred for  
20 min. Triisopropysilyltrifluoromethanesulfonate  (0.88 mL, 3.27 mmol) was then 
added slowly and the reaction mixture stirred for a further 30 min at -78 ºC. The 
cooling bath was removed and the mixture stirred for 1 h at RT. The reaction mixture 
O
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was quenched with water (100 mL) and extracted with Et2O (3 x 100 mL). The 
organic extracts were washed with brine (100 mL), dried (MgSO4), filtered and 
solvent removed in vacuo. Purification performed via flash chromatography (0-2% 
EtOAc/hexane) produced iodooxazole 87 (819 mg, 81%) as a pale yellow oil. 
 
 Rf 0.65 (10% EtOAc/hexane); 1H NMR (300 MHz, CDCl3) δ 7.80 (1H, s, ArH), 1.40 
(3H, m, Si(CH(CH3)2)3) and 1.12 (18H, d, J = 7.4 Hz, Si(CH(CH3)2)3); 13C NMR   
(75 MHz, CDCl3) δ 171.2, 144.4, 82.0, 18.5 and 11.1; HRMS (ES+) calcd. for 
C12H23NOSiI [M +H]+ 352.0588, found 352.0591. 
 
 
(E)-3-(Tributylstannyl)but-2-en-1-ol (89)53  
 
 
 
To a suspension of CuCN (2.56 g, 28.6 mmol) in THF (84 mL) at -78 ºC was added 
n-BuLi (1.6 M solution in hexanes, 37.5 mL, 60.0 mmol). This solution was stirred 
for 10 min at -40 ºC (producing a pale yellow solution), before cooling to -78 ºC and 
addition of tributyltin hydride (16.3 mL, 60.0 mmol). The solution was again stirred at 
-40 ºC for 10 min (giving a golden coloured solution), cooled to -78 ºC and a solution 
of 2-butyn-1-ol (1.00 g, 14.3 mmol) in MeOH (42 mL) was added. The mixture was 
allowed to warm to -10 ºC, stirred for 2 h and then poured into a saturated aqueous 
solution of NH4Cl/conc ammonia (5 : 1) at -10 ºC. This was stirred for 30 min before 
extraction with Et2O (3 x 100 mL). The organic extracts were washed with brine, 
dried (MgSO4), filtered and concentrated in vacuo. Purification was performed by 
flash column chromatography on silica gel (0-20% EtOAc/hexane) yielding stannane 
89 (4.40 g, 85%) as a very pale yellow oil.  
 
Rf 0.25 (10% EtOAc/hexane); 1H NMR (300 MHz, CDCl3) δ 5.76 (1H, td, J = 6.0, 
1.9 Hz, J 1H-117Sn = J 1H-119Sn = 45.0 Hz, C=CHCH2OH), 4.27 (2H, t, J = 6.0 Hz, 
C=CHCH2OH), 1.89 (3H, s, J 1H-117Sn = J 1H-119Sn = 45.0 Hz, CH3SnBu3C=C), 
1.56-1.43 (6H, m, SnBu3), 1.38-1.26 (6H, m, SnBu3) and 0.94-0.86 (15H, m, SnBu3); 
Bu3Sn OH
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13C NMR (75 MHz, CDCl3) δ 143.0, 139.5, 59.3, 29.5, 27.7, 19.8, 14.0 and 9.4; 
HRMS (ASAP) calcd. for C16H35OSn [M+H]+  363.1707, found 363.1714. 
 
 
(E)-3-(Tributylstannyl)but-2-enal (31)55 
 
 
 
To a solution of stannane alcohol 89 (300 mg, 0.84 mmol) in CH2Cl2 (10 mL) was 
added MnO2 (1.30 g, 15.0 mmol) and Na2CO3 (1.60 g, 15.1 mmol) and the resulting 
mixture stirred for 3 h. The solution was then filtered through a silica pad and solvent 
removed in vacuo to yield aldehyde 31 (270 mg, 90%) as a colourless oil.  
 
Rf 0.30 (10% EtOAc/hexane); 1H NMR (300 MHz, CDCl3) δ 10.06 (1H, d, J = 8.0 
Hz), 6.21 (1H, dd, J = 8.0, 1.8 Hz, J 1H-117Sn = J 1H-119Sn = 60.0 Hz, CH(O)C=CH), 
2.45 (3H, d, J = 1.8 Hz, J 1H-117Sn = J 1H-119Sn = 43.3 Hz, CH=C(CH3)), 1.44-1.56 
(6H, m, SnBu3), 1.24-1.38 (6H, m, SnBu3), 1.03-0.95 (6H, m, SnBu3), 0.89 (9H, t,     
J = 7.4 Hz, SnBu3). 13C NMR (75 MHz, CDCl3) δ 188.1, 140.2, 29.4, 27.7, 20.9, 13.9 
and 9.7.  
 
 
(E)-3-(2-(Triisopropylsilyl)oxazol-4-yl)but-2-enal (91)  
 
 
 
Method A: To a solution of TIPS protected iodooxazole 87 (100 mg, 0.280 mmol) 
and stannane 31 (98 mg, 0.280 mmol) in DMF (6 mL) was added the scavenger 
[Bu4N]+[Ph2PO2]- (188 mg, 0.410 mmol). Pd(PPh3)4 (227 mg, 0.196 mmol) was 
introduced, followed by CuTC (188 mg, 0.410 mmol) and the reaction mixture stirred 
for 6 h before quenching with water (50 mL). The aqueous phase was extracted with 
Et2O (4 x 20 mL) and the combined organic extracts dried (Na2SO4), filtered and 
Bu3Sn H
O
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concentrated in vacuo. The crude product was purified via flash column 
chromatography (0-2% EtOAc/hexane) yielding aldehyde 91 (24 mg, 29%) as a 
yellow oil. 
 
Method B: To a stirred solution of Pd(MeCN)2Cl2 (5 mg, 0.019 mmol) and LiCl      
(50 mg, 1.17 mmol) in DMF (3 mL) was added iodide 87 (100 mg, 0.280 mmol) as a 
solution in DMF (1.5 mL), and the reaction was heated to 90 °C. The stannane 31   
(99 mg, 0.280 mmol) in DMF (1.5 mL) was then added and the reaction stirred for   
16 h. The mixture was then concentrated in vacuo, to remove the DMF before being 
partitioned between water (10 mL) and Et2O (3 x 25 mL). The combined organic 
extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification was 
achieved by flash column chromatography (5-25% EtOAc/hexane) to yield aldehyde 
91 (27 mg, 34%) as a pale yellow oil.  
 
Method C: To a stirred suspension of MnO2 (1.00 g, 11.5 mmol) and Na2CO3     
(1.20 g, 11.5 mmol) in CH2Cl2 (25 mL) was added alcohol 92 (285 mg, 0.970 mmol) 
in CH2Cl2 (2 mL). After 2 h the reaction mixture was filtered through a pad of silica 
and flushed with CH2Cl2 (3 x 50 mL). The filtrate was concentrated in vacuo to yield 
91 (235 mg, 81%) as a pale yellow oil. 
 
Rf 0.80 (10% EtOAc/hexane); IR: 2946, 2867, 1668, 1624, 1462, 1127 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 10.18 (1H, d, J = 8.4 Hz, H5), 8.04 (1H, s, H9), 6.92 (1H, 
dd, J = 8.4, 1.1 Hz, H6), 2.47 (3H, s, Me7), 1.39 (3H, m, Si(CH(CH3)2)3) and 1.14 
(18H, d, J = 7.3 Hz, Si(CH(CH3)2)3); 13C NMR (75 MHz, CDCl3) δ 191.2, 146.7, 
141.2, 140.0, 128.9, 125.7, 18.3, 14.6 and 11.0. HRMS (ES+) calcd. for C16H28NO2Si 
[M+ H]+ 294.1884, found 294.1887. 
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(E)-3-(2-(Triisopropylsilyl)oxazol-4-yl)but-2-en-1-ol (92) 
 
 
 
To a stirred solution of Pd(MeCN)2Cl2 (25 mg, 0.096 mmol) and LiCl (250 mg,     
11.2 mmol) in DMF (3 mL) was added iodide 87 (500 mg, 1.38 mmol) as a solution 
in DMF (1.5 mL), and the reaction heated to 90 °C. The stannane 89 (500 mg,       
1.40 mmol) in DMF (1.5 mL) was then added and the reaction stirred for 16 h. The 
mixture was then concentrated in vacuo, to remove the DMF before being partitioned 
between H2O (10 mL) and Et2O (3 x 25 mL). The combined organic extracts were 
dried (MgSO4) and concentrated in vacuo. Purification was achieved by flash column 
chromatography  (5-25% EtOAc/hexane) to yield alcohol 92 (16 mg, 75%) as a pale 
yellow oil.  
 
 Rf 0.45 (10% EtOAc/hexane); IR: 3407, 2947, 2869, 1265, 913, 743 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.69 (1H, s, H9), 6.61 (1H, td, J = 7.0, 1.2 Hz, H6), 4.37 (2H, d, 
J = 7.0 Hz, H5), 1.98 (3H, s, Me7), 1.38 (3H, m, Si(CH(CH3)2)3 and 1.14 (18H, d,       
J = 7.3 Hz, Si(CH(CH3)2)3); 13C NMR (75 MHz, CDCl3) δ 168.5, 142.0, 135.9, 
128.1, 125.5, 59.24, 18.41, 14.3 and 11.0; HRMS (ES+) calcd. for C16H30NO2Si    
[M+ H]+ 296.2040, found 296.2042. 
 
(E)-3-(Oxazol-4-yl)but-2-en-1-ol (93) 
 
 
 
Pale yellow oil (86%) Rf 0.1 (30% EtOAc/hexane), 1H NMR (300 MHz, CDCl3)       
δ 7.83 (1H, s, H10), 7.59 (1H, s, H9), 6.52 (1H, td, J = 7.7, 1.3 Hz, H6), 4.37 (2H, d,       
J = 8.0 Hz, H5) and 1.97 (3H, s, Me7). 13C NMR (75 MHz, CDCl3) δ 151.0, 142.0, 
134.0, 127.2, 126.5, 59.1 and 14.1; HRMS (ASAP) calcd. for C7H10NO2H [M+ H]+ 
140.0706, found 140.0702. 
9O
N
TIPS 6
5
OH
9O
10
N
6
5
OH
 130 
tert-Butyl(1-methoxypenta-1-Z-dien-1-yloxy)dimethylsilane (86)134  
 
 
 
To a stirred solution of diisopropylamine (4.55 mL, 32.1 mmol) in THF (70 mL) at    
0 °C was added n-BuLi (1.6 M in hexane, 20.00 mL, 32.1 mmol). The mixture was 
further cooled to -78 °C and the following were added dropwise in succession every 
15 min; DMPU (5.20 mL, 43.0 mmol), methyl-trans-2-pentenoate (3.25 g, 28.5 
mmol) and finally a solution of TBSCl (5.25 g, 35.0 mmol) in THF (15 mL). After 30 
min the reaction was brought up to RT for 1.5 h then quenched with aq NaHCO3 (30 
mL). The mixture was extracted with hexane (2 x 100 mL), washed with aq NaHCO3 
(5 x 50 mL) and brine, dried (MgSO4), filtered and concentrated in vacuo. 
Purification by Kugelrohr distillation afforded 86 (5.20 g, 80%) as a  pale yellow oil.  
 
Rf 0.65 (10% EtOAc/hexane); B.pt. 85 ºC / 1 mbar, (Lit.134 53-55 ºC / 0.3 mbar); 1H 
NMR (300 MHz, CDCl3) δ 6.18 (1H, app tq, J = 10.7, 1.8, CH3CHCH), 5.11 (1H, 
dqd, J = 10.8, 6.9, 0.9, CH3CH), 4.54 (1H, dd, J = 10.7, 0.9, CH3CHCHCH), 3.61 
(3H, s, OCH3), 1.68 (3H, dd, J = 6.9, 1.7, CH3), 0.96 (9H, s, Si(CH3)2C(CH3) 3) and 
0.18 (6H, s, Si(CH3)2C(CH3) 3). 
 
 
(2E,6E)-Methyl 5-hydroxy-4-methyl-7-(2-(triisopropylsilyl)oxazol-4-yl)octa-2,6-
dienoate (105) 
 
 
 
To a suspension of 4 Å molecular sieves (400 mg, 400 mg/mmol) and (S)-BINOL 
(115 mg, 0.400 mmol, 40 mol%) in Et2O (9 mL) at RT was added titanium 
tetraisopropoxide (119 µL, 0.400 mmol, 40 mol%) and the resulting slurry stirred for 
1 h. The reaction mixture was then cooled to -50 ºC and a solution of aldehyde 91 
OMe
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(293 mg, 1.00 mmol) in Et2O (3 mL) added. After a further 30 min a solution of tert-
butyl(1-methoxypenta-1-Z-dien-1-yloxy)dimethylsilane (86) (457 mg, 2.00 mmol) in 
Et2O (3 mL) was slowly added. The mixture was stirred at -50 ºC for 72 h, after 
which time the reaction mixture was poured into aq NaHCO3 (15 mL) at 0 ºC and 
diluted with Et2O (15 mL). The aqueous layer was extracted with Et2O (3 x 15 mL) 
and the combined organic extracts were dried (MgSO4), filtered and concentrated in 
vacuo. The product was purified by flash column chromatography (2% 
EtOAc/hexane) to yield 105 (144 mg, 35%, d.r. 3 : 1, anti : syn). 
 
Rf 0.56 (10% EtOAc/hexane); IR 3433, 2945, 2866, 1720, 1707, 1654, 1460, 1435, 
1273, 999, 961, 883 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.68 (major, 1H, s, H9), 
7.68 (minor, 1H, s, H9), 7.05 (major, 1H, dd, J=15.8, 8.3 Hz, H3), 7.04 (minor, 1H, 
dd, J = 15.8, 7.3 Hz, H3) 6.38 (1H, dd, J = 9.3, 1.6 Hz, H6), 5.94 (major, 1H, dd,         
J = 15.7, 1.1 Hz, H2), 5.90 (minor, 1H, dd, J = 15.7, 1.4 Hz, H2), 4.50 (minor, 1H, dd, 
J = 9.1, 5.8 Hz, H5), 4.42 (major, 1H, dd, J = 9.2, 7.3 Hz, H5), 3.74 (major, 3H, s, 
OCH3), 3.72 (minor, 3H, s, OCH3), 2.68-2.60 (minor, 1H, m, H4), 2.62-2.51 (major, 
1H, m, H4), 2.00 (major, 3H, d, J = 1.4 Hz, Me7), 1.99 (minor, 3H, d, J = 1.4 Hz, 
Me7), 1.46-1.32 (3H, m, Si(CH(CH3)2)3), 1.18-1.11 (18H, m, Si(CH(CH3)2)3) and 
1.10-1.05 (3H, m, Me4); 13C NMR (126 MHz, CDCl3) δ 168.4*, 167.1, 167.1, 151.3, 
150.7, 141.8*, 136.1*, 128.7, 128.6, 127.1, 126.7, 121.5, 121.3, 71.3, 71.0, 51.5, 51.5, 
43.4, 42.9, 18.6, 15.6, 14.8, 14.8, 14.4 and 11.0*; HRMS (ES+) calcd. for 
C22H38NO4Si [M+H]+ 408.2565, found 408.2562 
 
*Second peak obscured under signals at 168.4, 141.8, 136.1 and 11.0 ppm, resolution 
not possible. 
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(S)-2-Hydroxy-N-methoxy-N-methylpropanamide (108)80 
 
 
 
To a solution of ethyl (S)-lactate (4.00 g, 33.8 mmol) and MeO(Me)NH•HCl (8.20 g, 
84.0 mmol) in THF (100 mL) at -30 °C was added iPrMgCl (82.00 mL, 168 mmol) 
such that the temperature did not exceed -15 °C during addition. The mixture was 
then allowed to warm to 0 °C and stirred for 2 h, after this time the reaction was 
quenched with aq NH4Cl (150 mL). The aqueous layer was extracted with Et2O (3 x 
150 mL) and CH2Cl2 (2 x 150 mL), The combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. Kugelrohr distillation gave the Weinreb 
amide 108 (8.32 g, 90%) as a colourless oil.  
 
Rf 0.10 (10% EtOAc/hexane); B.pt. 65 ºC / 1 mbar, (Lit.80 63-65 ºC / 0.67 mbar); 
 -45.3 (c 2.2, CHCl3), (Lit.80 -50.0 (c 2.2, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 4.48 (1H, quin, J = 6.9 Hz, CHOH), 3.71 (3H, s, NOCH3), 3.33 (1H, d,  J = 7.8 Hz, 
OH), 3.24 (3H, s, NCH3) and 1.36 (3H, d, J = 6.6 Hz, CHCH3). 
 
 
(S)-3-Oxopentan-2-yl benzoate (106)80 
 
 
 
To a stirred solution of Weinreb amide 108 (1.80 g, 13.5 mmol) in THF (60 mL) at    
0 °C was added ethylmagnesium chloride (2 M in Et2O, 16.00 mL, 32.4 mmol) and 
the resulting solution stirred at RT for 3 h. The mixture was quenched with NH4Cl (75 
mL) and extracted with Et2O (3 x 75 mL), then CH2Cl2 (2 x 75 mL). The combined 
organic extracts were dried (Na2SO4), filtered and concentrated in vacuo to around 75 
mL. Benzoic anhydride (4.59 g, 22.5 mmol), Et3N (3.56 mL, 25.6 mmol) and DMAP 
(93 mg, 0.760 mmol) were added and the solution stirred at RT. After 16 h            
N,N-dimethylethylenediamine (2.39 mL, 20.25 mmol) was added and the reaction 
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further stirred for 15 min before being partitioned between aq Na2CO3 (75 mL) and 
Et2O (4 x 75 mL). The combined organic extracts were washed with aq potassium 
sodium tartrate (50 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
product was purified by flash chromatography (10-20% EtOAc/hexane) to give 
ketone 106 (2.15 g, 77%) as a colourless oil. 
 
Rf 0.50 (10% EtOAc/hexane);  +20.0 (c 1.0, CHCl3), (Lit.80 +20.7 (c 1.7 
CHCl3)); 1H NMR (300 MHz, CDCl3) δ 8.09 (2H, dd, J = 8.4, 1.4 Hz, ArH), 7.59 
(1H, t, J = 7.5 Hz, ArH), 7.46 (2H, t, J = 7.9 Hz, ArH), 5.36 (1H, q, J = 7.0 Hz, 
CHOBz) 2.66 (1H, dq, J = 18.4, 7.3 Hz, CHaHbCH3), 2.53 (1H, dq, J = 18.4, 7.3 Hz, 
CHaHbCH3), 1.53 (3H, d, J = 7.0 Hz, CHCH3) and 1.10 (3H, t, J = 7.3, CH2CH3); 
HRMS (ES+) calcd. for C12H15O3 [M+H]+ 207.1016, found 207.1016. 
 
 
(2S,4R,5R,6E)-5-Hydroxy-4-methyl-3-oxo-7-(2-(triisopropylsilyl)oxazol-4-yl)oct-
6-en-2-yl benzoate (110) 
 
 
 
To a solution of c-Hex2BCl (0.98 mL, 4.50 mmol) in Et2O (10 mL) at -78 °C was 
added dropwise Et3N (0.76 mL, 5.40 mmol) followed by a solution of ketone 106 
(618 mg, 3.00 mmol) in Et2O (7.5 mL). The reaction mixture was stirred for 2 h at      
-78 °C, before aldehyde 91 (460 mg, 1.57 mmol) was added and the resulting solution 
was further stirred at -78 °C for 3 h and then kept at -20 °C for 16 h. The mixture was 
partitioned between a pH 7 buffer (20 mL) and Et2O (3 x 40 mL). The combined 
organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The 
resulting oil was taken up in MeOH (7.5 mL) and cooled to 0 °C, before addition of a 
pH 7 buffer (1 mL) and H2O2 30% (5 mL). The reaction was then stirred for 2 h at RT 
before being partitioned between H2O (20 mL) and CH2Cl2 (20 mL) with the aqueous 
layer extracted with CH2Cl2 (2 × 40 mL). The combined organic extracts were 
washed with aq NaHCO3 (25 mL) and brine (25 mL), dried (Na2SO4), filtered and 
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concentrated in vacuo. Purification by flash column chromatography (5% EtOAc/ 
hexane) gave product 110 (580 mg, 74%, d.r. = 97 : 3) as a yellow oil. 
 
Rf 0.30 (20 % EtOAc/hexane); +18.5 (c 1.20, CHCl3); IR: 2930, 2857, 1719, 
1452, 1266, 1116, 1066, 837 cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.10 (2H, d,           
J = 8.3 Hz, ArH), 7.68 (1H, s, H9), 7.63-7.54 (1H, m, ArH), 7.46 (2H, t, J = 7.7 Hz, 
Ar-H), 6.35 (1H, dd, J = 9.5, 1.5 Hz, H6), 5.47 (1H, q, J = 7.1 Hz, H2), 4.78 (1H, td,   
J = 9.1, 4.3 Hz, H5), 3.05 (1H, dq, J = 8.7, 7.2 Hz, H4), 2.01 (3H, d, J = 1.5 Hz, Me7), 
1.60 (3H, d, J = 7.1 Hz, Me2), 1.45-1.32 (3H, m, Si(CH(CH3)2)3), 1.20 (3H, d,            
J = 7.2 Hz, Me4) and 1.13 (18H, d, J = 7.4 Hz, Si(CH(CH3)2)3); 13C NMR (126 MHz, 
CDCl3) δ 211.2, 168.4, 165.9, 141.7, 136.2, 133.3, 129.8, 129.5, 129.1, 128.4, 126.5, 
115.4, 75.0, 72.4, 70.3, 48.8, 18.4, 15.5, 14.9, 14.4 and 11.0; HRMS (ES+) calcd. for 
C28H42NO5Si [M+H]+ 500.2827, found 500.2815. 
 
 
(2S,4R,5R,6E)-4-Methyl-3-oxo-7-(2-(triisopropylsilyl)oxazol-4-yl)-5-
((triisopropylsilyl)oxy)oct-6-en-2-yl benzoate (111) 
 
 
 
To solution of alcohol 110 (530 mg, 1.06 mmol) in CH2Cl2 (10 mL) at -78 °C was 
added 2,6-lutidine (1.33 mL, 1.22 g, 11.4 mmol) and TIPSOTf (1.33 mL, 1.52 g, 4.95 
mmol). The solution was stirred for 3 h before quenching with aq NaHCO3 (15 mL) 
and extracting with CH2Cl2 (3 x 20mL). The organic extracts were washed with brine 
(15 mL), dried (Na2SO4), filtered and concentrated in vacuo. The resulting oil was 
purified via flash chromatography (10% EtOAc/hexane) to yield silyl ether 111 (693 
mg, 99%) as a yellow oil.  
 
Rf 0.80 (10% EtOAc/hexane);  -17.3 (c 1.00, CHCl3); IR: 2930, 2857, 1719, 
1452, 1266, 1116, 1066, 837 cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.09 (2H, dd,         
J = 8.4, 1.4 Hz, Ar-H), 7.64 (1H, s, H9), 7.62–7.52 (1H, m, Ar-H), 7.45 (2H, t, J = 7.7 
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Hz, Ar-H), 6.35 (1H, dd, J = 9.6, 1.5 Hz, H6), 5.48 (1H, q, J = 7.0 Hz, H2), 4.97 (1H, 
t, J = 9.6 Hz, H5), 3.05 (1H, dq, J = 9.3, 7.1 Hz, H4), 1.95 (3H, d, J = 1.5 Hz, Me7), 
1.57 (3H, d, J = 7.0 Hz, Me2), 1.37 (3H, qd, J = 7.4, 0.9 Hz, Si(CH(CH3)2)3),        
1.31-1.19 (3H, m, Si(CH(CH3)2)3), 1.13 (18H, dd, J = 10.4, 7.4 Hz, Si(CH(CH3)2)3), 
1.07 (3H, d, J = 7.1, Me4) and 1.04-0.95 (18H, m, Si(CH(CH3)2)3); 13C NMR       
(101 MHz, CDCl3) δ 209.4, 168.0, 165.8, 141.9, 135.7, 133.2, 129.8, 129.8, 128.8, 
128.4, 126.5, 75.5, 71.9, 49.7, 18.3, 18.0, 15.1, 14.3, 12.7, 12.4 and 11.0; HRMS 
(ES+) calcd. for C37H62NO5Si2 [M+H]+ 656.4161, found 656.4160. 
 
 
(2S,4S,5R,6E)-4-Methyl-7-(2-(triisopropylsilyl)oxazol-4-yl)-5-
((triisopropylsilyl)oxy)oct-6-ene-2,3-diol (112) 
 
 
 
To a stirred solution of NaBH4 (80 mg, 2.00 mmol) in MeOH (20 mL) at 0 °C was 
added a solution of benzoate 111 (650 mg, 1.00 mmol) in MeOH (7.5 mL). After     
30 min the reaction mixture was warmed to RT before the reaction was quenched 
with pH 7 buffer (20 mL) and the MeOH removed in vacuo.  The aqueous phase was 
extracted with CH2Cl2 (3 x 25 mL), the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo.  The residue was redissolved in MeOH 
(20 mL) and stirred at RT before K2CO3 (550 mg, 4.00 mmol) was added. After 20 h 
the reaction mixture was diluted with brine (25 mL) and extracted with CH2Cl2 (3 x 
25 mL). The combined organic extracts were dried (NaSO4), filtered and concentrated 
in vacuo. Flash chromatography (10-40% EtOAc/hexane) yielded diol 112 (424 mg, 
77%, d.r. 14 : 1) as a colourless oil.  
 
Rf 0.10 (40% EtOAc/hexane); -25.1 (c 1.15, CHCl3); IR: 3444, 3020, 2941, 
2866, 1462, 1385, 1051, 881 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.65 (1H, s, H9), 
6.44 (1H, dd, J = 9.5, 1.5 Hz, H6), 4.77 (1H, dd, J = 9.5, 6.9 Hz, H5), 3.98 (1H, s, 
OH), 3.89-3.78 (1H, m, H2), 3.69-3.60 (1H, m, H3), 2.37, (1H, d, J = 8.1 Hz, OH), 
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1.94, (3H, s, Me7), 1.85-1.78 (1H, m, H4), 1.48-1.31 (3H, m, Si(CH(CH3)2)3), 1.17 
(3H, d, J = 6.3 Hz, Me2), 1.15-1.10 (18H, m, Si(CH(CH3)2)3), 1.07-1.03 (21H, m, 
Si(CH(CH3)2)3, Si(CH(CH3)2)3) and 0.83 (3H, d, J = 7.0 Hz, Me4); 13C NMR (101 
MHz, CDCl3) δ 168.1, 141.9, 135.6, 128.8, 125.9, 77.5, 74.5, 68.5, 42.6, 18.4, 18.1, 
16.0, 15.0, 12.7, 11.9 and 11.0; HRMS (ES+) calcd. for C30H59NO4Si2Na [M+Na]+ 
576.3875, found 576.3873. 
 
 
(2E,4S,5S,6E)-Methyl 4-methyl-7-(2-(triisopropylsilyl)oxazol-4-yl)-5-
((triisopropylsilyl)oxy)octa-2,6-dienoate (85) 
 
 
 
To a stirred solution of diol 112 (400 mg, 0.710 mmol) in MeOH (20 mL) and H2O 
(10 mL) was added NaIO4 (833 mg, 3.90 mmol). After 30 min the resulting white 
suspension was partitioned between H2O (20 mL) and CH2Cl2 (3 x 30 mL). The 
combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. 
The residue was dissolved in MeCN (5 mL) and added to a stirred solution of 
trimethyl phosphonoacetate (160 µL, 180 mg, 1.00 mmol), lithium chloride (190 mg, 
4.50 mmol) and i-Pr2NEt (130 µL, 0.750 mmol) in MeCN (15 mL). The mixture was 
stirred at RT for 18 h before H2O (15 mL) was added and the organics extracted with 
EtOAc (3 x 20 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. Purification was achieved by flash chromatography (5-50% 
CH2Cl2/hexane) to provide (E)-enoate 85 (50 mg, 61%).  
 
Rf 0.6 (10% EtOAc/hexane); -30.7 (c 1.00, CHCl3); IR: 2943, 2867, 1728, 
1656, 1462, 1435, 1385, 1271, 1059 and 881 cm-1; 1H NMR (CDCl3, 500 MHz)        
δ 7.65 (1H, s, H9), 7.10 (1H, dd, J = 15.8, 8.1 Hz, H3), 6.41 (1H, d, J = 9.2 Hz, H6), 
5.87 (1H, d, J = 15.8 Hz, H2), 4.57 (1H, dd, J = 9.2, 6.2 Hz, H5), 3.75 (3H, s, OCH3), 
2.59 (1H, hex, J = 7.0 Hz, H4), 1.92 (3H, d, J = 1.4 Hz, Me7), 1.40 (3H, hept,              
J = 7.5 Hz, Si(CH(CH3)2)3), 1.16 (18H, t, J = 7.5 Hz, Si(CH(CH3)2)3), 1.10 (3H, d,     
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J = 7.0 Hz, Me4) and 1.08-1.00 (21H, m, Si(CH(CH3)2)3, Si(CH(CH3)2)3); 13C NMR 
(101 MHz, CDCl3) δ 167.9, 167.1, 152.2, 142.0, 135.4, 129.2, 125.4, 120.7, 72.7, 
51.3, 44.8, 18.3, 18.1, 18.0, 14.9, 12.5 and 11.0; HRMS (ES+) calcd. for 
C31H58NO4Si2 [M+H]+ 564.3899, found 564.3889. 
 
 
(S)-2-((tert-Butyldimethylsilyl)oxy)-N-methoxy-N-methylpropanamide (115)88 
 
 
 
To a solution of Weinreb amide 108 (2.10 g, 16.0 mmol) in CH2Cl2 (150 mL) was 
added imidazole (2.20 g, 32.0 mmol) and tert-butyldimethylsilyl chloride (3.60 g, 
24.0 mmol). The mixture was stirred for 2 h at RT before the reaction was quenched 
with H2O (150 mL) and extracted with CH2Cl2 (3 x 150 mL). The combined organic 
fractions were washed with brine (150 mL), dried (Na2SO4), filtered and the solvent 
removed in vacuo. Flash column chromatography (20% EtOAc/hexane) yielded 
Weinreb amide 115 (3.82 g, 98%) as pale yellow oil.  
 
Rf 0.30 (20% EtOAc/hexane) -15.3 (c 1.00, CHCl3), (Lit.88 -24.6 (c 1.00, 
CHCl3)); 1H NMR (CDCl3, 400 MHz) δ 4.68 (1H, d, J = 6.7 Hz, CHOTBS), 3.70 
(3H, s, NOCH3), 3.21 (3H, s NCH3), 1.36 (3H, d, J = 6.7 Hz, CHCH3), 0.90 (9H, s, 
OSi(CH3)2C(CH3)3), 0.11 (3H, s, OSi(CH3)2C(CH3)3) and 0.08 (3H, s, 
OSi(CH3)2C(CH3)3). 
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(S)-2-((tert-Butyldimethylsilyl)oxy)pentan-3-one (116)88 
 
 
 
Ethylmagnesium chloride (2 M in Et2O, 30.3 mL, 60.6 mmol) was added dropwise to 
a solution of TBS-Weinreb amide 115 (5.00 g, 20.2 mmol) in THF (100 mL) at 0 °C 
and stirred for 3 h.  After this time the mixture was diluted with Et2O (100 mL), 
washed with aq NH4Cl solution (200 mL), followed by brine (100 mL). The organic 
extracts were then dried (MgSO4), filtered and concentrated to give 116 (4.05 g, 93%) 
as a pale yellow oil. 
 
Rf 0.40 (10% EtOAc/hexane);  -10.0 (c 2.05 CHCl3), (Lit.53 -10.8 (c 2.0 CHCl3); 
1H NMR (300 MHz, CDCl3) δ 4.15 (1H, q, J = 6.8 Hz, CHCH3), 2.65 (1H, dq,          
J = 18.5, 7.3 Hz, CH3CHaHb), 2.33 (1H, dq, J = 18.5, 7.3 Hz, CH3CHaHb), 1.27 (3H, 
d, J = 6.8 Hz, CHCH3), 1.03 (3H, t, J = 7.3, CH3CH2), 0.91 (9H, s, 
OSi(CH3)2C(CH3)3) and 0.07 (6H, s, OSi(CH3)2C(CH3)3). HRMS (ES+) calcd. for 
C11H24O2Si [M+H]+ 217.1618, found 217.1620. 
 
 
(2S,4R,5S,6E)-2-((tert-Butyldimethylsilyl)oxy)-5-hydroxy-4-methyl-7-(2-
(triisopropylsilyl)oxazol-4-yl)oct-6-en-3-one (117) 
 
 
 
Method A To a solution of c-Hex2BCl (0.26 mL, 1.20 mmol) in Et2O (3 mL) at          
-78 °C was added dropwise Et3N (0.21 mL, 1.50 mmol) followed by a solution of 
ketone 116  (216 mg, 1.00 mmol) in Et2O (2 mL). The reaction mixture was stirred 
for 2 h at -78 °C, before aldehyde 91 (1.50 mmol) was added and the resulting 
solution further stirred at -78 °C for 3 h before being kept at -20 °C overnight. The 
mixture was partitioned between a pH 7 buffer (20 mL) and Et2O (3 x 20 mL). The 
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combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. 
The resulting oil was diluted in MeOH (5 mL), a pH 7 buffer (1 mL), and H2O2 30% 
(2 mL) at 0 °C; warmed to RT; and stirred for 2 h. The mixture was partitioned 
between H2O (20 mL) and CH2Cl2 (3 × 20 mL). The combined organic extracts were 
washed with aq NaHCO3 (15 mL) and brine (15 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (5% 
EtOAc/hexane) afforded the aldol product 117 (325 mg, 64%, d.r. > 95 : 5) as a pale 
yellow oil. 
 
Method B: To a solution of silyl ketone 116 (216 mg, 1.00 mmol) in CH2Cl2 (5 mL) 
at -78 ºC was added TiCl4 (0.12 mL, 1.10 mmol) and stirred for 5 min before i-Pr2NEt 
(0.19 mL, 1.10 mmol) was added add the reaction stirred for 30 min. A solution of 
aldehyde 91 (63 mg, 0.22 mmol) in THF (2 mL) was added and the reaction mixture 
stirred for a further 1.5 h at -78 ºC before quenching with aq NH4Cl (5 mL) and 
vigorous stirring at RT. The reaction mixture was diluted with ether (7.5 mL) and 
washed with H2O (7.5 mL), aq NaHCO3 (7.5 mL) and brine (7.5 mL) before 
extraction of the aqueous layer with Et2O (3 x 10 mL). The combined organic layers 
were dried (Na2SO4), filtered and solvent removed in vacuo. Purification by flash 
column chromatography (5% EtOAc/hexane) yielded aldol product 117 (105 mg, 
90%, d.r. = 95 : 5) as a pale yellow oil. 
 
Rf 0.38 (10% EtOAc/hexane);  -17.8 (c 1.07 CHCl3); IR: 3433, 3020, 1948, 
2868, 1707, 1654, 1464, 1216, 837, 769 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.64 
(1H, s, H9), 6.36 (1H, dd, J = 8.8, 1.3 Hz, H6), 4.75 (1H, dd, J = 8.8, 5.7 Hz, H5), 4.18 
(1H, q, J = 6.8 Hz, H2), 3.24 (1H, dq, J = 7.1, 5.7 Hz, H4), 1.95 (3H, d, J = 1.3 Hz, 
Me7), 1.36 (3H, m, Si(CH(CH3)2)3), 1.29 (3H, d,   J = 6.8 Hz, Me2), 1.26 (3H, d,        
J = 7.1 Hz, Me4), 1.11 (18H, d, J = 7.4, Si(CH(CH3)2)3), 0.90 (9H, s, 
Si(CH3)2C(CH3)3), 0.09 (3H, s, Si(CH3)2C(CH3)3) and 0.06 (3H, s, Si(CH3)2C(CH3)3). 
13C NMR  (75 MHz, CDCl3) δ 216.9, 168.2, 141.9, 1366.0, 128.0, 126.8, 74.5, 68.8, 
53.4, 46.5, 25.8, 20.6, 18.4, 14.7, 12.6, 11.0, -4.8 and -4.9; HRMS (ES+) calcd. for 
C27H52NO4Si2 [M+H]+ 510.3429, found 510.3421. 
 
 
20
D][α
 140 
(5S,7R,8S)-10,10-Diisopropyl-2,2,3,3,5,7,11-heptamethyl-8-((E)-2-(2-
(triisopropylsilyl)oxazol-4-yl)prop-1-en-1-yl)-4,9-dioxa-3,10-disiladodecan-6-one 
(118) 
 
 
 
To solution of alcohol 117 (560 mg, 0.840 mmol) in CH2Cl2 (8 mL) at -78 °C was 
added 2,6-lutidine (1.33 mL, 1.22 g, 11.4 mmol) and TIPSOTf (1.33 mL, 1.52 g, 4.95 
mmol). The solution was stirred for 3 h at 0 ºC before quenching with aq NaHCO3  
(15 mL) and extracting with CH2Cl2 (3 x 20 mL). The organic extracts were washed 
with brine (15 mL), dried (Na2SO4), filtered and concentrated in vacuo. The resulting 
oil was purified via flash chromatography (10% EtOAc/hexane) to yield silyl ether 
118 (717 mg, 98%) as a yellow oil.  
 
Rf 0.85 (10% EtOAc/hexane); -17.8 (c 1.07 CHCl3); IR 2927, 2866, 1713, 
1462, 1254, 1061, 995, 881, 775 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.58 (1H, s, 
H9), 6.35 (1H, dd, J = 9.7, 1.5 Hz, H6), 4.73 (1H, t, J = 9.4 Hz, H5), 4.08 (1H, q,         
J = 6.7 Hz, H2), 3.29 (1H, dq, J = 9.0, 6.9 Hz, H4), 1.86 (3H, d, J = 1.5 Hz, Me7), 
1.41-1.27 (3H, m, Si(CH(CH3)2)3), 1.25 (3H, d, J = 6.9 Hz, Me4), 1.18 (3H, d,            
J = 6.7 Hz, Me2), 1.15-1.07 (18H, m, Si(CH(CH3)2)3), 1.06-1.01 (21H, m, 
Si(CH(CH3)2)3, Si(CH(CH3)2)3) 0.89 (9H, s, Si(CH3)2C(CH3)3), 0.05 (3H, s, 
Si(CH3)2C(CH3)3) and 0.00 (3H, s, Si(CH3)2C(CH3)3); 13C NMR (101 MHz, CDCl3) 
δ 214.4, 154.1, 141.9, 135.7, 129.6, 125.3, 74.4, 70.7, 48.8, 25.8, 20.0, 18.3, 17.7, 
15.2, 14.7, 12.6, 12.3, 11.0, -4.8 and -4.9; HRMS (ES+) calcd. for C36H72NO4Si3 
[M+H]+ 666.4764, found 666.4761. 
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(2S,4S,5S,6E)-4-Methyl-7-(oxazol-4-yl)-5-((triisopropylsilyl)oxy)oct-6-ene-2,3-
diol (119) 
 
 
 
To a stirred solution of NaBH4 (34 mg, 0.890 mmol) in MeOH (7 mL) at 0 °C was 
added a solution of ketone 118 (295 mg, 0.440 mmol) in MeOH (3 mL). After 30 min 
the reaction mixture was warmed to RT, quenched with pH 7 buffer (10 mL) and the 
MeOH concentrated in vacuo.  The aqueous phase was extracted with CH2Cl2 (3 x 25 
mL), the combined organic extracts were dried (Na2SO4), filtered and concentrated in 
vacuo.  The residue was redissolved in MeOH (10 mL) and stirred at 0 ºC before HCl 
(3 M, 250 µL) was added. After 2 h (at the first appearance of the tri-deprotected 
product by TLC) the reaction mixture was diluted with water (15 mL) and extracted 
with CH2Cl2 (3 x 25 mL). The combined organic extracts were dried (NaSO4), filtered 
and concentrated in vacuo. Flash chromatography (50% EtOAc/hexane) yielded the 
diol 119 (72 mg, 41%, d.r. 12 : 1) as a colourless oil. 
 
Rf 0.10 (40% EtOAc/hexane);  -2.3 (c 0.13, CHCl3); IR 3422, 2961, 2928, 
2866, 1670, 1458, 1381, 1258, 1089, 881 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.82 
(1H, d, J = 1.0 Hz, H10), 7.58 (1H, d, J = 1.0 Hz, H9), 6.53 (1H, dd, J = 9.5, 1.4 Hz, 
H6), 4.88 (1H, dd, J = 9.5, 3.0 Hz, H5), 4.44 (1H, s, OH), 3.84 (1H, dd, J = 9.6,        
3.2 Hz, H3), 3.80-3.70 (1H, m, H2), 2.02-1.89 (1H, m, H4) 1.95 (3H, d, J = 1.4 Hz, 
Me7), 1.17 (3H, d, J = 6.3 Hz, Me2), 1.11-0.99 (21H, m, Si(CH(CH3)2)3, 
Si(CH(CH3)2)3) and 0.79 (3H, d, J = 7.1 Hz, Me4); 13C NMR (75 MHz, CDCl3)         
δ 151.3, 142.4, 134.2, 128.1, 126.2, 76.2, 74.3, 69.2, 42.4, 18.3, 16.2, 15.3, 12.7 and 
12.6; HRMS (ES+) calcd. for C21H39NO4SiH [M+H]+ 398.2721, found 398.2723. 
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(2E,4S,5R,6E)-Methyl 4-methyl-7-(oxazol-4-yl)-5-((triisopropylsilyl)oxy)octa-2,6-
dienoate (84) 
 
 
 
To a stirred solution of diol 119 (50 mg, 0.130 mmol) in MeOH (3 mL) and H2O (1.5 
mL) was added NaIO4 (134 mg, 0.630 mmol). After 30 min the resulting white 
suspension was partitioned between H2O (5 mL) and CH2Cl2 (3 x 10 mL). The 
combined organics were dried (MgSO4), filtered and concentrated in vacuo. The 
residue was dissolved in MeCN (1 mL) and added to a stirred solution of trimethyl 
phosphonoacetate (30 µL, 34 mg, 0.190 mmol), lithium chloride (40 mg, 0.950 mmol) 
and i-Pr2NEt (22 µL, 0.130 mmol) in MeCN (3 mL). The mixture was stirred at RT 
for 18 h before H2O (5 mL) was added and the aqueous phase extracted with EtOAc 
(3 x 10 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. Purification was achieved by flash chromatography (5-50% 
CH2Cl2/hexane) to provide (E)-enoate 84 (22 mg, 42%).  
 
Rf 0.40 (10% EtOAc/hexane); -2.3 (c 0.64, CHCl3); IR: 3020, 2943, 2866, 
1724, 1654, 1462, 1273, 1063, 881 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.84 (1H, s, 
H10), 7.57 (1H, m, H9), 7.15 (1H, dd, J = 15.8, 7.2 Hz, H3), 6.29 (1H, dd, J = 9.2,   
1.4, Hz, H6), 5.84 (1H, dd, J = 15.8, 1.4 Hz, H2), 4.66 (1H, dd, J = 9.2, 5.0 Hz, H5), 
3.74 (3H, s, OCH3), 2.72-2.55 (1H, m, H4), 1.94 (3H, d, J = 1.4 Hz, Me7), 1.11 (3H, d, 
J = 6.8 Hz, Me4), 1.10-1.00 (21H, m, Si(CH(CH3)2)3, Si(CH(CH3)2)3); 13C NMR     
(75 MHz, CDCl3) δ 167.1, 151.2, 150.9, 142.0, 133.7, 129.6, 124.8, 120.9, 72.4, 51.4, 
44.3, 18.0, 14.7, 14.3 and 12.4; HRMS (ES+) calcd. for C22H37NO4SiH [M+H]+ 
408.2565, found 408.2561. 
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6.4 Experimental for Chapter 3 
 
(2S,3S)-Dimethyl 1,4-dioxaspiro[4.4]nonane-2,3-dicarboxylate (126)90 
 
 
To a solution of acetyl chloride (9.06 g, 10.0 ml, 115 mmol) in methanol at 0 ºC was 
added (S,S)-tartaric acid (50.0 g, 333 mmol) in portions. The resulting solution was 
stirred for 30 min before being warmed to RT and stirred for a further 16 h. The 
reaction was then concentrated in vacuo yielding a thick colourless oil. A portion of 
the oil (15.75 g, 88.5 mmol) was dissolved in toluene (50 mL) and added to a solution 
of cyclopentanone (39.40 mL, 445 mmol) and camphorsulfonic acid (2.05 g,         
8.82 mmol) in toluene (140 mL). The reaction mixture was then heated under reflux 
using Dean-Stark apparatus. After 72 h the reaction was allowed to cool before 
quenching with solid NaHCO3, the solid was then removed by filtration and filtrate 
concentrated in vacuo. The resulting oil was purified by flash column 
chromatography (5-10% EtOAc/hexane) to afford ester 126 (14.2 g, 66%).  
 
Rf 0.40 (20% EtOAc/hexane); +33.7 (c 1.02, CHCl3), (Lit.90 +35.5, (c 2.2 
CHCl3)) 1H NMR (CDCl3, 400 MHz) δ 4.77 (2H, s, H16, H17), 3.82 (3H, s, OCH3) 
and 2.10-1.63 (8H, m, (CH2CH2)2C(OR)2). 
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(2R,3R)-1,4-Dioxaspiro[4.4]nonane-2,3-diyldimethanol (127)91 
 
 
 
To a suspension of lithium aluminium hydride (2.65 g, 69.8 mmol) in THF (85 mL) at 
0 ºC was added diester 126 (8.50 g, 34.8 mmol) in THF (85 mL) over 30 min. The 
reaction was allowed to stir for 30 min at 0 ºC before warming to RT. After 2 h the 
reaction mixture was cooled back to 0 ºC, H2O (3 mL) and aq NaOH (15%, 2 mL) 
were added dropwise and the reaction stirred for a further 2 h. The resulting 
suspension was filtered through Celite®, dried (Na2SO4), filtered and the solvent 
removed in vacuo. The resulting oil was purified by flash column chromatography 
(50%-100% EtOAc/hexane) to give diol 127 (5.24 g, 80%).  
 
Rf  0.20 (50% EtOAc/hexane); +4.6 (c 4.11, CHCl3), (Lit.91 +6.7 (c 4.08 
CHCl3)); 1H NMR (CDCl3, 300 MHz) δ 3.95 (2H, td, J = 2.7, 1.4 Hz, H16, H17),  
3.89-3.62 (4H, m, H15, H18), 2.16 (2H, br s, OH)  and 1.94-1.55 (8H, m, 
(CH2CH2)2C(OR)2). 
 
 
((2R,3R)-3-(((tert-Butyldimethylsilyl)oxy)methyl)-1,4-dioxaspiro[4.4]nonan-2-
yl)methanol (128) 
 
 
 
To a suspension of NaH (60 wt% in mineral oil, 2.45 g, 61.3 mmol) in THF (30 mL) 
at 0 ºC was added diol 127 (5.50 g, 29.2 mmol) in THF (30 mL) over 30 min. The 
reaction mixture was then stirred for 1 h at 0 ºC before addition of TBSCl (4.40 g, 
29.2 mmol) in THF (30 mL) via cannula. After a further 2 h stirring at RT the reaction 
was quenched with aq K2CO3 (10% w/w, 20 mL) and the aqueous layer extracted 
with EtOAc (3 x 100 mL). The combined organic layers were dried (Na2SO4), filtered 
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and concentrated in vacuo. The resulting oil was purified by flash column 
chromatography (10% EtOAc/hexane) to yield alcohol 128 (7.95 g, 90%) as a pale 
yellow oil.  
 
Rf 0.50 (20% EtOAc/hexane); IR 3447, 2955, 2859, 1472, 1335, 1254, 1098, 835, 
775 cm-1; 1H NMR (CDCl3, 500 MHz) δ 3.94 (1H, dt, J = 7.3, 4.8 Hz, H17), 3.87 (1H, 
dd, J = 9.8, 4.2 Hz, H15a), 3.83 (1H, td, J = 7.3, 4.2 Hz, H16), 3.79-3.70 (2H, m, H18), 
3.64 (1H, dd, J = 9.8, 7.1 Hz, H15b), 2.33 (1H, dd, J= 7.8, 4.7 Hz, OH), 1.93-1.74 (4H, 
m, (CH2CH2)2C(OR)2), 1.74-1.61 (4H, m, (CH2CH2)2C(OR)2), 0.90 (9H, s, 
Si(CH3)2C(CH3)3) and 0.08 (6H, s, Si(CH3)2C(CH3)3); 13C NMR (75 MHz, CDCl3)   
δ 119.2 , 80.1 , 78.0 , 63.8 , 63.0 , 37.3 , 37.2 , 25.9 , 23.5 , 23.4 , 18.3 and -5.5; 
HRMS (ES+) calcd. for C15H31O4Si [M+H]+ 303.1986, found 303.1988. 
 
 
(E)-Ethyl 3-((2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-1,4-dioxaspiro[4.4] 
nonan-2-yl)-2-methylacrylate (129) 
 
 
 
To a stirred solution of oxalyl chloride (4.50 mL, 52.4 mmol) in CH2Cl2 (20 mL) at    
-78 ºC was added DMSO (4.86 mL, 68.4 mmol).  After 30 min a solution of alcohol 
128 (7.60 g, 25.1 mmol) in CH2Cl2 (60 ml) was added and allowed to stir for a further 
hour at -78 ºC. Et3N (14.25 mL, 102 mmol) was then added and the reaction mixture 
allowed to warm to RT. After 1 h the reaction was quenched with aq NH4Cl (80 mL) 
and the aqueous layer extracted with Et2O (3 x 100 mL). The combined organic layers 
were dried (Na2SO4), filtered and concentrated in vacuo. The resultant oil was cooled 
to 0 ºC and a solution of ylide 132 (10.7 g, 29.6 mmol) in CH2Cl2 (40 mL) was added 
to it via cannula. After 30 min the reaction mixture was warmed to RT and stirred for 
a further 1.5 h. The reaction was then concentrated in vacuo before the crude product 
was treated with cold hexane (10 mL), resulting in a white precipitate forming. The 
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precipitate was removed by filtration before the solvent removed in vacuo and the 
process repeated. The crude oil was then be purified by flash column chromatography 
(1-5% EtOAc/hexane) to give unsaturated ester 129 (6.80 g, 70%, E : Z = 96 : 4) as a 
pale yellow oil.  
 
Rf  0.42 (10% EtOAc/hexane) +23.0 (c 1.60, CHCl3); IR 2955, 2930, 2857, 
1715, 1258, 1107, 835, 775 cm-1; 1H NMR (CDCl3, 500 MHz) δ 6.68 (1H, dd,           
J = 8.8, 1.5 Hz, H18), 4.75 (1H, dd, J = 8.8, 7.1 Hz, H17), 4.20 (2H, qd, J = 7.1, 1.9 Hz, 
C(O)CH2CH3), 3.83-3.72 (2H, m, H16, H15a), 3.71-3.64 (1H, m, H15b), 1.92 (3H, d,     
J = 1.5 Hz, Me19), 1.89-1.77 (4H, m, (CH2CH2)2C(OR)2), 1.75-1.61 (4H, m, 
(CH2CH2)2C(OR)2), 1.29 (3H, t, J = 7.1 Hz, C(O)CH2CH3), 0.88 (9H, s, 
Si(CH3)2C(CH3)3) and 0.06 (6H, s, Si(CH3)2C(CH3)3); 13C NMR (101 MHz, CDCl3) 
δ 167.5, 137.3, 131.8, 119.6, 81.1, 74.1, 61.9, 60.8, 37.4, 37.3, 25.8, 23.4, 23.4, 18.3, 
14.2, 13.0, -5.3 and -5.5. HRMS (ES+) calcd. for C20H36O5Si [M+H]+ 385.2405, 
found 385.2405. 
 
 
Triphenyl(1-ethoxycarbonylethyl)phosphonium bromide (132)93 
 
 
 
Bromopropionate (16.49 g, 11.96 mL, 92.1 mmol) was added to Ph3P (16.12 g, 61.4 
mmol) and stirred at 50 ºC for 16 h. Hexane (50 mL) was then added to the solid and 
the solid cake broken up in to small pieces. The solid was then filtered, crushed in to 
smaller pieces and washed with hexane (2 x 50 mL). The solid was then dried under 
reduced pressure to yield phosphonium salt 132 as a white powder (23.2 g, 80 %).  
 
1H NMR (CDCl3, 400 MHz) δ 8.05-7.93 (6H, m, ArH), 7.83-7.61 (9H, m, ArH), 6.92 
(1H, dq, J = 15.8, 7.2 Hz, +P(Ph)3CHCH3), 4.11-3.92 (2H, m, OCH2CH3), 1.68 (3H, 
dd, J = 18.5, 7.2 Hz, +P(Ph)3CHCH3) and 1.00 (3H, t, J = 7.2 Hz, OCH2CH3). 
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Triphenyl(1-ethoxycarbonylethyl)phosphorane (130)93 
 
 
 
To a solution of NaOH (2.00 g, 50.0 mmol) in water (20 mL) at 0 ºC was added a 
solution of salt 132 (10.80 g, 24.4 mmol) in CH2Cl2 (20 mL). The reaction mixture 
was warmed to RT and stirred for 30 min. The organic layer was then separated and 
the aqueous layer extracted with CH2Cl2 (3 x 25 mL). The combined organic extracts 
were washed with brine (2 x 20 mL), dried (Na2SO4), filtered and concentrated in 
vacuo to yield the desired ylide 130 as a yellow crystalline solid (9.00 g, quant).  
 
M.pt. 156-157 ºC (Lit.93 157-158 ºC); 1H NMR (300 Hz, CDCl3, 2.4 : 1 rotameric 
ratio) δ 7.70-7.37 (15H, m, ArH), 4.05 (minor, 2H, q, J = 7.0 Hz, OCH2CH3), 3.71 
(major, 2H, q, J = 7.1 Hz, OCH2CH3), 1.62 (major, 3H, d, J = 13.8 Hz, CH3C=P), 
1.60 (minor, 3H, d, J = 14.3 Hz, CH3C=P) 1.26 (minor, 3H, t, 7.1 Hz, OCH2CH3) and 
0.45 (major, 3H, t, J = 7.1 Hz, OCH2CH3). 
 
 
2-((tert-Butyldimethylsilyl)oxy)ethanol (136)102 
 
 
 
To a suspension of NaH (60 wt% in mineral oil, 16.00 g, 0.400 mol) in THF (450 mL) 
was added freshly distilled ethylene glycol (10.0 g, 0.160 mol) dropwise, and the 
mixture stirred for 45 min. A solution of TBSCl (24.00 g, 0.160 mol) in THF (50 mL) 
was then added via cannula and stirring continued for 45 min. The reaction mixture 
was partitioned between Et2O (250 mL) and aq K2CO3 (10%, 250 mL) and the 
aqueous layer extracted with Et2O (3 x 500 mL). The combined organic extracts were 
washed with aq NaCl, dried (MgSO4), filtered and concentrated in vacuo. The 
resulting oil was purified by flash column chromatography (10% EtOAc/hexane) to 
give monoprotected glycol 136 (25 g, 88%)  
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Rf 0.35 (25% EtOAc/Hexane); 1H NMR (CDCl3, 400 MHz) δ 3.76-3.57 (4H, m, H11, 
H12), 2.01 (1H, bs, OH), 0.91 (9H, s, Si(CH3)2C(CH3)3) and 0.08 (6H, s, 
Si(CH3)2C(CH3)3). 
 
 
tert-Butyl(2-iodoethoxy)dimethylsilane (135)135 
 
 
 
To a solution of alcohol 136 (1.50 g, 8.52 mmol in THF (35 mL) was added imidazole 
(0.87 g, 12.8 mmol) and triphenylphosphine (2.90 g, 11.1 mmol) and the reaction 
stirred for 10 min. Iodine (2.58 g, 10.2 mmol) was then added and the mixture stirred 
for a further 30 min after which time the reaction was quenched with aq Na2S2O3    
(50 mL) and the aqueous layer extracted with Et2O (3 x 50 mL). The combined 
organic extracts were dried (MgSO4), filtered and concentrated in vacuo. The 
resulting oil was then purified by flash column chromatography (100% hexane) to 
give iodide 135 (1.70 g, 70%).  
 
Rf 0.80 (10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz) δ 3.83 (1H, t, J = 7.0 Hz, 
H11), 3.20 (1H, t, J = 7.0 Hz, H12), 0.91 (9H, s, Si(CH3)2C(CH3)3) and 0.09 (6H, s, 
Si(CH3)2C(CH3)3). 
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(S,S)-Pseudoephedrine propionamide (134)98,100  
 
 
 
To a solution of (+)-pseudoephedrine (4.00 g, 24.2 mmol) in CH2Cl2 (50 mL) was 
added triethylamine (4.05 mL, 2.94 g, 29.1 mmol) followed by dropwise addition of 
propionyl chloride (2.32 mL, 2.46 g, 26.6 mmol). The solution was stirred for 1 h 
before quenching the excess propionyl chloride with H2O (30 mL). The organic phase 
was separated and washed consecutively with half saturated aq NaHCO3 (10 mL) and 
HCl (1 N, 10 mL). The organic phase was then dried (MgSO4), filtered and 
concentrated in vacuo to furnish a viscous yellow oil. Recrystallisation from toluene 
afforded 134 as a white solid (4.76 g, 89%).  
 
Rf 0.35 (50% EtOAc/hexane); M.Pt. 113-114 ºC (Lit98 114-115 ºC, toluene);      
+111.3 (c 1.00, CHCl3), (Lit.136 +111.8 (c 1.00, CHCl3)); 1H NMR (CDCl3,  
300 MHz, 3 : 1 rotameric mixture) δ 7.45-7.29 (5H, m, ArH), 4.58 (1H, t, J = 8.1 Hz, 
CHOH), 4.49-4.38 (major, 1H, m, CHCH3), 4.09-3.95 (minor, 1H, m, CHCH3), 2.93 
(minor, 3H, s, NCH3), 2.81 (major, 3H, s, NCH3), 2.53 (minor, 1H, td, J = 15.2,      
7.6 Hz, CHaHbCH3), 2.45-2.37 (minor, 1H, m, CHaHbCH3), 2.32 (major, 2H, qd,       
J = 7.5, 5.8 Hz, CH2CH3), 1.13 (6H, m, CH2CH3, CHCH3) and 0.98 (minor, 3H, d,     
J = 6.8 Hz, CHCH3). 
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(R)-4-((tert-Butyldimethylsilyl)oxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-
N,2-dimethylbutanamide (137)97 
 
 
 
To a suspension of LiCl (3.13 g, 121 mmol) and diisopropylamine (6.03 mL, 4.35 g, 
43.0 mmol) in THF (30 mL) at -78 ºC was added n-BuLi (2.5 M solution in hexane, 
16.2 mL, 40.3 mmol). The resulting solution was warmed to 0 ºC briefly before 
cooling to -78 ºC. A solution of propionamide 134 (4.76 g, 21.5 mmol) in THF       
(75 mL) was cooled to 0 ºC and added via cannula. The mixture was stirred for 1 h at 
-78 ºC, 0 ºC for 15 min and RT for 5 min before cooling to 0 ºC. A solution of iodide 
135 (3.85 g, 13.4 mmol) in THF (8 mL) was then added and the mixture stirred for   
18 h at RT. The reaction was quenched by addition of aq NH4Cl (50 mL). The 
aqueous layer was extracted with EtOAc (3 x 150 mL), the combined organic extracts 
dried (Na2SO4), filtered and concentrated in vacuo. The resultant oil was purified by 
flash column chromatography (20% EtOAc/hexane) to afford amide 137 (450 mg, 
88%).  
 
Rf 0.53 (50% EtOAc/hexane); 1H NMR (C6D6, 400 MHz, 3 : 1 rotameric mixture) δ 
7.38-7.28 (2H, m, ArH), 7.20-7.13 (3H, m, ArH), 4.86 (1H, br s, OH), 4.54 (1H, t,     
J = 7.0 Hz, PhCHOH), 4.27-4.18 (major, 1H, m, CHOHCHCH3), 4.08-3.97 (minor, 
1H, m, CHOHCHCH3), 3.79-3.61 (minor, 1H, m, H11), 3.46 (major, 1H, ddd,             
J = 10.6, 6.2, 4.9 Hz, H11a), 3.37 (major, 1H, ddd, J = 10.6, 7.6, 4.6 Hz, H11b), 3.19-
3.07 (minor, 1H, m, H13), 2.84-2.65 (major, 1H, m, H13), 2.79 (minor, 3H, s, NCH3), 
2.53-2.44 (minor, 1H, m, H12a), 2.43 (major, 3H, s, NCH3), 1.93 (major, 1H, dddd,     
J = 13.7, 7.6, 6.2, 4.6 Hz, H12a), 1.64-1.56 (minor, 1H, m, H12b), 1.55-1.39 (major, 1H, 
m, H12b), 1.11 (minor, 3H, d, J = 6.9 Hz, Me13), 1.05 (major, 3H, d, J = 6.8 Hz, Me13), 
1.02 (major, 3H, d, J = 7.0 Hz, CHCH3N), 0.98 (minor, 9H, s, Si(CH3)2C(CH3)3), 
0.93 (major, 9H, s, Si(CH3)2C(CH3)3), 0.63 (minor, 3H, d, J = 6.7 Hz, CHCH3N), 
0.07 (minor, 3H, s, Si(CH3)2C(CH3)3), 0.07 (minor, 3H, s, Si(CH3)2C(CH3)3) 0.02 
(major, 3H, s, Si(CH3)2C(CH3)3) and 0.00 (major, 3H, s Si(CH3)2C(CH3)3). 
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(2R)-4-((tert-Butyldimethylsilyl)oxy)-2-methylbutan-1-ol (138)104 
 
 
 
To a solution of diisopropylamine (2.32 mL, 16.6 mmol) in THF (16 mL) at 0 °C was 
added n-BuLi (1.6 M solution in hexane, 9.60 mL, 15.4 mmol,). The resulting 
solution was stirred at 0 °C for 20 min. Borane-ammonia complex (90% purity,      
489 mg, 15.8 mmol) was added in one portion, and the suspension was stirred at 0 °C 
for 15 min and then warmed to RT. After 15 min, the suspension was cooled to 0 °C 
and a solution of amide 137 (1.50 g, 3.95 mmol) in THF (10 mL) was added via 
cannula. The reaction mixture was warmed to RT, stirred for 2 h, before cooling to    
0 °C where excess hydride was quenched by the addition of aq HCl (0.01 M, 10 mL). 
The mixture was stirred for 30 min at 0 °C and then extracted with EtOAc (4 x         
20 mL). The combined organic extracts were washed with aq HCl (0.1 M, 20 mL),    
1 M NaOH (2 x 60 mL), and brine (25 mL). The organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (10% Et2O/hexanes) to afford alcohol 138 (761 mg, 88%).  
Rf 0.30 (20% EtOAc/hexane); +11.4 (c 1.0, CHCl3) (Lit.104 +9.8 (c 1.0, 
CHCl3)), 1H NMR (CDCl3, 500 MHz) δ 3.79 (1H, dt, J = 10.5, 5.2 Hz, H11a), 3.69 
(1H, dt, J = 10.5, 6.0 Hz, H11b), 3.54 (1H, ddd, J = 11.2, 7.4, 4.7 Hz, H14a), 3.44 (1H, 
ddd, J = 11.2, 7.0, 5.0 Hz, H14b), 3.04 (1H, ddd, J = 7.4, 5.1, 2.2 Hz, OH), 1.94-1.76 
(1H, m, H13), 1.58 (2H, q, J = 6.2 Hz, H12), 0.94 (3H, d, J = 7.1 Hz, Me13), 0.93 (9H, 
s, Si(CH3)2C(CH3)3) and 0.10 (6H, s, Si(CH3)2C(CH3)3). 
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(3R)-tert-Butyl(4-iodo-3-methylbutoxy)dimethylsilane (122)104 
 
 
 
To a solution of Ph3P (360 mg, 1.37 mmol) and imidazole (117 mg, 1.71 mmol) in 
THF (8 mL) at 0 ºC was added a solution alcohol 138 (300 mg, 1.14 mmol) in THF  
(3 mL). The reaction was stirred for 10 min and then iodine (392 mg, 1.55 mmol) was 
added and the reaction mixture warmed to RT. After 30 min the reaction was 
quenched with addition of aq Na2S2O3 (10 mL) and the aqueous layer extracted with 
Et2O (3 x 15 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(2% EtOAc/hexane) to yield iodide 122 (380 mg, 85%).  
 
Rf 0.85 (20% EtOAc/hexane); -5.0 (c 1.04, CHCl3), (Lit.104 -4.9 (c 1.0, CHCl3)), 
1H NMR (CDCl3, 300 MHz) δ 3.64 (2H, td, J = 6.1, 1.3 Hz, H11), 3.28 (1H, dd,         
J = 9.6, 4.2 Hz, H14a), 3.20 (1H, dd, J = 9.6, 5.6 Hz, H14b), 1.73-1.51 (2H, m, H12), 
1.50-1.34 (1H, m, H13), 0.99 (3H, d, J = 6.4 Hz, Me13), 0.89 (9H, s, Si(CH3)2C(CH3)3) 
and 0.05 (6H, s, Si(CH3)2C(CH3)3). 
 
 
4-Benzyloxy-1-butanoic acid (140)105  
 
 
 
To a suspension of crushed potassium hydroxide (50.4 g, 0.884 mol) in toluene     
(300 mL) was added benzyl bromide (83.0 mL, 0.700 mol) and γ-butyrolactone 
(15.00 mL, 0.195 mol). The mixture was heated under reflux for 3 d, then was cooled 
to RT and allowed to stand for 1 d, before being partitioned between Et2O (300 mL) 
and H2O (200 mL). The aqueous phase was extracted with Et2O (3 x 300 mL) and the 
combined organic extracts were used as described below. The aqueous phase was 
cooled to 0 °C and slowly acidified with sulfuric acid (3 M). The acidic wash was 
extracted with Et2O (3 x 300 mL), the combined organic extracts dried (Na2SO4), 
filtered, and concentrated in vacuo to give a colourless oil. To the initial organic 
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phase from above was concentrated in vacuo to remove the Et2O, before addition of 
H2O (80 mL) and KOH (28.8 g, 0.500 mol), and the mixture heated under reflux for  
1 d. The resulting solution was diluted with H2O (200 mL) and extracted with Et2O   
(3 x 200 mL). The aqueous phase was cooled and acidified as above and extracted 
with Et2O (3 x 200 mL). The organic extracts were combined, dried (Na2SO4), 
filtered, and concentrated in vacuo to give a yellow oil. This oil was combined with 
that obtained previously, and the material was purified by Kugelrohr distillation to 
yield carboxylic acid 140 (27.5 g, 73%).  
 
Rf 0.30 (50% EtOAc/hexane); B.pt. 185 °C/1.0 mbar (Lit.105 135 ºC/1.0 mbar); 1H 
NMR (500 MHz, CDCl3) δ 7.43-7.27 (5H, m, ArH), 4.51 (2H, s, OCH2Ph), 3.54 (2H, 
t, J = 6.1 Hz, H11), 2.50 (2H, t, J = 7.3 Hz H13) and 1.95 (2H, tt, J = 7.3, 6.1 Hz, H12); 
 
 
(S,S)-4-Benzyloxy-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methylbutyramide 
(141)106 
 
 
 
To a stirred solution of carboxylic acid 140 (4.25 g, 21.9 mmol) in Et2O (160 mL) at 
RT was added Et3N (3.10 mL, 21.9 mmol). After 15 min the mixture was cooled to    
0 ºC and pivaloyl chloride (2.70 mL, 21.9 mmol) was added, immediately forming a 
thick white precipitate. The reaction was warmed to RT and stirred for a further hour 
before being cooled to 0 ºC. To the reaction mixture was then added a solution of  
(+)-pseudoephedrine (2.79 g, 16.9 mmol) and Et3N (2.63 mL, 16.9 mmol) in THF  
(45 mL). The mixture was then stirred at 0 ºC for 30 min before being warmed to RT 
and stirred for a further 30 min. The excess anhydride was then quenched through the 
addition of H2O (100 mL), the organic phase separated and washed with aq NaHCO3 
(50 mL) and HCl (1 M, 50 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography (20-40% 
EtOAc/hexane) to yield amide 141 (4.59 g, 80%) as a pale yellow oil.  
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Rf 0.20 (50% EtOAc/hexane); +78.8 (c 1.04, CHCl3), (Lit.106 +75.9 (c 1.08, 
CHCl3)); 1H NMR (CDCl3, 500 MHz, 3 : 1 rotameric mixture) δ 7.37-7.31 (10H, m, 
ArH), 4.62-4.57 (major, 1H, m, PhCHOH), 4.55-4.52 (minor, 1H, m, PhCHOH), 4.51 
(minor, 2H, s, OCH2Ph), 4.49 (major, 2H, s, OCH2Ph), 4.48-4.41 (major, 1H, m, 
CHOHCHCH3), 4.06 (minor, 1H, dd, J = 8.7, 6.7 Hz, CHOHCHCH3), 3.57 (minor, 
2H, td, J = 5.9, 2.6 Hz, H11), 3.52 (major, 2H, tt, J = 6.1, 3.2 Hz, H11), 2.90 (minor, 
3H, s, NCH3), 2.82 (major, 3H, s, NCH3), 2.62 (minor, 1H, dt, J = 14.9, 7.3 Hz, H13a), 
2.51 (minor, 1H, dt, J = 14.9, 7.3 Hz,, H13b), 2.47-2.36 (major, 2H, m, H13), 2.03-1.99 
(minor, 2H, m, H12), 1.99-1.89 (major, 2H, m, H12), 1.09 (major, 3H, d, J = 7.0 Hz, 
Me13) and 0.96 (minor, 1H, d, J = 6.8 Hz, Me13). 
 
 
(1S,2S,2’S)-4’-Benzyloxy-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl-2’-
methylbutyramide (142)106 
 
 
 
To a suspension of LiCl (2.87 g, 67.8 mmol) and i-Pr2NH (3.33 g, 4.68 mL,           
32.9 mmol) in THF (16 mL) at -78 ºC was added n-BuLi (2.5 M in hexane, 12.0 mL, 
30.0 mmol) dropwise over 15 min. The reaction mixture was warmed to 0 ºC for        
5 min before cooling back to -78 ºC and a solution of pseudoephedrine amide 141 
(3.30 g, 9.70 mmol) in THF (35 mL) was added via a cannula. The reaction was 
stirred for 1 h at -78 ºC, then 15 min at 0 ºC and 5 min at RT, before being cooled to  
0 ºC and MeI (4.12 g, 1.80 mL, 29.0 mmol) added to the reaction. The mixture was 
stirred for 15 min at 0 ºC, quenched with aq NH4Cl (50 mL) and then partitioned 
between EtOAc (50 mL) and aq NH4Cl and the aqueous layer extracted with EtOAc 
(3 x 50 mL). The combined organic extracts were washed with HCl (1 M, 25 mL), 
dried (Na2SO4), filtered and concentrated in vacuo to yield amide 142 (2.25 g, 66%) 
as a colourless oil.  
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Rf 0.33 (50% EtOAc/hexane); +93.9 (c 1.87, CHCl3), (Lit.106 +93.6 (c 1.88 
CHCl3)); 1H NMR (CDCl3, 500 MHz, 4.3 : 1 rotameric mixture) δ 7.39-7.29 (10H, 
m, ArH), 4.60 (major, 1H, t, J = 7.0 Hz, PhCHOH), 4.55 (minor, 1H, dd, J = 8.8,    
1.8 Hz, PhCHOH), 4.47 (major, 2H, s, OCH2Ph), 4.45 (minor, 2H, s, OCH2Ph), 4.42-
4.23 (1H, m, CHOHCHCH3), 3.58-3.46 (1H, m, H11a), 3.45-3.38 (1H, m, H11b), 3.24-
3.09 (minor, 1H, m, H13), 2.98-2.87 (major, 1H, m, H13), 2.91 (minor, 3H, s, NCH3) 
2.81 (major, 3H, s NCH3), 2.05-1.94 (1H, m, H12a), 1.72-1.61 (1H, m, H12b), 1.16 
(minor, 3H, d, J = 6.7 Hz, C(O)CHCH3), 1.12 (major, 3H, d, J = 7.0 Hz 
C(O)CHCH3), 1.03 (major, 3H, d, J = 6.8 Hz, Me13) and 0.96 (minor, 3H, d,               
J = 6.7 Hz, Me13) 
 
 
(2S)-4-(Benzyloxy)-2-methylbutan-1-ol (143) 
 
 
 
To a solution of diisopropylamine (958 µL, 6.75 mmol) in THF (10 mL) at 0 °C was 
added n-BuLi (2.5 M solution in hexane, 2.69 mL, 6.73 mmol,). The resulting 
solution was stirred at 0 °C for 20 min. Borane-ammonia complex (90% purity,      
304 mg, 6.80 mmol) was added in one portion, and the suspension was stirred at 0 °C 
for 15 min and then warmed to RT. After 15 min, the suspension was cooled to 0 °C 
and a solution of amide 142 (490 mg, 1.40 mmol) in THF (5 mL) was added via 
cannula. The reaction mixture was warmed to RT, stirred for 2 h, before cooling to 0 
°C where excess hydride was quenched by the addition of aq HCl (0.01 M, 5 mL). 
The mixture was stirred for 30 min at 0 °C and then extracted with EtOAc (4 x 20 
mL). The combined organic extracts were washed with aq HCl (0.1 M, 10 mL), aq 
NaOH (1 M, 2 x 20 mL), and brine (25 mL). The organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (20% EtOAc/hexanes) to afford alcohol 143 (230 mg, 86%).  
 
Rf 0.15 (20% EtOAc/hexane); +11.2 (c 1.12, CHCl3); IR 3370, 2953, 2924, 
2868, 1454, 1364, 1095, 1018, 908, 750 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.38-
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7.27 (5H, m, ArH), 4.52 (2H, s, OCH2Ph), 3.65-3.56 (1H, m, H11a), 3.57-3.47 (2H, m, 
H11b, H14a), 3.47-3.39 (1H, m, H14b), 2.53 (1H, br s, OH), 1.82 (1H, dh, J = 13.5,      
6.7 Hz, H13), 1.75-1.65 (1H, m, H12a), 1.65-1.52 (1H, m, H12b) and 0.92 (3H, d,           
J = 6.7 Hz, Me13); 13C NMR (100 MHz, CDCl3) δ 138.0, 128.5, 127.8, 127.7, 73.2, 
68.7, 68.1, 34.1, 34.1 and 17.2; HRMS (ES+) calcd. for C12H19O2 [M+H]+ 195.1380, 
found 195.1377. 
 
 
(3S)-((4-Iodo-3-methylbutoxy)methyl)benzene (123) 
 
 
 
To a suspension of PPh3 (212 mg, 0.800 mmol), imidazole (68 mg, 1.00 mmol) and 
iodine (230 mg, 0.900 mmol) in THF (2.5 mL) was added alcohol 143 (130 mg,  
0.700 mmol) in THF (2.5 mL). The reaction mixture was stirred for 15 min before 
being concentrated in vacuo and dry loaded on to a silica column for purification by 
flash column chromatography (0-2% EtOAc/hexane) to yield iodide 123 (180 mg, 
88%) as a colourless oil.  
Rf 0.55 (4% EtOAc/hexane); +8.0 (c 0.92, CHCl3); IR 3028, 2957, 2927, 2911, 
2855, 1452, 1364, 1194, 1096, 1026, 750 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.50-
7.30 (5H, m, ArH), 4.53 (2H, s, OCH2Ph), 3.53 (2H, t, J = 6.3 Hz, H11), 3.29 (1H, dd, 
J = 9.7, 4.2 Hz, H14a), 3.21 (1H, dd, J = 9.7, 5.6 Hz, H14b), 1.82-1.64 (2H, m, H12a, 
H13), 1.57 (1H, dt, J = 12.7, 6.3 Hz, H12b) and 1.02 (3H, d, J = 6.5 Hz, Me13);          
13C NMR (101 MHz, CDCl3) δ 138.4, 128.4, 127.6, 127.6, 73.0, 67.8, 36.2, 31.6, 
20.6 and 18.0; HRMS (ES+) calcd. for C12H21NIO [M+H]+ 322.0662, found 
322.0665. 
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(E)-3-((2R,3R)-3-(((tert-Butyldimethylsilyl)oxy)methyl)-1,4-dioxaspiro[4.4]nonan-
2-yl)-2-methylprop-2-en-1-ol (154) 
 
 
To a solution of ester 129 (6.80 g, 17.7 mmol) in CH2Cl2 (62 mL) at -78 ºC was added 
DIBAL (1 M in CH2Cl2, 38.90 mL, 38.9 mmol) dropwise. After 2 h, methanol       
(7.5 mL) was slowly added along with aq potassium sodium tartrate (125 mL) and the 
mixture allowed to warm to RT and stirred for an hour. The reaction was then 
partitioned between aq potassium sodium tartrate (180 mL) and Et2O (180 mL) and 
stirred for a further 2 h. The aqueous phase was then separated and extracted with 
Et2O (3 x 150 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography (15% EtOAc/hexane) to yield alcohol 154 (5.35 g, 88%) as a pale 
yellow oil. 
 
 Rf 0.4 (25% EtOAc/hexane); +17.2 (c 1.10, CHCl3); IR 3391, 2955, 2923, 
2857, 1252, 1107, 837, 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.48 (1H, dd,           
J = 9.0, 1.4 Hz, H18), 4.68 (1H, dd, J = 9.0, 7.8 Hz, H17), 4.01 (2H, s, H20), 3.81-3.71 
(1H, m, H15a), 3.70-3.60 (2H, m, H16, H15b), 1.92-1.75 (4H, m, (CH2CH2)2C(OR)2), 
1.73 (3H, d, J = 1.4 Hz, Me19), 1.70 – 1.57 (4H, m, (CH2CH2)2C(OR)2), 0.87 (9H, s, 
Si(CH3)2C(CH3)3), 0.05 (3H, s, Si(CH3)2C(CH3)3); and 0.03 (3H, s, 
Si(CH3)2C(CH3)3); 13C NMR (101 MHz, CDCl3) δ 141.5, 121.7, 118.9, 81.6, 73.8, 
67.8, 62.1, 37.5, 37.4, 25.9, 23.6, 23.4, 18.4, 14.2, -5.3 and -5.4; HRMS (ES+) calcd. 
for C18H34O4SiNa [M+Na]+ 365.2119, found 365.2120 
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tert-Butyl(((2R,3R)-3-((E)-3-((4-methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-
1,4-dioxaspiro[4.4]nonan-2-yl)methoxy)dimethylsilane (155) 
 
 
 
To a suspension of NaH (60 wt% in mineral oil, 175 mg, 4.39 mmol) and TBAI (275 
mg, 0.730 mmol) in THF (15 mL) at 0 ºC was added a solution of alcohol 154     
(0.50 g, 1.46 mmol) in THF (5 mL). The reaction mixture was stirred at 0 ºC for 30 
min before PMBCl (263 mg, 1.68 mmol) was added. The reaction was warmed to RT 
and stirred for 18 h before addition of sat aq NH4Cl (20 mL). The aqueous layer was 
extracted with Et2O (3 x 25 mL), the combined organic layers dried (MgSO4), filtered 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography (2.5-10% EtOAc/hexane) to yield PMB ether 155 (588 mg, 87%).  
 
Rf 0.40 (10% EtOAc/hexane); +13.4 (c 1.03, CHCl3); IR 2953, 2978, 2857, 
1612, 1512, 1246, 1103, 1036, 838, 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26 
(2H, d, J = 9.2, ArH), 6.89 (2H, d, J = 9.2 Hz, ArH), 5.52 (1H, dd, J = 8.9, 1.4 Hz, 
H18), 4.71 (1H, dd, J = 8.9, 7.7 Hz, H17), 4.40 (2H, s, OCH2PMP), 3.90 (2H, d,           
J = 1.3 Hz, H20), 3.83-3.75 (1H, m, H15a), 3.80 (3H, s, ArOCH3) 3.71-3.62 (2H, m, 
H16, H15b), 1.89-1.78 (4H, m, (CH2CH2)2C(OR)2), 1.76 (3H, d, J = 1.4 Hz, Me19), 
1.73-1.60 (4H, m, (CH2CH2)2C(OR)2), 0.90 (9H, s, Si(CH3)2C(CH3)3), 0.07 (3H, s, 
Si(CH3)2C(CH3)3) and 0.06 (3H, s, Si(CH3)2C(CH3)3); 13C NMR (101 MHz, CDCl3) 
δ 159.2, 138.6, 130.4, 129.3, 123.9, 118.9, 113.8, 81.6, 74.9, 73.7, 71.5, 62.0, 55.3, 
37.5, 37.5, 25.9, 23.5, 23.4, 18.3, 14.4, -5.4 and -5.5; HRMS (ES+) calcd. for 
C26H46NO5Si [M+NH4]+ 480.3140, found 480.3127. 
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((2R,3R)-3-((E)-3-((4-Methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-1,4-
dioxaspiro[4.4]nonan-2-yl)methanol (156) 
 
 
 
To a solution of TBS ether 155 (2.43 g, 5.26 mmol) in THF (50 mL) at 0 ºC was 
added TBAF (1.0 M in THF, 10.52 mL, 10.52 mmol). The reaction mixture was 
warmed to RT and stirred for 1 h, before being quenched with the addition of H2O (30 
mL) and the aqueous layer extracted with EtOAc (3 x 50 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated in vacuo. The crude product 
was purified by flash column chromatography (20-50% EtOAc/hexane) to yield 
alcohol 156 (1.78 g, 97%).  
 
Rf 0.28 (40% EtOAc/hexane); +19.2 (c 1.08, CHCl3); IR 3437, 2955, 2936, 
2872, 1612, 1512, 1333, 1246, 1101,1037, 819 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.27 (2H, d, J = 8.6 Hz, ArH), 6.89 (2H, d, J = 8.6 Hz, ArH), 5.52 (1H, dd, J = 8.9, 
1.4 Hz, H18), 4.66 (1H, t, J = 8.6 Hz, H17), 4.43 (2H, s, OCH2PMP), 3.92 (2H, s, H20), 
3.82 (3H, s, ArOCH3), 3.85-3.78 (1H, m, H15a) 3.74 (1H, ddd, J = 8.3, 4.1, 2.8 Hz, 
H15b), 3.58 (1H, ddd, J = 12.0, 7.9, 4.1 Hz, H16), 2.18 (1H, dd, J = 7.9, 4.9 Hz, 
CH2OH), 1.94 – 1.80 (4H, m, (CH2CH2)2C(OR)2), 1.77 (3H, d, J = 1.4 Hz, Me19) and 
1.75-1.66 (4H, m, (CH2CH2)2C(OR)2); 13C NMR (101 MHz, CDCl3) δC 159.2, 139.3, 
130.2, 129.3, 123.2, 119.1, 113.8, 81.4, 74.7, 73.1, 71.7, 60.9, 55.3, 37.5, 37.4, 23.5, 
23.4, and 14.4; HRMS (ES+) calcd. for C20H32NO5 [M+NH4]+ 366.2275, found 
366.2277. 
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(2S,3R)-3-((E)-3-((4-Methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-1,4-
dioxaspiro[4.4]nonane-2-carboxylic acid (162) 
 
 
 
To a suspension of DMP (5.12 g, 12.1 mmol) and NaHCO3 (1.68 g, 20.0 mmol) in 
CH2Cl2 (45 mL) at 0 ºC was added alcohol 156 (1.40 g, 4.02 mmol). The reaction 
mixture was stirred for 15 min at 0 ºC before warming to RT and stirring for a further 
2 h, when the reaction was quenched with aq Na2S2O3 (50 mL). The organic phase 
was separated and the aqueous layer extracted with CH2Cl2 (3 x 75 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4 and 
concentrated in vacuo. The resulting aldehyde 157 was taken up in a 3 : 1 mixture of 
tBuOH : H2O (36 mL : 12 mL) and cooled to 0 ºC. To the reaction mixture was added 
2-methyl-2-butene (2M in THF, 12.06 mL, 24.1 mmol), followed by dropwise 
addition of an aqueous solution of NaClO3 (727 mg, 8.04 mmol) and NaH2PO4!2H2O 
in H2O (24 mL). The reaction mixture was then allowed to warm to RT and stirred for 
16 h, before quenching with H2O (50 mL) and AcOH (4 drops). The reaction mixture 
was extracted with EtOAc (3 x 75 mL), the organic extracts combined, dried 
(Na2SO4), filtered and concentrated in vacuo to yield acid 162 as a viscous colourless 
oil. The acid was then taken forward without further purification.  
 
Rf 0.10 (40% EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 7.27 (2H, d, J = 8.5 Hz, 
ArH), 6.88 (2H, d, J = 8.5 Hz, ArH), 5.59 (1H, dd, J = 8.8, 1.4 Hz, H18), 4.87 (1H, dd, 
J = 8.8, 7.3 Hz, H17), 4.42 (2H, s, OCH2PMP), 4.20 (1H, d, J = 7.3 Hz, H16), 3.92 
(2H, s, H20), 3.81 (3H, s, ArOCH3), 2.01-1.79 (4H, m, (CH2CH2)2C(OR)2), 1.76 (3H, 
d, J = 1.4 Hz, Me19) and 1.75-1.64 (4H, m, (CH2CH2)2C(OR)2); HRMS (ES+) calcd. 
for C20H30NO6 [M+NH4]+ 380.2068, found 380.2063. 
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(2S,3R)-N-Methoxy-3-((E)-3-((4-methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-N-
methyl-1,4-dioxaspiro[4.4]nonane-2-carboxamide (163) 
 
 
 
To a stirred solution of crude acid 162 (1.50 g, 4.00 mmol) in CH2Cl2 (24 mL) at       
0 °C, were added MeNH(OMe)!HCl (585 mg, 6.00 mmol), DMAP (785 mg,         
7.00 mmol), and DCC (1.44 g, 7.00 mmol). The mixture was gradually warmed to RT 
over 3 h and filtered through a pad of Celite®. The filtrate was successively washed 
with aq NH4Cl (15 mL), aq NaHCO3 (15 mL) and brine, dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(15% hexane/EtOAc) to give amide 163 (1.16 g, 68%).  
 
Rf 0.35 (20% EtOAc/hexane); +15.1 (c 1.46, CHCl3); IR 2955, 2938, 2872, 
1724, 1611, 1512, 1337, 148, 1098, 1030, 817 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.25 (2H, d, J = 8.7 Hz, ArH), 6.88 (2H, d, J = 8.7 Hz, ArH), 5.58 (1H, d, J = 8.9 Hz, 
H18), 5.06 (1H, t, J = 8.7 Hz, H17), 4.51 (1H, d, J = 7.3 Hz, H16), 4.40 (2H, s, 
OCH2PMP), 3.89 (2H, s, H20), 3.81 (3H, s, ArOCH3), 3.68 (3H, s, NOCH3), 3.21 (3H, 
s, NCH3), 2.07-1.81 (4H, m, CH2CH2)2C(OR)2), 1.75 (3H, s, Me19) and 1.73-1.64 
(4H, m, CH2CH2)2C(OR)2); 13C NMR (101 MHz, CDCl3) δ 206.9, 159.2, 139.6, 
130.4, 129.3, 122.8, 120.7, 113.8, 76.4, 75.1, 74.6, 71.6, 68.9, 55.3, 37.0, 30.9, 23.9, 
23.3 and 14.4; HRMS (EP+) calcd. for C22H32NO6 [M+H]+ 406.2224, found 
406.2225. 
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(R)-5-((tert-Butyldimethylsilyl)oxy)-1-((2S,3R)-3-((E)-3-((4-methoxybenzyl)oxy)-
2-methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonan-2-yl)-3-methylpentan-1-one 
(164) 
 
 
 
To a solution of iodide 122 (160 mg, 0.530 mmol) in Et2O (4.5 mL) at -78 ºC was 
added t-BuLi (1.9 M in pentane, 0.56 mL, 1.05 mmol). After 15 min at -78 ºC the 
reaction mixture was warmed to 0 ºC and stirred for a further 20 min, before recooling 
to -78 ºC. Weinreb amide 163 (100 mg, 0.250 mmol) in THF (6 mL) was added 
dropwise and the mixture stirred for 15 min before warming to 0 ºC for 20 min. The 
reaction was quenched with aq NH4Cl (10 mL) and the aqueous phase extracted with 
Et2O (3 x 15 mL). The organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography (10% EtOAc/hexane) to yield ketone 164 (100 mg, 78%). 
 
Rf 0.21 (10% EtOAc/hexane);  +13.6 (c 1.0, CHCl3); IR, 2955, 2928, 2855, 
1717, 1612, 1512, 1248, 1096, 833, 757 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.27 
(2H, d, J = 8.6 Hz, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.57 (1H, dd, J = 9.0, 1.4 Hz, 
H18), 4.69 (1H, dd, J = 9.0, 7.6 Hz, H17) 4.41 (2H, s, OCH2PMP), 4.04 (1H, d,            
J = 7.6 Hz, H16), 3.91 (2H, s, H20), 3.81 (3H, s, ArOCH3), 3.71-3.57 (2H, m, H11), 
2.60 (1H, dd, J = 17.4, 5.6 Hz, H14a), 2.44 (1H, dd, J = 17.4, 7.8 Hz, H14b), 2.18 (1H, 
h, J = 6.9 Hz, H13), 1.99-1.61 (4H, m, (CH2CH2)2C(OR)2), 1.73 (3H, d, J = 1.4 Hz, 
Me19), 1.76-1.61 (4H, m, (CH2CH2)2C(OR)2), 1.51 (1H, dt, J = 13.7, 6.7 Hz, H12a), 
1.39 (1H, dt, J = 13.7, 6.9 Hz, H12b), 0.91 (3H, d, J = 6.6 Hz, Me13) 0.88 (9H, s, 
Si(CH3)2C(CH3)3) and 0.03 (6H, s, Si(CH3)2C(CH3)3); 13C NMR (126 MHz, CDCl3) 
δ 208.4, 159.2, 139.7, 130.3, 129.4, 122.9, 120.4, 113.8, 85.1, 74.5, 74.5, 71.5, 61.2, 
55.3, 46.5, 39.6, 37.0, 36.8, 26.0, 25.4, 23.7, 23.3, 20.0, 18.3, 14.5 and -5.3; HRMS 
(ES+) calcd. for C21H54NO6Si [M+NH4]+ 564.3715, found 564.3706. 
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(1S,3R)-5-((tert-Butyldimethylsilyl)oxy)-1-((2R,3R)-3-((E)-3-((4-
methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonan-2-yl)-3-
methylpentan-1-ol (166) 
 
 
 
To a solution of ketone 164 (25 mg, 48.0 µmol) in THF (2.5 mL) at -78 ºC was added 
K-Selectride® (1.0 M in THF, 0.18 mL, 0.18 mmol) and the reaction stirred at  -78 ºC 
for 16 h. The reaction mixture was quenched by addition of aq NH4Cl (3 mL) and the 
aqueous phase was extracted with Et2O (3 x 10 mL). The combined organic extracts 
were then dried (Na2SO4), filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (10% EtOAc/hexane) to yield alcohol 166 
(17 mg, 69%, d.r. 6.4 : 1) as a colourless oil. 
 
Rf 0.30 (20% EtOAc/hexane);  +10.8 (c 1.40, CHCl3); IR 3432, 2953, 2926, 
2855, 1514, 1248, 1097, 1037, 933, 773 cm-1; 1H NMR (CDCl3, 500 MHz, d.r. 6.4 : 
1) δ 7.27 (1H, d, J = 8.9 Hz, ArH), 6.89 (1H, d, J = 8.7 Hz, ArH), 5.51 (1H, dd,          
J = 9.1, 1.5 Hz, H18), 4.77 (minor, 0.15H, dd, J = 9.4, 7.6 Hz, H17), 4.67 (major, 
0.85H, dd, J = 9.1, 7.9 Hz, H17), 4.42 (major, 1.7H, s, OCH2PMP), 4.40 (minor, 0.3H, 
s, OCH2PMP), 3.92 (2H, s, H20), 3.82 (3H, s, ArOCH3), 3.73-3.57 (3H, m, H11, H15), 
3.52 (1H, dd, J = 7.9, 3.5 Hz, H16), 2.02 (1H, d, J  = 7.8 Hz, OH), 1.97-1.80 (5H, m, 
H13, (CH2CH2)2C(OR)2), 1.79 (3H, d, J = 1.5 Hz, Me19), 1.76-1.65 (4H, m, 
(CH2CH2)2C(OR)2), 1.65-1.60 (1H, m, H14a), 1.59-1.48 (1H, m, H12a), 1.48-1.38 (1H, 
m, H12b), 1.12 (1H, ddd, J=14.0, 9.9, 2.9 Hz, H14b), 0.95 (minor, 0.45H, d, J = 6.8 Hz, 
Me13), 0.93 (major, 2.55H, d, J = 6.6 Hz, Me13), 0.90 (9H, s, Si(CH3)2C(CH3)3) and 
0.05 (6H, s, Si(CH3)2C(CH3)3); 13C NMR (126 MHz, CDCl3) δ 208.4, 159.2, 139.7, 
130.3, 129.4, 122.9, 120.4, 113.8, 85.1, 74.5, 74.5, 71.5, 61.2, 55.3, 46.5, 39.6, 37.0, 
36.8, 26.0, 25.4, 23.7, 23.3, 20.0, 18.3, 14.5 and -5.3; HRMS (ES+) calcd. for 
C21H56NO6Si [M+NH4]+ 566.3871, found 566.3867. 
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(R)-Mosher ester of alcohol 166 137,138  
 
 
 
To a solution of (R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (8.2 mg,      
36.5 µmol) in n-hexane (1.6 mL) at RT was added DMF (3 µL, 36.5 µmol) and oxalyl 
chloride (14 µL, 0.164 mmol). After 1 h the reaction mixture was filtered and 
concentrated in vacuo. The resultant acid chloride and DMAP (4.4 mg, 36.5 µmol) 
were taken up in CH2Cl2 (1 mL) and to this solution was added alcohol 166 (9.8 mg, 
18.0 µmol) in CH2Cl2 (1 mL) and DBU (7 µL, 46.8 µmol). The reaction mixture was 
stirred for 18 h before being quenched with H2O (2 mL) and extracted with CH2Cl2  
(3 x 5 mL). The combined organic extracts were dried (Na2SO4), filtered and the 
solvent removed in vacuo. The crude product was purified by flash column 
chromatography (100% CH2Cl2) to yield the Mosher ester (7 mg, 51%).  
 
Rf 0.35 (10% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz) δ 7.63-7.57 (2H, m, 
ArH), 7.43-7.35 (3H, m, ArH), 7.24 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J = 8.6 Hz, 
ArH), 5.43 (1H, dd, J = 9.2, 1.6 Hz, H18), 5.29 (1H, ddd, J = 9.5, 5.6, 3.5 Hz, H15), 
4.41-4.36 (1H, m, H17), 4.38 (2H, s, OCH3PMP), 3.87 (2H, s, H20), 3.80 (3H, s, 
ArOCH3), 3.69 (1H, dd, J = 7.7, 5.6 Hz, H16), 3.61-3.52 (2H, m, H11), 3.55 (3H, s, 
MTPA-OCH3) 1.87-1.72 (5H, m, H14a, (CH2CH2)2C(OR)2), 1.70 (3H, d, J = 1.4 Hz, 
Me19), 1.69-1.58 (5H, m, H13, (CH2CH2)2C(OR)2), 1.52-1.45 (1H, m, H12a), 1.37-1.20 
(2H, m, H12b, H14b), 0.95 (3H, d, J = 6.5 Hz, Me13), 0.86 (9H, s, Si(CH3)2C(CH3)3) 
and 0.01 (6H, d, J=1.1 Hz Si(CH3)2C(CH3)3) 
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(S)-Mosher ester of alcohol 166 
 
 
 
To a stirred mixture of alcohol 166 (5 mg, 9.12 µmol), DCC (7.5 mg, 36.5 µmol) and 
DMAP (2.2 mg. 18.2 µmol) in CH2Cl2 at RT was added (S)-α-methoxy-α-
(trifluoromethyl)-phenylacetic acid (4.2 mg, 18.2 µg). The reaction was stirred for 18 
h before the solvent was removed in vacuo and the crude product purified by flash 
column chromatography (100% CH2Cl2) to yield the Mosher ester (5.1 mg, 72%) as a 
pale yellow oil.  
 
Rf 0.35 (10% EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 7.71-7.59 (2H, m, 
ArH), 7.44-7.34 (3H, m, ArH), 7.24 (2H, d, J = 8.7 Hz, ArH), 6.87 (2H, d, J = 8.7 Hz, 
ArH), 5.49 (1H, dd, J = 9.2, 1.4 Hz, H18), 5.37 (1H, ddd, J = 10.7, 6.6, 2.5 Hz, H15), 
4.46 (1H, dd, J = 9.2, 7.5 Hz, H17), 4.39 (2H, s, OCH3Ph), 3.89 (2H, s, H20), 3.80 (3H, 
s, ArOCH3), 3.75 (1H, dd, J = 7.5, 6.6 Hz, H16), 3.59 (3H, s, MTPA-OCH3), 3.52-
3.39 (2H, m, H11), 1.94-1.75 (4H, m, (CH2CH2)2C(OR)2), 1.72 (3H, d, J = 1.4 Hz, 
Me19), 1.69-1.61 (5H, m, H14a, (CH2CH2)2C(OR)2), 1.45-1.19 (3H, m, H12, H13), 1.14-
1.05 (1H, m, H14b), 0.89 (3H, d, J = 6.2 Hz, Me13), 0.85 (9H, s, Si(CH3)2C(CH3)3) and 
-0.01 (6H, d, J = 1.3 Hz, Si(CH3)2C(CH3)3) 
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167: (S)-MTPA ester
168: (R)-MTPA ester
δ(S)/ppm
5.49
4.46
3.75
5.37
1.66
1.36
0.89
Assignment
18-H
17-H
16-H
15-H
14-H2
13-H
13-Me
Δδ(S-R)
+0.06
+0.07
+0.06
+0.08
-0.10
-0.30
-0.06
δ(R)/ppm
5.43
4.39
3.69
5.29
1.77
1.66
0.95
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tert-Butyl(((3R,5S)-5-methoxy-5-((2R,3R)-3-((E)-3-((4-methoxybenzyl)oxy)-2-
methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonan-2-yl)-3-methylpentyl)oxy) 
dimethylsilane (169) 
 
 
 
NaH (60 wt% in mineral oil, 79 mg, 1.64 mmol) was sealed in an argon-purged flask 
and washed with hexane (2 x 1 mL). The NaH was then suspended in THF (3 mL) 
and cooled to 0 ºC before alcohol 166 (275 mg, 0.500 mmol) in THF (6 mL) was 
added. The reaction was stirred for 15 min at 0 ºC and then allowed to warm to RT, 
before MeI (233 mg, 102 µL, 1.64 mmol) was added. The reaction mixture was 
stirred for 3 h before cooling to 0 ºC and H2O (5 mL) was added. The aqueous phase 
was extracted with EtOAc (3 x 10 mL) and the combined organic extracts were then 
dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (10% EtOAc/hexane) to yield methyl ether 169       
(265 mg, 94%) as a colourless oil.  
 
Rf 0.65 (20% EtOAc/hexane);  +90.7 (c 0.38 CHCl3); IR 2953, 2928, 2855, 
1612, 1512, 1462, 1247, 1095, 1036, 833, 773 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.25 (2H, d, J = 8.6 Hz, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.49 (1H, dd, J = 9.3, 
1.4 Hz, H18), 4.55 (1H, dd, J = 9.3, 7.9 Hz, H17), 4.39 (2H, d, J = 2.7 Hz, OCH2PMP), 
3.91 (2H, dd, J = 4.0, 1.3 Hz, H20), 3.80 (3H, s, ArOCH3), 3.70 (1H, dd, J = 7.9,      
5.4 Hz, H16), 3.68-3.58 (2H, m, H11), 3.45 (3H, s, CHOCH3), 3.31 (1H, ddd, J = 9.1, 
5.4, 3.5 Hz, H15), 1.93-1.79 (5H, m, H13, (CH2CH2)2C(OR)2), 1.77 (3H, d, J = 1.4 Hz, 
Me19), 1.76-1.60 (4H, m, (CH2CH2)2C(OR)2), 1.58-1.49 (2H, m, H12a, H14a), 1.39-1.30 
(1H, m, H12b), 1.15 (1H, ddd, J = 14.0, 9.4, 3.5 Hz, H14b), 0.92 (3H, d, J = 6.6 Hz, 
Me13), 0.88 (9H, s, Si(CH3)2C(CH3)3) and 0.03 (6H, s, Si(CH3)2C(CH3)3); 13C NMR 
(126 MHz, CDCl3) δ 159.2, 138.8, 130.3, 129.3, 124.3, 118.7, 113.8, 83.3, 78.3, 74.8, 
73.5, 71.4, 61.2, 58.6, 55.3, 40.7, 38.5, 37.4, 37.2, 26.0, 26.0, 23.6, 23.5, 19.5, 18.3, 
14.4, and -5.3; HRMS (ES+) calcd. for C32H58NO6Si [M+NH4]+ 580.4028, found 
580.4018. 
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(S)-5-(Benzyloxy)-1-((2S,3R)-3-((E)-3-((4-methoxybenzyl)oxy)-2-methylprop-1-
en-1-yl)-1,4-dioxaspiro[4.4]nonan-2-yl)-3-methylpentan-1-one (170) 
 
 
 
To a solution of iodide 123 (160 mg, 0.530 mmol) in Et2O (4.5 mL) at -78 ºC was 
added t-BuLi (1.9M in pentane, 0.56 mL, 1.05 mmol). After 15 min at -78 ºC the 
reaction mixture was warmed to 0 ºC and stirred for a further 20 min, before recooling 
to -78 ºC. Weinreb amide 163 (100 mg, 0.250 mmol) in THF (6 mL) was added 
dropwise and the mixture stirred for 15 min before warming to 0 ºC for 20 min. The 
reaction was quenched with aq NH4Cl (10 mL) and the aqueous phase extracted with 
Et2O (3 x 15 mL). The combined organic extracts, dried (Na2SO4), filtered and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography (10% EtOAc/hexane) to yield ketone 170 (100 mg, 78%).  
 
Rf 0.15 (10% EtOAc/hexane);  +15.8  (c 1.02, CHCl3); IR 2955, 2928, 2855, 
1715, 1612, 1512, 1454, 1248, 1099, 1028, 820 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
7.39-7.30 (5H, m, ArH), 7.28-7.24 (2H, m, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.55 
(1H, dd, J = 9.0, 1.4 Hz, H18), 4.74-4.65 (1H, m, H17), 4.47 (2H, s, OCH2Ph), 4.41 
(2H, s, OCH2PMP), 4.02 (1H, d, J = 7.6 Hz, H16), 3.91 (2H, s, H20), 3.80 (3H, s, 
ArOCH3), 3.49 (2H, td, J = 6.6, 1.5 Hz, H11), 2.61 (1H, dd, J = 17.5, 5.3 Hz, H14a), 
2.45 (1H, dd, J = 17.5, 8.1 Hz, H14b), 2.31-2.22 (1H, m, H13), 1.93-1.75 (H, m, 
(CH2CH2)2C(OR)2), 1.72 (3H, d, J = 1.4 Hz, Me19), 1.71–1.58 (5H, m, H12a, 
(CH2CH2)2C(OR)2), 1.59-1.46 (1H, m, H12b) and 0.92 (3H, d, J = 6.7 Hz, Me13);     
13C NMR (101 MHz, CDCl3) δ 208.4, 159.2, 139.7, 138.5, 130.3, 129.4, 128.4, 
127.6, 127.5, 122.9, 120.4, 113.8, 85.1, 74.5, 74.4, 72.9, 71.5, 68.4, 55.3, 46.3, 37.0, 
36.8, 36.5, 25.7, 23.6, 23.3, 20.1 and 14.4; HRMS (ES+) calcd. for C32H46NO6 
[M+NH4]+ 540.3320, found 542.3312. 
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(1S,3S)-5-(Benzyloxy)-1-((2R,3R)-3-((E)-3-((4-methoxybenzyl)oxy)-2-
methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonan-2-yl)-3-methylpentan-1-ol (171) 
 
 
 
To a solution of ketone 170 (25 mg, 48.0 µmol) in THF (2.5 mL) at -78 ºC was added 
K-Selectride (1.0 M in THF, 0.18 mL, 0.180 mmol) and the reaction stirred at -78 ºC 
for 16 h. The reaction mixture was quenched by addition of aq NH4Cl (3 mL) and the 
aqueous phase extracted with Et2O (3 x 10 mL). The combined organic extracts were 
then dried (Na2SO4), filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (10% EtOAc/hexane) to yield alcohol 171 
(24.5 mg, 98%, d.r. = 5 : 1).  
 
Rf 0.43 (20% EtOAc/hexane);  +4.6 (c 0.46 CHCl3); IR 3416, 3221, 2953, 
2927, 2868, 1612, 1512, 1454, 1248, 1100, 1034, 820 cm-1; 1H NMR (CDCl3,        
500 MHz) δ 7.38-7.30 (5H, m ArH), 7.25 (2H, d, J = 8.7 Hz, ArH), 6.87 (2H, d,         
J = 8.7 Hz ArH), 5.49 (1H, dd, J = 9.2, 1.4 Hz, H18), 4.65 (1H, dd, J = 9.2, 7.9 Hz, 
H17), 4.50 (2H, s, OCH2Ph), 4.40 (2H, s, OCH2PMP), 3.90 (2H, s, H20), 3.80 (3H, s, 
ArOCH3), 3.68-3.58 (1H, m, H15), 3.56-3.46 (3H, m, H11, H16), 1.96-1.79 (5H, m, H13, 
(CH2CH2)2C(OR)2), 1.78 (3H, s, Me19), 1.72-1.58 (5H, m, H12a, (CH2CH2)2C(OR)2), 
1.57-1.43 (1H, m, H14a), 1.43-1.31 (2H, m, H12b, H14b) and 0.93 (3H, d, J = 6.6 Hz, 
Me13); 13C NMR (126 MHz, CDCl3) δ 159.2, 139.5, 138.5, 130.2, 129.3, 128.4, 
127.7, 127.5, 123.3, 118.9, 113.8, 83.8, 74.7, 73.7, 73.0, 72.9, 71.6, 68.6, 67.9, 55.3, 
42.1, 37.5, 35.9, 26.9, 23.5, 23.5 20.6 and 14.5; HRMS (ES+) calcd. for C32H48NO6 
[M+NH4]+ 542.3476, found 542.3466. 
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(2R,3R)-2-((1S,3S)-5-(Benzyloxy)-1-methoxy-3-methylpentyl)-3-((E)-3-((4-
methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonane (172) 
 
 
 
NaH (60 wt% in mineral oil, 2.7 mg, 67.0 µmol) was sealed in an argon-purged flask 
and washed with hexane (2 x 0.25 mL). The NaH was then suspended in THF (1 mL) 
and cooled to 0 ºC before alcohol 171 (7 mg, 13.0 µmol) in THF (1 mL) was added. 
The reaction was stirred for 15 min at 0 ºC and then allowed to warm to RT, when 
MeI (9.5 mg, 4.2 µL, 67 µmol) was added. The reaction mixture was then stirred for 3 
h before cooling to 0 ºC and H2O (2 mL) was added. The aqueous phase was 
extracted with EtOAc (3 x 5 mL) and the combined organic extracts were then dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (10% EtOAc/hexane) to yield methyl ether 172 (5 mg, 70%) 
as a colourless oil.  
 
Rf 0.65 (20% EtOAc/hexane);  +7.3 (c 0.46 CHCl3); IR 2953, 2928, 2870, 
1612, 1514, 1454, 1248, 1100, 1038, 820 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.39-
7.29 (3H, m, ArH), 7.31-7.20 (4H, m, ArH), 6.87 (2H, d, J = 8.6 Hz, ArH), 5.48 (1H, 
dd, J = 9.3, 1.6 Hz, H18), 4.58 (1H, dd, J = 9.3, 7.9 Hz, H17), 4.55-4.45 (2H, m, 
CH2Ph), 4.43-4.34 (2H, m, OCH2PMP), 3.95-3.87 (2H, m, H20), 3.80 (3H, d,              
J = 4.1 Hz, ArOCH3), 3.69 (1H, dd, J = 7.9, 4.6 Hz, H16), 3.51 (2H, dtd, J = 13.0, 9.2, 
6.7 Hz, H11), 3.43 (3H, s, CHOCH3), 3.27 (1H, td, J = 6.3, 4.6 Hz, H15), 1.92-1.72 
(9H, m, H12, H13, (CH2CH2)2C(OR)2), 1.76 (3H, d, J = 1.6 Hz, Me19), 1.72-1.60 (4H, 
m, (CH2CH2)2C(OR)2), 1.47-1.34 (2H, m, H14) and 0.90 (3H, d, J = 6.4 Hz, Me13); 
13C NMR (126 MHz, CDCl3) δ 159.2, 138.9, 138.6, 130.3, 129.3, 128.4, 127.6, 
127.5, 124.3, 118.7, 113.8, 82.7, 78.1, 74.8, 73.3, 73.0, 71.4, 68.5, 58.5, 55.3, 38.1, 
37.4, 37.2, 36.4, 26.6, 23.6, 23.5, 20.5 and 14.4; HRMS (ES+) calcd. for C33H50NO6 
[M+NH4]+ 556.3633, found 556.3621. 
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6.5 Experimental for Chapter Four 
 
(3R,5S)-5-Methoxy-5-((2R,3R)-3-((E)-3-((4-methoxybenzyl)oxy)-2-methylprop-1-
en-1-yl)-1,4-dioxaspiro[4.4]nonan-2-yl)-3-methylpentan-1-ol (178) 
 
 
 
To a solution of silyl ether 169 (250 mg, 0.444 mmol) in THF (20 mL) at 0 ºC was 
added TBAF (1.0 M in THF, 0.88 mL, 0.880 mmol) and the reaction stirred for 2 h. 
After this time the reaction was quenched with H2O (20 mL) and extracted with 
EtOAc (3 x 40 mL). The organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The product was purified by flash column chromatography 
(25% EtOAc/hexane) to afford alcohol 178 (197 mg, 99%) as a colourless oil. 
 
Rf 0.42 (50% EtOAc/hexane); +7.9 (c 2.36, CHCl3); IR 3428, 2953, 2932, 
2872, 1612,1512, 1333, 1246, 1097, 1034, 818 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
7.25 (2H, d, J = 8.6 Hz, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.50 (1H, dd, J = 9.4, 
1.4 Hz, H18), 4.51 (1H, dd, J = 9.4, 7.9 Hz, H17), 4.44 (2H, d, J = 6.8 Hz, OCH2PMP), 
3.91 (2H, d, J = 2.3 Hz, H20), 3.79 (3H, s, ArOCH3), 3.71 (1H, dd, J = 7.9, 5.7 Hz, 
H16), 3.69-3.54 (2H, m, H11), 3.47 (3H, s, CHOCH3), 3.33 (1H, ddd, J = 9.2, 5.7,     
3.3 Hz, H15), 2.03 (1H, s, OH), 1.90-1.78 (5H, m, H13, (CH2CH2)2C(OR)2), 1.76 (3H, 
d, J = 1.4 Hz, Me19), 1.73-1.61 (4H, m, (CH2CH2)2C(OR)2), 1.57-1.33 (3H, m, H12, 
H14a), 1.20-1.08 (1H, m, H14b) and 0.93 (3H, d, J = 6.7 Hz, Me13); 13C NMR         
(101 MHz, CDCl3) δ 159.2, 138.8, 130.2, 129.3, 124.3, 118.7, 113.8, 83.3, 79.0, 74.8, 
73.6, 71.5, 60.5, 58.9, 55.3, 40.4, 37.9, 37.4, 37.2, 25.9, 23.6, 23.5, 19.8 and 14.5. 
HRMS (ES+) calcd. for C26H44NO6 [M+NH4]+ 446.3163, found 466.3155. 
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(2R,3R)-2-((1S,3S)-5-Iodo-1-methoxy-3-methylpentyl)-3-((E)-3-((4-
methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonane (179) 
 
 
 
To a suspension of PPh3 (47 mg, 0.180 mmol) and imidazole (12 mg, 0.180 mmol) at    
0 ºC in THF (1 mL) was added alcohol 178 (20 mg, 44.0 µmol) in THF (0.5 mL). The 
reaction mixture was stirred for 15 min before iodine (46 mg, 0.180 mmol) was added 
and the reaction mixture stirred for a further 30 min before being quenched with aq 
Na2S2O3 (2 mL). The aqueous phase was extracted with Et2O (3 x 5 mL) and the 
combined organic extracts dried (Na2SO4), filtered and concentrated in vacuo. The 
product was purified by flash column chromatography (5% EtOAc/hexane) to yield 
iodide 179 (24 mg, 97%) as a colourless oil.  
 
Rf 0.53 (25% EtOAc/hexane); +18.7 (c 1.4, CHCl3); IR 2953, 2930, 2870, 
1642, 1512, 1246, 1099, 1033, 820 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.30-7.22 
(2H, m, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 5.49 (1H, dd, J = 9.4, 1.4 Hz, H18), 4.53 
(1H, dd, J = 9.4, 7.8 Hz, H17), 4.40 (2H, d, J = 3.6 Hz, OCH2PMP), 3.91 (2H, d,         
J = 4.6 Hz, H20), 3.80 (3H, s, ArOCH3), 3.71 (1H, dd, J = 7.8, 5.3 Hz, H16), 3.46 (3H, 
s, CHOCH3), 3.31 (1H, ddd, J = 9.1, 5.3, 3.4 Hz, H15), 3.27-3.19 (1H, m, H11a), 3.17-
3.09 (1H, m, H11b), 1.93-1.78 (6H, m, H13, H12a, (CH2CH2)2C(OR)2), 1.77 (3H, d,       
J = 1.4 Hz, Me19), 1.73-1.63 (5H, m, H12b, (CH2CH2)2C(OR)2), 1.56-1.49 (1H, m, 
H14a), 1.21-1.15 (1H, m, H14b) and 0.92 (3H, d, J = 6.5 Hz, Me13); 13C NMR         
(126 MHz, CDCl3) δ 159.2, 139.0, 130.3, 129.3, 124.2, 118.8, 113.8, 83.2, 78.2, 74.8, 
73.5, 71.5, 58.8, 55.3, 41.7, 37.6, 37.5, 37.2, 30.6, 23.6, 23.5, 18.7, 14.5 and 4.4; 
HRMS (ES+) calcd. for C26H43NIO5 [M+NH4]+ 576.2180, found 576.2181. 
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(2R,3R)-2-((1S,3R)-1-Methoxy-3-methyl-5-phenylpentyl)-3-((E)-3-((4-
methoxybenzyl)oxy)-2-methylprop-1-en-1-yl)-1,4-dioxaspiro[4.4]nonane (180) 
 
 
 
To a solution of iodide 179 (27 mg, 48.0 µmol) in Et2O (1 mL) at -78 ºC was added   
t-BuLi (1.9 M in pentane, 60.0 µL, 0.120 mmol) and the reaction mixture stirred for  
3 min. After this time B-methoxy-9-BBN (1.0 M in THF, 120 µL, 0.120 mmol) and 
THF (1 mL) were added and the reaction stirred for 10 min before warming to RT. 
After 1.5 h aq K3PO4 (3 M, 36.0 µL, 0.110 mmol), phenyl iodide (12.0 mg,           
58.0 µmol) in DMF (1 mL) and PdCl2(dppf) (3.5 mg, 4.8 µmol) were added and the 
reaction stirred for a further 16 h. Et2O (5 mL) was then added and the organic phase 
washed with H2O (5 mL) and brine (5 mL). The aqueous phase was then extracted 
with Et2O (3 x 10 mL) and the combined organic extracts dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography afforded coupled 
product 180 (13 mg, 53%) as a pale yellow oil. 
 
Rf 0.50 (25% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz) δ 7.25-7.20 (4H, m, 
ArH), 7.17-7.11 (3H, m, ArH), 6.84 (2H, d, J = 8.6 Hz, ArH), 5.49 (1H, dd, J = 9.3, 
1.4 Hz, H18), 4.52 (1H, dd, J = 9.3, 7.8 Hz, H17), 4.38 (2H, d, J = 3.8 Hz, OCH2PMP), 
3.91 (2H, d, J = 5.9 Hz, H20), 3.79 (3H, s, ArOCH3), 3.69 (1H, dd, J = 7.8, 5.5 Hz, 
H16), 3.45 (3H, s, CHOCH3), 3.32 (1H, ddd, J = 9.3, 5.5, 3.4 Hz, H15), 2.64 (1H, ddd, 
J = 13.6, 10.7, 5.6 Hz, H11a), 2.56 (1H, ddd, J = 13.6, 10.5, 5.9 Hz, H11b), 1.92-1.78 
(6H, m, H13, H12a, (CH2CH2)2C(OR)2), 1.77 (3H, d, J = 1.4 Hz, Me19), 1.72-1.59 (5H, 
m, H12b, (CH2CH2)2C(OR)2), 1.59-1.55 (1H, m, H14a), 1.22-1.13 (1H, m, H14b) and 
0.98 (3H, d, J = 6.5 Hz, Me13). 
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(2E,4S,5S,6E)-Methyl 7-(2-iodooxazol-4-yl)-4-methyl-5-((triisopropylsilyl)oxy) 
octa-2,6-dienoate (181) 
 
 
 
To a stirred solution of oxazole 85 (25 mg, 44.4 µmol) and iodine (34 mg, 0.13 mmol) 
in THF (1 mL) at -78 ºC was added TBAF (1M in THF, 44 µL, 44 µmol) and stirred 
for 3 hours. The reaction was quenched with aq Na2S2O3 (2 mL) and the aqueous 
phase extracted with Et2O (3 x 3 mL). The combined organic extracts were dried 
(Na2SO4), filtered and the solvent removed in vacuo. The product was purified by 
flash column chromatography (15-35% EtOAc/hexane) to yield iodooxazole 181      
(9 mg, 38%) as a colourless oil and oxazole by-product 182 (10 mg, 55%) as a 
colourless oil. 
 
Rf 0.23 (30% EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 7.60 (1H, s, H9), 6.96 
(1H, dd, J = 15.8, 8.0 Hz, H3), 6.28 (1H, dd, J = 9.1, 1.5 Hz, H6), 5.83 (1H, dd,           
J = 15.8, 1.2 Hz, H2), 4.57 (1H, dd, J = 9.1, 5.7 Hz, H5), 3.72 (3H, s, OCH3), 2.65-
2.51 (1H, m, H4), 1.85 (3H, d, J = 1.5 Hz, Me7), 1.08 (3H, d, J = 6.9 Hz, Me4) and 
1.06-1.00 (21H, m, Si(CH(CH3)2)3, Si(CH(CH3)2)3); HRMS (ES+) calcd. for 
C22H37INO4Si [M+H]+ 534.1531, found 534.1521. 
 
 
(S)-Citronellal (193)139 
 
 
 
To a stirred solution of oxalyl chloride (487 mg, 330 µL, 3.84 mmol) in CH2Cl2      
(15 mL) at -78 ºC was added DMSO (550 mg, 500 µL, 7.14 mmol).  After 30 min a 
solution of (S)-citronellol (500 mg, 3.20 mmol) in CH2Cl2 (5 ml) was added and the 
reaction mixture was stirred for 1 h at -78 ºC. Et3N (0.97 g, 1.34 mL, 9.60 mmol) was 
then added and the reaction mixture allowed to warm to RT. After 1 h the reaction 
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was quenched with NH4Cl (sat aq, 20 mL) and the aqueous phase extracted with Et2O 
(3 x 25 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. The product was purified by flash column chromatography 
(1.5% EtOAc/hexane) to yield (S)-citronellal (474 mg, 96%) as a pale yellow oil.  
 
Rf 0.62 (20% EtOAc/hexane);  -16.1 (c 1.00 CHCl3), (Lit.139 -16.2, (c 1.00, 
CHCl3)); 1H NMR (CDCl3, 500 MHz) δ 9.75 (1H, s, H11), 5.12-5.05 (1H, m, H16), 
2.41 (1H, ddd, J = 16.1, 5.6, 2.0 Hz, H12a), 2.23 (1H, ddd, J = 16.1, 8.0, 2.7 Hz, H12b), 
2.13-1.92 (3H, m, H13, H15), 1.68 (3H, s, (CH3)2C=CH), 1.60 (3H, s, (CH3)2C=CH), 
1.42-1.32 (1H, m, H14a), 1.32-1.22 (1H, m, H14b) and 0.97 (3H, d, J = 6.7 Hz, Me13). 
 
 
(3S)-1-(4-Iodooxazol-2-yl)-3,7-dimethyloct-6-en-1-ol (194) 
 
 
 
To a solution of diiodooxazole 88 (280 mg, 0.880 mmol) at -78 ºC in THF (7.5 mL) 
was added n-BuLi (2.5 M in hexane, 438 µL, 1.10 mmol) and stirred for 30 min. 
After this time a solution of (S)-citronellal (193) (90 mg, 0.580 mmol) in THF        
(2.5 mL) was added and the reaction stirred for a further 30 min before warming the 
reaction mixture to 0 ºC for 1 h. The reaction was quenched with the addition of aq 
NH4Cl (10 mL) and the aqueous phase extracted with Et2O (3 x 20 mL). The 
combined organic extracts were dried (Na2SO4), filtered and the solvent removed in 
vacuo with product purified by flash column chromatography (20% EtOAc/hexane) to 
give alcohol 194 (90 mg, 44%) as a yellow oil.  
 
Rf 0.20 (20% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz, d.r. 1 : 1) δ 7.65 (1H, s, 
H8), 5.14-5.04 (1H, m, H16), 4.93-4.85 (1H, m, H11), 3.07-2.95 (1H, m, OH), 2.09-
1.93 (2H, m, H15), 1.95-1.87 (isomer A, 2H, m, H12), 1.81-1.72 (isomer A, 1H, m, 
H13), 1.81-1.72 (isomer B, 1H, m, H12a), 1.69 (3H, (CH3)2C=CH), 1.68-1.61 (isomer 
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B, 1H, m, H12b) 1.65-1.56 (isomer B, 1H, m, H13b), 1.61 (3H, s, (CH3)2C=CH), 1.48-
1.32 (1H, m, H14a), 1.27-1.14 (1H, m, H14b), 0.97 (isomer A, 3H, d, J = 2.1 Hz, Me13) 
and  0.96 (isomer B, 1H, d, J = 2.2 Hz, Me13); 13C NMR (75 MHz, CDCl3) δ 168.2, 
168.0, 143.0, 131.9, 124.8, 81.8, 66.4, 66.1, 43.1, 42.9, 37.8, 36.9, 29.3, 29.0, 26.1, 
25.8, 25.6, 20.3, 19.3 and 18.1. 
 
 
O-((3S)-1-(4-Iodooxazol-2-yl)-3,7-dimethyloct-6-en-1-yl) S-methyl 
carbonodithioate (195) 
 
 
 
To a stirred suspension of NaH (60 wt% in mineral oil, 38 mg, 0.800 mmol) and 
imidazole (2.4 mg, 35.3 µmol) in THF (3 ml) was added a solution of alcohol 194  
(60 mg, 0.170 mmol) in THF (2 mL) and stirred for 1 h. Carbon disulfide (458 µL, 
7.60 mmol) was then added and the reaction mixture stirred for a further 30 min 
before the addition of methyl iodide (458 mL, 7.36 mmol). After 30 min the reaction 
was quenched with acetic acid (150 µL), diluted with H2O (5 mL) and the aqueous 
phase extracted with Et2O (3 x 10 mL). The combined organic extracts were washed 
with H2O (5 mL) and brine (5 mL), dried (Na2SO4), filtered and the solvent removed 
in vacuo. The product was then purified by flash column chromatography                  
(2 % EtOAc/hexane) to yield xanthate 195 (60 mg, 80 %) as a yellow oil.  
 
Rf 0.50 (4 % EtOAc/hexane); 1H NMR (CDCl3, 500 MHz d.r. 1 : 1) δ 7.65 (1H, s, 
H9), 7.64 (1H, s, H9), 6.77-6.71 (1H, m, H11), 5.18-4.96 (1H, m, H16), 2.58 (1H, s, 
SCH3), 2.58 (1H, s, SCH3), 2.27 (isomer A, 1H, ddd, J = 14.2, 9.5, 4.8 Hz, H12a), 2.14-
2.01 (isomer B, 2H, m, H12) 2.03-1.89 (2H, m, H15), 1.83 (isomer A, 1H, ddd,             
J = 14.2, 9.0, 4.9 Hz, H12b), 1.68 (3H, s, (CH3)2C=CH), 1.66 (3H, s, (CH3)2C=CH), 
1.60 (3H, s, CH3)2C=CH), 1.58 (3H, s, CH3)2C=CH), 1.59-1.53 (isomer A, 1H, m, 
H13), 1.53-1.45 (isomer B, 1H, m, H13), 1.42-1.33 (1H, m, H14a), 1.24-1.14 (1H, m, 
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H14b), 0.97 (isomer B, 3H, d, J = 6.7 Hz, Me13) and 0.94 (isomer A, 3H, d, J = 6.6 Hz, 
Me13); HRMS (ES+) calcd. for C15H23INO2S2 [M+H]+ 440.0209, found 440.0209. 
 
 
 (S)-2-(3,7-Dimethyloct-6-en-1-yl)oxazole (196) 
 
 
 
To a refluxing solution of xanthate 195 (55 mg, 0.130 mmol) and AIBN (4 mg,     
24.0 µmol) in toluene (2.5 mL) was added tributyltin hydride (58 µL, 0.220 mmol). 
The reaction mixture was heated under reflux for 3 h before cooling to RT and the 
solvent removed in vacuo. The crude product was then purified by flash column 
chromatography (10% EtOAc/hexane) to yield reduced product 196 (25 mg, 88%). 
 
IR 2954, 2922, 2870, 2853, 1574, 1456, 1377, 1134, 1064, 916 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 7.54 (1H, d, J = 0.9 Hz, H9), 7.00 (1H, d, J = 0.9 Hz, H8), 5.08 
(1H, tt, J= 7.1, 1.4 Hz, H16), 2.86-2.69 (2H, m, H11), 2.11-1.90 (2H, m, H15), 1.90-
1.73 (1H, m, H12a), 1.67 (3H, d, J = 1.4 Hz, (CH3)2C=CH), 1.59 (3H, s, 
(CH3)2C=CH), 1.61-1.51 (1H, m, H12b), 1.53-1.43 (1H, m, H13), 1.42-1.33 (1H, m, 
H14a), 1.24-1.14 (1H, m, H14b) and 0.93 (3H, d, J = 6.5 Hz, Me13); 13C NMR         
(101 MHz, CDCl3) δ 165.4, 138.1, 131.3, 126.8, 124.6, 36.7, 33.9, 32.0, 25.8, 25.7, 
25.4, 19.2 and 17.6; HRMS (ES+) calcd. for C13H22NO [M+H]+ 208.1696, found 
208.1695. 
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(E)-4-(4-(Benzyloxy)but-2-en-2-yl)oxazole (197) 
 
 
 
To a stirred suspension of NaH (60 wt% in mineral oil, 104 mg, 2.60 mmol) at 0 ºC in 
THF (10 ml) was added alcohol 93 (180 mg, 1.29 mmol) in THF (5 mL) and the 
reaction stirred for 30 min. Benzyl bromide (0.178 mL, 256 mg, 2.00 mmol) and 
TBAI (24 mg, 64.5 µmol) were then added, the reaction mixture warmed to RT and 
stirred for 16 h. The reaction was quenched with H2O (15 mL) and the THF removed 
in vacuo before extraction of the aqueous phase with EtOAc (3 x 25 mL). The 
combined organic extracts were dried (MgSO4), filtered and the solvent removed in 
vacuo.  The product was purified by flash column chromatography (10% 
EtOAc/hexane) to give benzyl ether 197 (206 mg, 70%) as a colourless oil. 
 
Rf 0.40 (20% EtOAc/hexane); IR 3130, 3063, 3028, 2920, 2857, 1521, 1452, 1364, 
1096, 11053 and 908 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.82 (1H, s, H10), 7.58 (1H, 
s, H9), 7.42-7.28 (5H, m, ArH), 6.58-6.51 (1H, m, H6), 4.57 (2H, s, OCH2Ph), 4.24 
(2H, dd, J = 6.9, 1.0 Hz, H5) and 1.95 (3H, d, J =1.4 Hz, Me7); 13C NMR (126 MHz, 
CDCl3) δ 150.9, 142.0, 138.3, 133.9, 128.4, 128.0, 127.8, 127.6, 124.3, 72.2, 66.0 and 
14.3; HRMS (ES+) calcd. for C14H16NO2 [M+H]+ 230.1176, found 230.1177. 
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